

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|----|--------|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | Apr 08 | "Ask CAS" for self-help around the clock |
| NEWS | 3 | Jun 03 | New e-mail delivery for search results now available |
| NEWS | 4 | Aug 08 | PHARMAMarketLetter(PHARMAML) - new on STN |
| NEWS | 5 | Aug 19 | Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN |
| NEWS | 6 | Aug 26 | Sequence searching in REGISTRY enhanced |
| NEWS | 7 | Sep 03 | JAPIO has been reloaded and enhanced |
| NEWS | 8 | Sep 16 | Experimental properties added to the REGISTRY file |
| NEWS | 9 | Sep 16 | CA Section Thesaurus available in CAPLUS and CA |
| NEWS | 10 | Oct 01 | CASREACT Enriched with Reactions from 1907 to 1985 |
| NEWS | 11 | Oct 24 | BEILSTEIN adds new search fields |
| NEWS | 12 | Oct 24 | Nutraceuticals International (NUTRACEUT) now available on STN |
| NEWS | 13 | Nov 18 | DKILIT has been renamed APOLLIT |
| NEWS | 14 | Nov 25 | More calculated properties added to REGISTRY |
| NEWS | 15 | Dec 04 | CSA files on STN |
| NEWS | 16 | Dec 17 | PCTFULL now covers WP/PCT Applications from 1978 to date |
| NEWS | 17 | Dec 17 | TOXCENTER enhanced with additional content |
| NEWS | 18 | Dec 17 | Adis Clinical Trials Insight now available on STN |
| NEWS | 19 | Jan 29 | Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC |
| NEWS | 20 | Feb 13 | CANCERLIT is no longer being updated |
| NEWS | 21 | Feb 24 | METADDEX enhancements |
| NEWS | 22 | Feb 24 | PCTGEN now available on STN |
| NEWS | 23 | Feb 24 | TEMA now available on STN |
| NEWS | 24 | Feb 26 | NTIS now allows simultaneous left and right truncation |
| NEWS | 25 | Feb 26 | PCTFULL now contains images |
| NEWS | 26 | Mar 04 | SDI PACKAGE for monthly delivery of multifile SDI results |
| NEWS | 27 | Mar 20 | EVENTLINE will be removed from STN |
| NEWS | 28 | Mar 24 | PATDPAFULL now available on STN |
| NEWS | 29 | Mar 24 | Additional information for trade-named substances without structures available in REGISTRY |
| NEWS | 30 | Apr 11 | Display formats in DGENE enhanced |
| NEWS | 31 | Apr 14 | MEDLINE Reload |
| NEWS | 32 | Apr 17 | Polymer searching in REGISTRY enhanced |
| NEWS | 33 | Apr 21 | Indexing from 1947 to 1956 being added to records in CA/CAPLUS |
| NEWS | 34 | Apr 21 | New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX |
| NEWS | 35 | Apr 28 | RDISCLOSURE now available on STN |
| NEWS | 36 | May 05 | Pharmacokinetic information and systematic chemical names added to PHAR |
| NEWS | 37 | May 15 | MEDLINE file segment of TOXCENTER reloaded |
| NEWS | 38 | May 15 | Supporter information for ENCOMPPAT and ENCOMPLIT updated |
| NEWS | 39 | May 16 | CHEMREACT will be removed from STN |
| NEWS | 40 | May 19 | Simultaneous left and right truncation added to WSCA |
| NEWS | 41 | May 19 | RAPRA enhanced with new search field, simultaneous left and right truncation |

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003

| | | |
|----------------------|------------|---------|
| => file reg | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2003 HIGHEST RN 520505-31-1
 DICTIONARY FILE UPDATES: 26 MAY 2003 HIGHEST RN 520505-31-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

| | | |
|----------------|-------|----------------|
| => e strvudine | | |
| E1 | 2 | STRV/BI |
| E2 | 1 | STRVS/BI |
| E3 | 0 --> | STRVUDINE/BI |
| E4 | 5 | STRW/BI |
| E5 | 3 | STRX/BI |
| E6 | 44 | STRY/BI |
| E7 | 1 | STRYACRYL/BI |
| E8 | 17 | STRYCH/BI |
| E9 | 18 | STRYCHAN/BI |
| E10 | 7 | STRYCHANE/BI |
| E11 | 2 | STRYCHANOL/BI |
| E12 | 7 | STRYCHANONE/BI |

=> s strvudine

L1 0 STRVUDINE

=> s d4t

L2 0 D4T

=> e d4t

| | | |
|-----|-------|------------|
| E1 | 2 | D4SN/BI |
| E2 | 2 | D4ST/BI |
| E3 | 0 --> | D4T/BI |
| E4 | 1 | D4TA5/BI |
| E5 | 1 | D4TI/BI |
| E6 | 1 | D4TI2ZR/BI |
| E7 | 1 | D4TM1/BI |
| E8 | 1 | D4TMP/BI |
| E9 | 1 | D4UCLA1/BI |
| E10 | 2 | D4UCLA2/BI |
| E11 | 1 | D4UWM1/BI |
| E12 | 1 | D4UWM2/BI |

=> s stavudine

L3 5 STAVUDINE

=> d 13 1-5

L3 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2003 ACS

RN 501939-31-7 REGISTRY

CN Thymidine, 2',3'-didehydro-3'-deoxy-, compd. with N,N-dimethylacetamide
(4:3) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Stavudine DMA solvate (1:0.75)**

FS STEREOSEARCH

MF C10 H12 N2 O4 . 3/4 C4 H9 N O

SR CA


LC STN Files: CA, CAPLUS

CM 1

CRN 3056-17-5

CMF C10 H12 N2 O4


Absolute stereochemistry.



CM 2

CRN 127-19-5

CMF C4 H9 N O




2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 118910-37-5 REGISTRY
CN Thymidine 5'-(trihydrogen diphosphate), 2',3'-didehydro-3'-deoxy- (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN **Stavudine diphosphate**
FS STEREOSEARCH
MF C10 H14 N2 O10 P2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 27646-59-9 REGISTRY
CN 5'-Thymidylic acid, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)-,
5'-(dihydrogen phosphate) (8CI)

OTHER NAMES:

CN d4TMP
CN **Stavudine monophosphate**
FS STEREOSEARCH
MF C10 H13 N2 O7 P
CI COM
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

26 REFERENCES IN FILE CA (1957 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 27 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2003 ACS
 RN 26194-89-8 REGISTRY
 CN Thymidine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy-3'-deoxy- (9CI)
 (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)-,
 5'-(tetrahydrogen triphosphate) (8CI)
 OTHER NAMES:
 CN 2',3'-Dideoxy-3'-deoxythymidine 5'-triphosphate
 CN **Stavudine triphosphate**
 FS STEREOSEARCH
 DR 146369-73-5
 MF C10 H15 N2 O13 P3
 CI COM
 LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
 CANCERLIT, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, MEDLINE,
 TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


54 REFERENCES IN FILE CA (1957 TO DATE)
 54 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2003 ACS
 RN 3056-17-5 REGISTRY
 CN Thymidine, 2',3'-dideoxy-3'-deoxy- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2'-Thymidinene, 3'-deoxy- (8CI)
 CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)- (7CI, 8CI)

OTHER NAMES:

CN 2',3'-Didehydro-3'-deoxythymidine
 CN 3'-Deoxy-2',3'-didehydrothymidine
 CN BMY 27857
 CN D 4T
 CN D 4T (nucleoside)
 CN Sanilvudine
 CN **Stavudine**
 CN Zerit
 FS STEREOSEARCH
 DR 132425-31-1
 MF C10 H12 N2 O4
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
 CBNB, CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHM, DDFU, DIOGENES, DRUGNL,
 DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT,
 RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1253 REFERENCES IN FILE CA (1957 TO DATE)
 34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1260 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s paraoxon

L4 42 PARAOXON

=> d 14 38-42

L4 ANSWER 38 OF 42 REGISTRY COPYRIGHT 2003 ACS
 RN 2255-19-8 REGISTRY
 CN Phosphoric acid, dibutyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phosphoric acid, dibutyl p-nitrophenyl ester (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN Ba 2667
 CN BAY 11686
 CN **Butyl paraoxon**
 CN **Di-n-butyl paraoxon**
 FS 3D CONCORD
 MF C14 H22 N O6 P


LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CHEMINFORMRX,
NIOSHTIC, RTECS*, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1957 TO DATE)
18 REFERENCES IN FILE CAPLUS (1957 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 39 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 1153-30-6 REGISTRY
CN Phosphoric acid, 4-nitrophenyl dipropyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoric acid, p-nitrophenyl dipropyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN BAY 55640
CN **Paraoxon propyl**
CN **Propyl paraoxon**
CN Propyl-E 600
FS 3D CONCORD
MF C12 H18 N O6 P
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, NIOSHTIC, RTECS*,
TOXCENTER
(*File contains numerically searchable property data)




514/132

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1957 TO DATE)
20 REFERENCES IN FILE CAPLUS (1957 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 40 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 950-35-6 REGISTRY
CN Phosphoric acid, dimethyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoric acid, dimethyl p-nitrophenyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN BAY 11678
CN Desmethylnitrophos
CN Dimethyl 4-nitrophenyl phosphate
CN Dimethyl p-nitrophenyl phosphate

CN **Dimethyl paraoxon**
 CN Methyl-E 600
 CN **Methylparaoxon**
 CN Methylparathion oxon
 CN p-Nitrophenyl dimethyl phosphate
 CN **Paraoxon methyl**
 FS 3D CONCORD
 MF C8 H10 N O6 P
 LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX,
 CHEMLIST, CSCHEM, CSNB, EMBASE, IPA, MEDLINE, MSDS-OHS, NIOSHTIC,
 RTECS*, SPECINFO, TOXCENTER, ULIDAT, USPATFULL
 (*File contains numerically searchable property data)




****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

319 REFERENCES IN FILE CA (1957 TO DATE)
 319 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 36 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 41 OF 42 REGISTRY COPYRIGHT 2003 ACS
 RN 311-45-5 REGISTRY
 CN Phosphoric acid, diethyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phosphoric acid, diethyl p-nitrophenyl ester (6CI, 8CI)
 OTHER NAMES:
 CN 4-Nitrophenyl diethyl phosphate
 CN Chinorto
 CN Diethyl 4-nitrophenyl phosphate
 CN Diethyl p-nitrophenyl phosphate
 CN E 600
 CN E 600 (pesticide)
 CN Ester 25
 CN **Ethyl paraoxon**
 CN Eticol
 CN Fosfakol
 CN HC 2072
 CN Mintacol
 CN Miotisal
 CN Miotisal A
 CN Oxyparathion
 CN p-Nitrophenyl diethyl phosphate
 CN Paraoxon
 CN **Paraoxon**
 CN **Paraoxon-ethyl**
 CN Phosphachole
 CN Phosphacol
 CN Phosphakol
 CN Ts 219
 FS 3D CONCORD

MF C10 H14 N O6 P
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHÈM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2060 REFERENCES IN FILE CA (1957 TO DATE)
 18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2061 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 211 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 42 OF 42 REGISTRY COPYRIGHT 2003 ACS
 RN 311-44-4 REGISTRY
 CN Phosphoric acid, bis(2-chloroethyl) 4-nitrophenyl ester (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Ethanol, 2-chloro-, p-nitrophenyl phosphate (2:1)
 CN Phosphoric acid, bis(2-chloroethyl) p-nitrophenyl ester (7CI, 8CI)

OTHER NAMES:

CN 110H60
 CN **2-Chloroethyl paraoxon**
 CN Nitrophenylhalon
 CN PE 304
 FS 3D CONCORD
 DR 14714-91-1

MF C10 H12 Cl2 N O6 P
 LC STN Files: BIOSIS, CA, CAOLD, CAPLUS, RTECS*, TOXCENTER
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1957 TO DATE)
 9 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s phyostigmine
L5 0 PHYOSTIGMINE

=> s phyostigmine
L6 0 PHYOSTIGMINE


=> s physostigmine
L7 54 PHYSOSTIGMINE

=> d 17 45-54

L7 ANSWER 45 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 6091-09-4 REGISTRY
CN **Physostigmine, sulfite (2:1) (8CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H21 N3 O2 . 1/2 H2 O3 S

CM 1


CRN 7782-99-2
CMF H2 O3 S



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).




L7 ANSWER 46 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 6091-08-3 REGISTRY
CN **Physostigmine, tartrate (2:1) (8CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H21 N3 O2 . 1/2 C4 H6 O6

CM 1

CRN 87-69-4
CMF C4 H6 O6


Absolute stereochemistry.



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2


Absolute stereochemistry. Rotation (-).



L7 ANSWER 47 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 6091-07-2 REGISTRY
CN **Physostigmine, compd. with boric acid (H3BO3) (1:1) (8CI) (CA INDEX NAME)**
OTHER CA INDEX NAMES:
CN **Boric acid, compd. with physostigmine (1:1)**
FS STEREOSEARCH
MF C15 H21 N3 O2 . B H3 O3

CM 1


CRN 10043-35-3
CMF B H3 O3



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



L7 ANSWER 48 OF 54 REGISTRY COPYRIGHT 2003 ACS

RN 6091-06-1 REGISTRY

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, monobenzoate (salt) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1)

CN **Physostigmine, monobenzoate (8CI)**

OTHER NAMES:

CN **Physostigmine benzoate**

FS STEREOSEARCH

MF C15 H21 N3 O2 . C7 H6 O2


LC STN Files: BEILSTEIN*

(*File contains numerically searchable property data)

CM 1

CRN 65-85-0

CMF C7 H6 O2




CM 2

CRN 57-47-6

CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).




L7 ANSWER 49 OF 54 REGISTRY COPYRIGHT 2003 ACS
 RN 5990-00-1 REGISTRY
 CN **Physostigmine, p-(benzyloxy)benzenesulfonate (7CI, 8CI) (CA INDEX NAME)**
 OTHER CA INDEX NAMES:
 CN **Benzenesulfonic acid, p-(benzyloxy)-, compd. with physostigmine (1:1)**
 FS STEREOSEARCH
 MF C15 H21 N3 O2 . C13 H12 O4 S
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXCENTER
 (*File contains numerically searchable property data)

CM 1

CRN 5950-16-3

CMF C13 H12 O4 S




CM 2

CRN 57-47-6

CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).




2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 50 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 1399-96-8 REGISTRY
CN **Isophysostigmine, sulfate (8CI)** (CA INDEX NAME)
MF C15 H21 N3 O2 . 1/2 H2 O4 S

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 1399-95-7
CMF C15 H21 N3 O2
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 51 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 1399-95-7 REGISTRY
CN **Isophysostigmine (8CI)** (CA INDEX NAME)
MF C15 H21 N3 O2
CI COM, MAN
LC STN Files: NAPRALERT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 52 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 64-47-1 REGISTRY
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-, sulfate (2:1) (salt) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN **Physostigmine, sulfate (2:1) (8CI)**
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, sulfate (2:1) (salt)

OTHER NAMES:

CN Eserine sulfate
CN Eserine sulphate
CN **Physostigmine hemisulfate**
CN **Physostigmine sulfate**
CN **Physostigmine sulphate**

FS STEREOSEARCH

DR 11036-67-2, 11041-29-5

MF C15 H21 N3 O2 . 1/2 H2 O4 S

CI COM

LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, HODOC*, HSDB*, IPA, MRCK*, MSDS-OHS, NIOSHTIC, RTECS*, TOXCENTER, USAN,

USPATFULL

(*File contains numerically searchable property data)


Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 57-47-6

CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



364 REFERENCES IN FILE CA (1957 TO DATE)

364 REFERENCES IN FILE CAPLUS (1957 TO DATE)

3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 53 OF 54 REGISTRY COPYRIGHT 2003 ACS

RN 57-64-7 REGISTRY

CN Benzoic acid, 2-hydroxy-, compd. with (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1)

CN **Physostigmine salicylate (6CI)**

CN **Physostigmine, monosalicylate (8CI)**

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-, mono(2-hydroxybenzoate) (salt) (9CI)

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, mono(2-hydroxybenzoate) (salt)

CN **Salicylic acid, compd. with physostigmine (1:1) (8CI)**


OTHER NAMES:

CN **(-)-Physostigmine salicylate**

CN Eserine salicylate
 CN Isopto Eserine
 FS STEREOSEARCH
 DR 11033-04-8, 11036-66-1
 MF C15 H21 N3 O2 . C7 H6 O3
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,
 CHEMLIST, CSChem, DDFU, DETHERM*, DRUGU, EMBASE, HSDB*, IPA, MEDLINE,
 MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS*, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

CM 1


CRN 69-72-7
 CMF C7 H6 O3



CM 2

CRN 57-47-6
 CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



675 REFERENCES IN FILE CA (1957 TO DATE)
 675 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 59 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 54 OF 54 REGISTRY COPYRIGHT 2003 ACS

RN 57-47-6 REGISTRY

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,
 methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN **Physostigmine (8CI)**

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,
 methylcarbamate (ester), (3aS-cis)-

OTHER NAMES:

CN (-)-Eserine
 CN (-)-Physostigmine
 CN Cogmine
 CN Eserine
 CN Esromiotin
 CN MCV.4484
 CN NIH 10421
 CN Physostol
 FS STEREOSEARCH
 DR 511-49-9, 50975-37-6
 MF C15 H21 N3 O2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
 CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE,
 GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
 MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO,
 SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3507 REFERENCES IN FILE CA (1957 TO DATE)
 34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3509 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

| | |
|----|--------------------|
| | E STRVUDINE |
| L1 | 0 S STRVUDINE |
| L2 | 0 S D4T |
| | E D4T |
| L3 | 5 S STAVUDINE |
| L4 | 42 S PARAOXON |
| L5 | 0 S PHYOSTIGMINE |
| L6 | 0 S PHYOSTIGMINE |
| L7 | 54 S PHYSOSTIGMINE |

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 68.74 | 68.95 |

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 26 May 2003 (20030526/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

| | |
|----|--------------------|
| | E STRVUDINE |
| L1 | 0 S STRVUDINE |
| L2 | 0 S D4T |
| | E D4T |
| L3 | 5 S STAVUDINE |
| L4 | 42 S PARAOXON |
| L5 | 0 S PHYOSTIGMINE |
| L6 | 0 S PHYOSTIGMINE |
| L7 | 54 S PHYSOSTIGMINE |

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

=> s 13

L8 1300 L3

=> s 14

L9 2913 L4

=> s 17

L10 4718 L7

=> e hiv

| | | |
|----|-----------|-----------|
| E1 | 1 | HIUTI/BI |
| E2 | 1 | HUVECS/BI |
| E3 | 49410 --> | HIV/BI |
| E4 | 1 | HIV0/BI |
| E5 | 4 | HIV01/BI |
| E6 | 1 | HIV02/BI |

| | | |
|-----|-------|----------------|
| E7 | 13089 | HIV1/BI |
| E8 | 1 | HIV111B/BI |
| E9 | 1 | HIV183/BI |
| E10 | 1 | HIV1BRU/BI |
| E11 | 1 | HIV1D117III/BI |
| E12 | 1 | HIV1E/BI |

```
=> s e3 or e7
      49410 HIV/BI
      13089 HIV1/BI
L11    50075 HIV/BI OR HIV1/BI
```

```
=> e herpes
E1      9      HERPERVIRUS/BI
E2      1      HERPERVIRUSES/BI
E3     21343 --> HERPES/BI
E4      3      HERPES1/BI
E5      1      HERPES6/BI
E6      2      HERPESELECT/BI
E7      2      HERPESEVIRUS/BI
E8      1      HERPESIRUS/BI
E9      1      HERPESIVIRUS/BI
E10     1      HERPESIVRUSES/BI
E11     4      HERPESLIKE/BI
E12     1      HERPESSAIMIRI/BI
```

```
=> s e3
L12     21343 HERPES/BI
```

```
=> s hhv or hsv or hcmv or cmv
      1071 HHV
      9489 HSV
      2298 HCMV
      5317 CMV
L13    17244 HHV OR HSV OR HCMV OR CMV
```

```
=> s l12 or l13
L14    29657 L12 OR L13
```

```
=> s phosphate ester
      481122 PHOSPHATE
      518186 ESTER
L15    7547 PHOSPHATE ESTER
      (PHOSPHATE(W)ESTER)
```

```
=> d his
```

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

| | | |
|----|----|-----------------|
| | E | STRVUDINE |
| L1 | 0 | S STRVUDINE |
| L2 | 0 | S D4T |
| | E | D4T |
| L3 | 5 | S STAVUDINE |
| L4 | 42 | S PARAOXON |
| L5 | 0 | S PHYOSTIGMINE |
| L6 | 0 | S PHYOSTIGMINE |
| L7 | 54 | S PHYSOSTIGMINE |

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

| | | |
|----|------|------|
| L8 | 1300 | S L3 |
|----|------|------|

L9 2913 S L4
 L10 4718 S L7
 E HIV
 L11 50075 S E3 OR E7
 E HERPES
 L12 21343 S E3
 L13 17244 S HHV OR HSV OR HCMV OR CMV
 L14 29657 S L12 OR L13
 L15 7547 S PHOSPHATE ESTER

=> s 18 and 115

L16 2 L8 AND L15

=> d 115 1-2

L15 ANSWER 1 OF 7547 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:398106 CAPLUS
 TI Absorption Rate Limit Considerations for Oral Phosphate Prodrugs
 AU Heimbach, Tycho; Oh, Doo-Man; Li, Lilian Y.; Forsberg, Markus; Savolainen, Jouko; Leppaenen, Jukka; Matsunaga, Yasushi; Flynn, Gordon; Fleisher, David
 CS The University of Michigan, College of Pharmacy, 428 Church Street, Ann Arbor, MI, 48109, USA
 SO Pharmaceutical Research (2003), 20(6), 848-856
 CODEN: PHREEB; ISSN: 0724-8741
 PB Kluwer Academic/Plenum Publishers
 DT Journal
 LA English

L15 ANSWER 2 OF 7547 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:397235 CAPLUS
 TI The XT-Tube Extractor: A Hollow Fiber-Based Supported Liquid Membrane Extractor for Bioanalytical Sample Preparation
 AU Jonsson, Ove B.; Nordloef, Ulrika; Nilsson, Ulrika L.
 CS Department of Analytical Chemistry, Stockholm University, Stockholm, Swed.
 SO Analytical Chemistry ACS ASAP
 CODEN: ANCHAM; ISSN: 0003-2700
 PB American Chemical Society
 DT Journal
 LA English

=> e ester

| | | |
|-----|------------|-------------------|
| E1 | 1 | ESTEQUATS/BI |
| E2 | 2 | ESTEQUIOMETRIA/BI |
| E3 | 518186 --> | ESTER/BI |
| E4 | 1 | ESTER1/BI |
| E5 | 1 | ESTER2/BI |
| E6 | 1 | ESTER20/BI |
| E7 | 1 | ESTER2HCL/BI |
| E8 | 1 | ESTER3/BI |
| E9 | 2 | ESTER4/BI |
| E10 | 1 | ESTER50/BI |
| E11 | 2 | ESTER8/BI |
| E12 | 1 | ESTER9/BI |

=> s e3

L17 518186 ESTER/BI

=> s ;17 and 18

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):s

L18 2414368 S

17 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 117 and 18

L19 54 L17 AND L8

=> d 119 20-54

L19 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 2000:742057 CAPLUS

DN 133:309791

TI Synthesis, activity and formulations of pharmaceutical compounds for
treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2000061541 | A2 | 20001019 | WO 2000-EP3239 | 20000411 |
| | WO 2000061541 | A3 | 20010927 | | |
| | W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | IT 1311923 | B1 | 20020320 | IT 1999-MI752 | 19990413 |
| | BR 2000009703 | A | 20020108 | BR 2000-9703 | 20000411 |
| | EP 1169298 | A2 | 20020109 | EP 2000-926870 | 20000411 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002541236 | T2 | 20021203 | JP 2000-610818 | 20000411 |
| | NO 2001004928 | A | 20011213 | NO 2001-4928 | 20011010 |
| PRAI | IT 1999-MI752 | A | 19990413 | | |
| | WO 2000-EP3239 | W | 20000411 | | |
| OS | MARPAT 133:309791 | | | | |

L19 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 2000:742053 CAPLUS

DN 133:310142

TI Synthesis, activity and formulations of pharmaceutical compounds for
treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2000061537 | A2 | 20001019 | WO 2000-EP3234 | 20000411 |
| | WO 2000061537 | A3 | 20010927 | | |

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 1311924 B1 20020320 IT 1999-MI753 19990413
 BR 2000009702 A 20020108 BR 2000-9702 20000411
 EP 1169294 A2 20020109 EP 2000-925203 20000411

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002541233 T2 20021203 JP 2000-610814 20000411
 NO 2001004927 A 20011213 NO 2001-4927 20011010

PRAI IT 1999-MI753 A 19990413
 WO 2000-EP3234 W 20000411

OS MARPAT 133:310142

L19 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 2000:725436 CAPLUS

DN 133:301171

TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

IN Chen, Feng-jing; Patel, Manesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2000059475 | A1 | 20001012 | WO 2000-US7342 | 20000316 |
| | W: | | | | |
| | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6383471 | B1 | 20020507 | US 1999-287043 | 19990406 |
| | EP 1165048 | A1 | 20020102 | EP 2000-916547 | 20000316 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| PRAI | US 1999-287043 | A | 19990406 | | |
| | WO 2000-US7342 | W | 20000316 | | |

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 2000:619245 CAPLUS

DN 133:329124

TI A QSAR study investigating the effect of l-alanine **ester** variation on the anti-HIV activity of some phosphoramidate derivatives of d4T

AU Knaggs, M. H.; McGuigan, C.; Harris, S. A.; Heshmati, P.; Cahard, D.; Gilbert, I. H.; Balzarini, J.

CS Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK

SO Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2075-2078

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.
DT Journal
LA English

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 2000:259989 CAPLUS
DN 132:293599
TI preparation of calanolide analogs for treating and preventing tuberculosis
IN Xu, Ze-Qi; Lin, Yuh-Meei; Flavin, Michael
PA Sarawak Medichem Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|--|-----------------|----------|
| PI | WO 2000021514 | A2 | 20000420 | WO 1999-US23689 | 19991014 |
| | W: | | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | RW: | | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | |
| | CA. 2346813 | AA | 20000420 | CA 1999-2346813 | 19991014 |
| | US 6268393 | B1 | 20010731 | US 1999-417672 | 19991014 |
| | EP 1143952 | A2 | 20011017 | EP 1999-960118 | 19991014 |
| | EP 1143952 | A3 | 20020911 | | |
| | EP 1143952 | B1 | 20030226 | | |
| | R: | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | |
| | AT 233089 | E | 20030315 | AT 1999-960118 | 19991014 |
| | US 2001027209 | A1 | 20011004 | US 2000-735067 | 20001211 |
| PRAI | US 1998-104409P | P | 19981015 | | |
| | US 1999-417672 | A1 | 19991014 | | |
| | WO 1999-US23689 | W | 19991014 | | |
| OS | MARPAT 132:293599 | | | | |

L19 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1999:644567 CAPLUS
DN 132:135
TI Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine
AU Saboulard, Didier; Naesens, Lieve; Cahard, Dominique; Salgado, Antonio; Pathirana, Ranjith; Velazquez, Sonsoles; McGuigan, Christopher; De Clercq, Erik; Balzarini, Jan
CS Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, Belg.
SO Molecular Pharmacology (1999), 56(4), 693-704
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1999:139847 CAPLUS
 DN 130:209924
 TI Preparation of amino acid-containing nucleoside esters as inhibitors of
 retroviral reverse transcriptase and hepatitis B virus DNA polymerase
 IN Zhou, Xiao-Xiong; Johansson, Nils-Gunnar; Wahling, Horst
 PA Medivir AB, Swed.
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 9909031 | A1 | 19990225 | WO 1998-SE1467 | 19980414 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9887548 | A1 | 19990308 | AU 1998-87548 | 19980814 |
| | AU 728892 | B2 | 20010118 | | |
| | EP 988304 | A1 | 20000329 | EP 1998-939041 | 19980814 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO | | | | |
| | NZ 502837 | A | 20010126 | NZ 1998-502837 | 19980814 |
| | AT 200900 | E | 20010515 | AT 1998-939041 | 19980814 |
| | EP 1123935 | A2 | 20010816 | EP 2001-103370 | 19980814 |
| | EP 1123935 | A3 | 20010905 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO | | | | |
| | JP 2001515079 | T2 | 20010918 | JP 2000-509711 | 19980814 |
| | NZ 508502 | A | 20020426 | NZ 1998-508502 | 19980814 |
| | ZA 9901148 | A | 19990812 | ZA 1999-1148 | 19990212 |
| | CA 2318975 | AA | 19990819 | CA 1999-2318975 | 19990212 |
| | WO 9941268 | A1 | 19990819 | WO 1999-SE189 | 19990212 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1058687 | A1 | 20001213 | EP 1999-932499 | 19990212 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | NZ 506033 | A | 20020201 | NZ 1999-506033 | 19990212 |
| | JP 2002503670 | T2 | 20020205 | JP 2000-531460 | 19990212 |
| | US 6458772 | B1 | 20021001 | US 1999-249317 | 19990212 |
| | CA 2318978 | AA | 19990819 | CA 1999-2318978 | 19990215 |
| | WO 9941275 | A1 | 19990819 | WO 1999-SE194 | 19990215 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |

AU 9932820 A1 19990830 AU 1999-32820 19990215
 AU 754733 B2 20021121
 EP 1054891 A1 20001129 EP 1999-932500 19990215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002503673 T2 20020205 JP 2000-531466 19990215
 CA 2325523 AA 19991014 CA 1999-2325523 19990330
 WO 9951613 A1 19991014 WO 1999-SE528 19990330
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1121366 A1 20010808 EP 1999-921327 19990330
 R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT, IE,
 SI, LT, LV, FI, RO
 JP 2002510698 T2 20020409 JP 2000-542334 19990330
 AU 9932819 A1 19990830 AU 1999-32819 19990830
 AU 732408 B2 20010426
 US 2002128301 A1 20020912 US 2001-927254 20010810
 PRAI SE 1997-2957 A 19970815
 SE 1997-4147 A 19971112
 SE 1998-452 A 19980213
 SE 1998-469 A 19980216
 SE 1998-1216 A 19980403
 WO 1998-SE1467 W 19980414
 ZA 1998-7267 A 19980813
 EP 1998-939041 A3 19980814
 NZ 1998-502837 A1 19980814
 SE 1998-3438 A 19981007
 US 1999-249317 A 19990212
 WO 1999-SE189 W 19990212
 WO 1999-SE194 W 19990215
 WO 1999-SE528 W 19990330
 WO 1999-SE1403 A2 19990818

OS MARPAT 130:209924

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1998:816112 CAPLUS

DN 130:47466

TI Inhibitors of human immunodeficiency virus integration that bind the
 tyrosine-29 pocket of the matrix protein and inhibit karyopherin .alpha.
 binding

IN Pan, Senliang; Bukrinsky, Michael; Haffar, Omar K.

PA The Picower Institute for Medical Research, USA

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|--------------------|-----------------|----------|
| PI | US 5849793 | A | 19981215 | US 1997-911883 | 19970815 |
| | CA 2300876 | AA | 19990225 | CA 1998-2300876 | 19980814 |
| | WO 9909005 | A1 | 19990225 | WO 1998-US16923 | 19980814 |
| | W: | | AU, CA, IL, JP, NZ | | |

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

AU 9890201 A1 19990308 AU 1998-90201 19980814
EP 1015422 A1 20000705 EP 1998-942068 19980814

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2001515063 T2 20010918 JP 2000-509689 19980814
PRAI US 1997-911883 A 19970815
WO 1998-US16923 W 19980814

OS MARPAT 130:47466

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1998:807805 CAPLUS

DN 130:177179

TI Synthesis, anti-human immunodeficiency virus activity and esterase
lability of some novel carboxylic ester-modified phosphoramidate
derivatives of stavudine (d4T)

AU McGuigan, C.; Sutton, P. W.; Cahard, D.; Turner, K.; O'Leary, G.; Wang,
Y.; Gumbleton, M.; De Clercq, E.; Balzarini, J.

CS Welsh School Pharmacy, Cardiff University, Cardiff, CF1 3XF, UK

SO Antiviral Chemistry & Chemotherapy (1998), 9(6), 473-479

CODEN: ACCHEH; ISSN: 0956-3202

PB International Medical Press

DT Journal

LA English

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1998:742529 CAPLUS

DN 130:38650

TI Preparation of polysaccharides sulfates binding anti-HIV nucleosides or
protease inhibitors and anti-AIDS drugs

IN Uryu, Toshiyuki; Kaneko, Utaro

PA Ajinomoto Co., Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 10306102 | A2 | 19981117 | JP 1997-130310 | 19970501 |
| PRAI | JP 1997-130310 | | 19970501 | | |

L19 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1998:330565 CAPLUS

DN 129:41360

TI Tri-N-Boc-tetraazamacrocyclic-nucleoside conjugates: synthesis and anti-HIV
activities

AU Dessolin, J.; Vlieghe, P.; Bouygues, M.; Medou, M.; Quelever, G.; Camplo,
M.; Chermann, J. C.; Kraus, J. L.

CS Laboratoire de Chimie Biomoléculaire, Faculté des Sciences de Luminy,
Université de la Méditerranée, Marseille, 13288, Fr.

SO Nucleosides & Nucleotides (1998), 17(5), 957-968

CODEN: NUNUD5; ISSN: 0732-8311

PB Marcel Dekker, Inc.

DT Journal

LA English

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:226576 CAPLUS
DN 128:316891
TI Direct transport of 2',3'-didehydro-3'-deoxythymidine (D4T) and its
ester derivatives to the cerebrospinal fluid via the nasal mucous
membrane in rats
AU Yajima, Toshiyuki; Juni, Kazuhiko; Saneyoshi, Mineo; Hasegawa, Tetsuya;
Kawaguchi, Takeo
CS Faculty of Pharmaceutical Sciences, Josai University, Saitama, 35002,
Japan
SO Biological & Pharmaceutical Bulletin (1998), 21(3), 272-277
CODEN: BPBLEO; ISSN: 0918-6158
PB Pharmaceutical Society of Japan
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 32 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:205372 CAPLUS
DN 128:289775
TI Synthesis and anti-HIV activity of some novel chain-extended
phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a
rapid predictive test for antiviral potency
AU McGuigan, C.; Tsang, H.-W.; Sutton, P. W.; De Clercq, E.; Balzarini, J.
CS Welsh School Pharmacy, University Wales Cardiff, Cardiff, CF1 3XF, UK
SO Antiviral Chemistry & Chemotherapy (1998), 9(2), 109-115
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press
DT Journal
LA English

L19 ANSWER 33 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:98348 CAPLUS
DN 128:176175
TI Compositions comprising an inducing agent and an antiviral agent for the
treatment of blood, viral and cellular disorders
IN Perrine, Susan P.; Faller, Douglas V.; White, Brian F.
PA Perrine, Susan P., USA; Faller, Douglas V.; White, Brian F.
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 9804290 | A2 | 19980205 | WO 1997-US12818 | 19970728 |
| | WO 9804290 | A3 | 19980813 | | |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5939456 | A | 19990817 | US 1996-687670 | 19960726 |
| | AU 9738891 | A1 | 19980220 | AU 1997-38891 | 19970728 |
| | EP 969869 | A2 | 20000112 | EP 1997-936153 | 19970728 |
| | R: BE, CH, DE, FR, GB, GR, IT, LI | | | | |

| | | | | | |
|------|-------------------|----|----------|----------------|----------|
| | JP 2001527517 | T2 | 20011225 | JP 1998-508931 | 19970728 |
| | US 2001009922 | A1 | 20010726 | US 2001-756489 | 20010108 |
| PRAI | US 1996-687670 | A | 19960726 | | |
| | US 1996-687671 | A | 19960726 | | |
| | WO 1997-US12818 | W | 19970728 | | |
| OS | MARPAT 128:176175 | | | | |

L19 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:42288 CAPLUS
DN 128:119660
TI Pharmaceuticals containing VX478, zidovudine and FTC and/or 3TC for HIV virus treatment
IN St. Clair, Martha Heider; Barry, David Walter
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|--|------------------|----------|
| PI | WO 9749411 | A1 | 19971231 | WO 1997-EP3247 | 19970623 |
| | W: | | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | RW: | | GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | |
| | CA 2258956 | AA | 19971231 | CA 1997-2258956 | 19970623 |
| | AU 9732627 | A1 | 19980114 | AU 1997-32627 | 19970623 |
| | AU 727983 | B2 | 20010104 | | |
| | BR 9709939 | A | 19990810 | BR 1997-9939 | 19970623 |
| | EP 938321 | A1 | 19990901 | EP 1997-928263 | 19970623 |
| | R: | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | |
| | CN 1228026 | A | 19990908 | CN 1997-197357 | 19970623 |
| | NZ 333099 | A | 20000623 | NZ 1997-333099 | 19970623 |
| | JP 2000515852 | T2 | 20001128 | JP 1998-502320 | 19970623 |
| | TW 469132 | B | 20011221 | TW 1997-86111193 | 19970805 |
| | US 6544961 | B1 | 20030408 | US 1998-202660 | 19981218 |
| | NO 9806034 | A | 19990223 | NO 1998-6034 | 19981222 |
| | KR 2000022226 | A | 20000425 | KR 1998-710646 | 19981224 |
| PRAI | US 1996-20543P | P | 19960625 | | |
| | US 1996-21027P | P | 19960702 | | |
| | GB 1996-14022 | A | 19960704 | | |
| | WO 1997-EP3247 | W | 19970623 | | |

L19 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1997:521950 CAPLUS
DN 127:171589
TI Managing the chemotherapy of patients who are HIV positive using a graphical representation of sensitivity of the pol gene products to inhibitors
IN De Bethune, Marie-Pierre; Hertogs, Kurt; Pauwels, Rudi
PA Virco N.V., Belg.; De Bethune, Marie-Pierre; Hertogs, Kurt; Pauwels, Rudi
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9727480 | A1 | 19970731 | WO 1997-IB71 | 19970124 |
| | W: AU, BA, BG, BR, CA, CN, CZ, HU, IL, IS, JP, KR, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9713168 | A1 | 19970820 | AU 1997-13168 | 19970124 |
| | AU 717755 | B2 | 20000330 | | |
| | EP 877937 | A1 | 19981118 | EP 1997-900712 | 19970124 |
| | EP 877937 | B1 | 20020522 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | CN 1209875 | A | 19990303 | CN 1997-191904 | 19970124 |
| | BR 9707204 | A | 19991228 | BR 1997-7204 | 19970124 |
| | RU 2174014 | C2 | 20010927 | RU 1998-116294 | 19970124 |
| | IL 125442 | A1 | 20020310 | IL 1997-125442 | 19970124 |
| | AT 217971 | E | 20020615 | AT 1997-900712 | 19970124 |
| | ES 2177922 | T3 | 20021216 | ES 1997-900712 | 19970124 |
| | ZA 9700669 | A | 19980625 | ZA 1997-669 | 19971227 |
| | NO 9803300 | A | 19980925 | NO 1998-3300 | 19980716 |
| | US 6221578 | B1 | 20010424 | US 1998-117217 | 19980724 |
| | US 2002042679 | A1 | 20020411 | US 2000-735487 | 20001214 |
| | US 6528251 | B2 | 20030304 | | |
| PRAI | EP 1996-200175 | A | 19960126 | | |
| | WO 1997-IB71 | W | 19970124 | | |
| | US 1998-117217 | A3 | 19980724 | | |

L19 ANSWER 36 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1997:262832 CAPLUS
DN 126:343796
TI The design and synthesis of nucleoside triphosphate isosteres as potential inhibitors of HIV reverse transcriptase
AU Weaver, Richard; Gilbert, Ian H.
CS Welsh School Pharmacy, Univ. Wales, Cardiff, CF1 3XF, UK
SO Tetrahedron (1997), 53(15), 5537-5562
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English

L19 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:594429 CAPLUS
DN 125:264892
TI Nasal absorption of 2',3'-didehydro-3'-deoxythymidine (D4T) and its esters in rats
AU Yajima, Toshiyuki; Hasegawa, Tetsuya; Juni, Kazuhiko; Saneyoshi, Mineo; Kawaguchi, Takeo
CS Faculty of Pharmaceutical Sciences, Josai Univ., Sakado, 350-02, Japan
SO Biological & Pharmaceutical Bulletin (1996), 19(9), 1234-1237
CODEN: BPBLEO; ISSN: 0918-6158
PB Pharmaceutical Society of Japan
DT Journal
LA English

L19 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:524251 CAPLUS
DN 125:196243
TI Process for bulk-scale preparation of 2',3'-didehydro-3'-dideoxythymidine
IN Skonezny, Paul M.; Eisenreich, Emerich; Stark, Derron R.; Boyhan, Brenda T.; Baker, Stephen R.
PA Bristol-Myers Squibb Co., USA
SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 152,155, abandoned.

CODEN: USXXAM

DT Patent
LA English
FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | US 5539099 | A | 19960723 | US 1994-309636 | 19940923 |
| | TW 399060 | B | 20000721 | TW 1994-83109894 | 19941026 |
| | EP 653435 | A1 | 19950517 | EP 1994-402483 | 19941103 |
| | EP 653435 | B1 | 19970205 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | AT 148707 | E | 19970215 | AT 1994-402483 | 19941103 |
| | ES 2098884 | T3 | 19970501 | ES 1994-402483 | 19941103 |
| | IL 111570 | A1 | 20010724 | IL 1994-111570 | 19941109 |
| | FI 9405322 | A | 19950516 | FI 1994-5322 | 19941111 |
| | AU 9478803 | A1 | 19950601 | AU 1994-78803 | 19941114 |
| | AU 686249 | B2 | 19980205 | | |
| | HU 69171 | A2 | 19950828 | HU 1994-3256 | 19941114 |
| | CA 2135853 | AA | 19950516 | CA 1994-2135853 | 19941115 |
| | JP 07196682 | A2 | 19950801 | JP 1994-315431 | 19941115 |
| | CN 1107856 | A | 19950906 | CN 1994-120105 | 19941115 |
| | CN 1043646 | B | 19990616 | | |
| | CN 1215057 | A | 19990428 | CN 1998-116706 | 19980725 |
| | CN 1069648 | B | 20010815 | | |
| PRAI | US 1993-152155 | B2 | 19931115 | | |
| | US 1993-152778 | B2 | 19931115 | | |
| | US 1994-309636 | A | 19940923 | | |

L19 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1996:430706 CAPLUS

DN 125:157743

TI Novel nucleoside phosphoramidates as inhibitors of HIV: studies on the stereochemical requirements of the phosphoramidate amino acid

AU McGuigan, C.; Salgado, A.; Yarnold, C.; Harries, T. Y.; De Clercq, E.; Balzarini, J.

CS Welsh Sch. Pharm., Univ. Wales Cardiff, Cardiff, CF1 3XF, UK

SO Antiviral Chemistry & Chemotherapy (1996), 7(4), 184-188

CODEN: ACCHEH; ISSN: 0956-3202

PB Blackwell

DT Journal

LA English

L19 ANSWER 40 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1996:380127 CAPLUS

DN 125:115042

TI Asymmetric Synthesis of Nucleosides via Molybdenum-Catalyzed Alkynol Cycloisomerization Coupled with Stereoselective Glycosylations of Deoxyfuranose Glycals and 3-Amidofuranose Glycals

AU McDonald, Frank E.; Gleason, Mark M.

CS Department of Chemistry, Northwestern University, Evanston, IL, 60208-3113, USA

SO Journal of the American Chemical Society (1996), 118(28), 6648-6659

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 125:115042

L19 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1995:812971 CAPLUS

DN 123:228218

TI Combination of quinoxalines and nucleosides for treating viral infection

and preparation of the quinoxalines.

IN Meichsner, Christoph; Riess, Guenther; Kleim, Joerg Peter; Roesner,
Manfred; Paessens, Arno; Blunck, Martin
PA Hoechst A.-G., Germany; Aventis Pharma Deutschland GmbH
SO Eur. Pat. Appl., 69 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 657166 | A1 | 19950614 | EP 1994-119146 | 19941205 |
| | EP 657166 | B1 | 20030409 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | DE 4342024 | A1 | 19950614 | DE 1993-4342024 | 19931209 |
| | AT 236642 | E | 20030415 | AT 1994-119146 | 19941205 |
| | CN 1108935 | A | 19950927 | CN 1994-119877 | 19941207 |
| | CA 2137605 | AA | 19950610 | CA 1994-2137605 | 19941208 |
| | AU 9480421 | A1 | 19950615 | AU 1994-80421 | 19941208 |
| | AU 697486 | B2 | 19981008 | | |
| | ZA 9409785 | A | 19950712 | ZA 1994-9785 | 19941208 |
| | JP 07196511 | A2 | 19950801 | JP 1994-330455 | 19941208 |
| | HU 70037 | A2 | 19950928 | HU 1994-3518 | 19941208 |
| | HU 221498 | B | 20021028 | | |
| PRAI | DE 1993-4342024 | A | 19931209 | | |
| OS | CASREACT 123:228218; MARPAT 123:228218 | | | | |

L19 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1995:703896 CAPLUS

DN 124:9257

TI Efficient transformation of thymidine into 2',3'-didehydro-2',3'-
dideoxythymidine (D4T) involving opening of a 2,3'-anhydro derivative by
phenylselenol.

AU Becouarn, Stefan; Czernecki, Stanislas; Valery, Jean-Marc

CS Laboratoire Chimie Glucides, Universite Pierre Marie Curie, Paris, 75005,
Fr.

SO Nucleosides & Nucleotides (1995), 14(6), 1227-32

CODEN: NUNUD5; ISSN: 0732-8311

PB Dekker

DT Journal

LA English

OS CASREACT 124:9257

L19 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1995:662363 CAPLUS

DN 123:56508

TI Preparation of (arylhydroxymethyl)phosphonate esters of nucleoside analogs
and related compounds as drugs.

IN Uhlmann, Eugen; Meier, Chris

PA Hoechst A.-G., Germany

SO Ger. Offen., 25 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | DE 4321946 | A1 | 19950112 | DE 1993-4321946 | 19930701 |
| | CA 2165971 | AA | 19950112 | CA 1994-2165971 | 19940629 |
| | WO 9501363 | A1 | 19950112 | WO 1994-EP2121 | 19940629 |
| | W: AU, CA, FI, JP, NO, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |

| | | | | |
|---|----|----------|----------------|----------|
| AU 9470735 | A1 | 19950124 | AU 1994-70735 | 19940629 |
| AU 698928 | B2 | 19981112 | | |
| EP 707591 | A1 | 19960424 | EP 1994-919670 | 19940629 |
| EP 707591 | B1 | 20010926 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| JP 08512039 | T2 | 19961217 | JP 1994-503269 | 19940629 |
| AT 206130 | E | 20011015 | AT 1994-919670 | 19940629 |
| ES 2165391 | T3 | 20020316 | ES 1994-919670 | 19940629 |
| NO 9505352 | A | 19960214 | NO 1995-5352 | 19951229 |
| FI 9506341 | A | 19960219 | FI 1995-6341 | 19951229 |
| US 6028182 | A | 20000222 | US 1996-578686 | 19960102 |
| PRAI DE 1993-4321946 | A | 19930701 | | |
| WO 1994-EP2121 | W | 19940629 | | |
| OS MARPAT 123:56508 | | | | |

L19 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1995:511464 CAPLUS

DN 122:265932

TI Preparation of nucleoside analog fatty esters as antiviral compounds

IN Boerretzen, Bernt; Dalen, Are; Myhren, Finn; Stokke, Kjell Torgeir

PA Norsk Hydro A/S, Norway

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9422887 | A1 | 19941013 | WO 1994-NO71 | 19940405 |
| | W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2158853 | AA | 19941013 | CA 1994-2158853 | 19940405 |
| | AU 9465141 | A1 | 19941024 | AU 1994-65141 | 19940405 |
| | AU 685104 | B2 | 19980115 | | |
| | EP 693077 | A1 | 19960124 | EP 1994-912709 | 19940405 |
| | EP 693077 | B1 | 19980923 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 08508477 | T2 | 19960910 | JP 1994-521952 | 19940405 |
| | JP 3049258 | B2 | 20000605 | | |
| | HU 73659 | A2 | 19960930 | HU 1995-2896 | 19940405 |
| | AT 171457 | E | 19981015 | AT 1994-912709 | 19940405 |
| | ES 2124883 | T3 | 19990216 | ES 1994-912709 | 19940405 |
| | RU 2139884 | C1 | 19991020 | RU 1995-119386 | 19940405 |
| | PL 177263 | B1 | 19991029 | PL 1994-310970 | 19940405 |
| | CZ 287755 | B6 | 20010117 | CZ 1995-2593 | 19940405 |
| | SK 281231 | B6 | 20010118 | SK 1995-1233 | 19940405 |
| | NO 9503768 | A | 19951110 | NO 1995-3768 | 19950922 |
| | FI 9504727 | A | 19951004 | FI 1995-4727 | 19951004 |
| | US 6153594 | A | 20001128 | US 1995-532754 | 19951129 |
| | HK 1003437 | A1 | 20000707 | HK 1998-102521 | 19980324 |
| | US 6335322 | B1 | 20020101 | US 1999-435641 | 19991109 |
| PRAI | GB 1993-7043 | A | 19930405 | | |
| | WO 1994-NO71 | W | 19940405 | | |
| | GB 1995-15279 | A | 19950725 | | |
| | US 1995-532754 | A2 | 19951129 | | |
| | US 1998-983483 | A3 | 19980526 | | |
| OS | CASREACT 122:265932; MARPAT 122:265932 | | | | |

L19 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1995:213452 CAPLUS
 DN 122:133729
 TI A phosphoramidite-based synthesis of phosphoramidate amino acid diesters
 of antiviral nucleosides
 AU Abraham, Timothy W.; Wagner, Carston R.
 CS College Pharmacy, Univ. Minnesota, Minneapolis, MN, 55455, USA
 SO Nucleosides & Nucleotides (1994), 13(9), 1891-903
 CODEN: NUNUD5; ISSN: 0732-8311
 PB Dekker
 DT Journal
 LA English
 OS CASREACT 122:133729

L19 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:173200 CAPLUS
 DN 120:173200
 TI Prodrugs of 2',3'-didehydro-3'-deoxythymidine
 AU Hasegawa, Tetsuya; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo;
 Kawaguchi, Takeo
 CS Fac. Pharm. Sci., Josai Univ., Saitama, 350-02, Japan
 SO Journal of Pharmaceutical Sciences (1993), 82(12), 1232-6
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English

L19 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:116622 CAPLUS
 DN 120:116622
 TI Prodrugs of 2',3'-Didehydro-3'-deoxythymidine (D4T): Synthesis, Antiviral
 Activity, and Rapid Pharmacokinetic Evaluation
 AU Tortolani, David R.; Russell, John W.; Whiterock, Valerie J.; Hitchcock,
 Michael J. M.; Ghazzouli, Ismail; Martin, John C.; Mansuri, Muzammil M.;
 Starrett, John E., Jr.
 CS Pharmaceutical Research Institute, Bristol-Myers Squibb Company,
 Wallingford, CT, 06492-7660., USA
 SO Journal of Pharmaceutical Sciences (1994), 83(3), 339-43
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English

L19 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2003 ACS
 AN 1993:480205 CAPLUS
 DN 119:80205
 TI Targeted drug delivery via mixed phosphate derivatives
 IN Bodor, Nicholas S.
 PA University of Florida, USA
 SO PCT Int. Appl., 248 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 9217185 | A1 | 19921015 | WO 1992-US2239 | 19920327 |
| | W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, | | | | |
| | KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US | | | | |
| | RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, | | | | |
| | GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG | | | | |
| | CA 2108041 | AA | 19920930 | CA 1992-2108041 | 19920327 |
| | AU 9216748 | A1 | 19921102 | AU 1992-16748 | 19920327 |
| | AU 668506 | B2 | 19960509 | | |
| | EP 577725 | A1 | 19940112 | EP 1992-909373 | 19920327 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
 JP 06510020 T2 19941110 JP 1992-508920 19920327
 PRAI US 1991-677304 19910329
 WO 1992-US2239 19920327
 OS MARPAT 119:80205

L19 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
 AN 1992:511992 CAPLUS
 DN 117:111992
 TI Phosphonate derivatives of certain nucleosides
 IN Halazy, Serge; Casara, Patrick; Neises, Bernhard; Jund, Karin
 PA Merrell Dow Pharmaceuticals, Inc., USA
 SO Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 477454 | A1 | 19920401 | EP 1990-402695 | 19900928 |
| | R: FR | | | | |
| | EP 479640 | A2 | 19920408 | EP 1991-402517 | 19910923 |
| | EP 479640 | A3 | 19930127 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | JP 04316589 | A2 | 19921106 | JP 1991-274878 | 19910927 |
| PRAI | EP 1990-402695 | | 19900928 | | |
| OS | MARPAT 117:111992 | | | | |

L19 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:435571 CAPLUS
 DN 115:35571
 TI Percutaneous penetration of 2',3'-didehydro-3'-deoxythymidine (D4T) and its **ester** prodrugs through rat skin
 AU Kawaguchi, Takeo; Hasegawa, Tetsuya; Endoh, Hirotaka; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo
 CS Life Sci. Res. Cent., Josai Univ., Saitama, Japan
 SO Drug Delivery System (1991), 6(1), 57-60
 CODEN: DDSYEI; ISSN: 0913-5006
 DT Journal
 LA Japanese

L19 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:164714 CAPLUS
 DN 114:164714
 TI Preparation of fatty acid derivatives of nucleosides or acyclic nucleosides as antiviral agents
 IN Horrobin, David Frederick; Stewart, John Charles Marshall; Winther, Michael David
 PA Efamol Holdings PLC, UK
 SO Eur. Pat. Appl., 26 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | EP 393920 | A2 | 19901024 | EP 1990-303904 | 19900411 |
| | EP 393920 | A3 | 19910703 | | |
| | EP 393920 | B1 | 19970709 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | US 5216142 | A | 19930601 | US 1990-521075 | 19900410 |
| | EP 693498 | A1 | 19960124 | EP 1995-114526 | 19900411 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

| | | | | |
|-------------------|----|----------|-----------------|----------|
| AT 155142 | E | 19970715 | AT 1990-303904 | 19900411 |
| ES 2108686 | T3 | 19980101 | ES 1990-303904 | 19900411 |
| CA 2014662 | AA | 19901017 | CA 1990-2014662 | 19900417 |
| CA 2014662 | C | 20020917 | | |
| AU 9053290 | A1 | 19901018 | AU 1990-53290 | 19900417 |
| AU 637362 | B2 | 19930527 | | |
| JP 02304084 | A2 | 19901217 | JP 1990-99445 | 19900417 |
| JP 2952505 | B2 | 19990927 | | |
| ZA 9002868 | A | 19910227 | ZA 1990-2868 | 19900417 |
| US 5276020 | A | 19940104 | US 1992-990190 | 19921214 |
| PRAI GB 1989-8646 | A | 19890417 | | |
| GB 1989-21266 | A | 19890920 | | |
| US 1990-521075 | A3 | 19900410 | | |
| EP 1990-303904 | A3 | 19900411 | | |

L19 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1990:503397 CAPLUS

DN 113:103397

TI Porphyrin and phthalocyanine antiviral compositions

IN Schinazi, Raymond F.; Dixon, Dabney White; Marzilli, Luigi G.

PA Georgia State University Foundation, Inc., USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 8911277 | A2 | 19891130 | WO 1989-US2256 | 19890523 |
| | WO 8911277 | A3 | 19891228 | | |
| | W: AU, DK, FI, JP, KR, NO | | | | |
| | RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE | | | | |
| | US 5192788 | A | 19930309 | US 1988-197764 | 19880523 |
| | US 5109016 | A | 19920428 | US 1989-355499 | 19890522 |
| | AU 8938306 | A1 | 19891212 | AU 1989-38306 | 19890523 |
| | US 5281616 | A | 19940125 | US 1992-873415 | 19920424 |
| PRAI | US 1988-197764 | | 19880523 | | |
| | US 1989-355499 | | 19890522 | | |
| | US 1989-355499 | | 19890522 | | |
| | US 1989-355499 | | 19890522 | | |
| | US 1989-355499 | | 19890522 | | |
| | US 1989-355499 | | 19890522 | | |
| | WO 1989-US2256 | | 19890523 | | |

L19 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1989:115257 CAPLUS

DN 110:115257

TI A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain

AU Palomino, Eduardo; Kessel, David; Horwitz, Jerome P.

CS Sch. Medicine, Wayne State Univ., Detroit, MI, 48201, USA

SO Journal of Medicinal Chemistry (1989), 32(3), 622-5

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 110:115257

L19 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1970:79401 CAPLUS

DN 72:79401

TI Synthesis of some nucleotides derived from 3'-deoxythymidine

AU Russell, Alan F.; Moffatt, J. G.
CS Inst. of Mol. Biol., Palo Alto, CA, USA
SO Biochemistry (1969), 8(12), 4889-96
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English

=> d 119 50 53 54 46 47 all

L19 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1991:435571 CAPLUS

DN 115:35571

TI Percutaneous penetration of 2',3'-didehydro-3'-deoxythymidine (D4T) and its **ester** prodrugs through rat skin

AU Kawaguchi, Takeo; Hasegawa, Tetsuya; Endoh, Hirotaka; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo

CS Life Sci. Res. Cent., Josai Univ., Saitama, Japan

SO Drug Delivery System (1991), 6(1), 57-60

CODEN: DDSYEI; ISSN: 0913-5006

DT Journal

LA Japanese

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1

AB In an attempt to develop a transdermal therapeutic system for the virucidal agents 2',3'-didehydro-3'-deoxythymidine (D4T) and its lipophilic prodrugs, percutaneous penetration of the drugs was examd. through the rat skin. The ability of penetration enhancers (azone and l-menthol) to increase the transdermal delivery of the drugs was evaluated in excised rat skin. Azone and l-menthol showed an enhancing effect on the penetration of D4T and its 5'-acetate at a concn. of 3% in water. The penetration of the 5'-octanoate was very small even in the presence of the enhancers. A D4T suspension contg. 3% l-menthol was applied on the abdominal skin and blood plasma concns. were measured. D4T was detected in plasma 12 after the application and stable plasma concns. (1-3 .mu.M) were maintained for 8 h.

ST didehydrodeoxythymidine prodrug transdermal formulation pharmacokinetics; skin didehydrodeoxythymidine prodrug penetration pharmacokinetics

IT Skin, metabolism

(didehydrodeoxythymidine and **ester** prodrugs penetration of, from transdermal formulations)

IT Drug bioavailability

(of didehydrodeoxythymidine and **ester** prodrugs, from transdermal formulations)

IT Biological transport

(absorption, of didehydrodeoxythymidine and **ester** prodrugs, from transdermal formulations)

IT Pharmaceutical dosage forms

(transdermal, prodrugs, of didehydrodeoxythymidine and **ester**, pharmacokinetics of)

IT 2216-51-5 59227-89-3, Azone

RL: BIOL (Biological study)

(as formulation component for didehydrodeoxythymidine and prodrugs, pharmacokinetics in relation to)

IT 3056-17-5, 2',3'-Didehydro-3'-deoxythymidine 77421-68-2
134767-53-6

RL: BIOL (Biological study)



(transdermal formulation of, pharmacokinetics of, azone and menthol in)

L19 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1989:115257 CAPLUS

DN 110:115257

TI A dihydropyridine carrier system for sustained delivery of
 2',3'-dideoxynucleosides to the brain
 AU Palomino, Eduardo; Kessel, David; Horwitz, Jerome P.
 CS Sch. Medicine, Wayne State Univ., Detroit, MI, 48201, USA
 SO Journal of Medicinal Chemistry (1989), 32(3), 622-5
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 CC 33-9 (Carbohydrates)
 Section cross-reference(s): 1
 OS CASREACT 110:115257
 GI



AB The present study evaluates the utility of the dihydropyridine .dblharw. pyridinium salt redox system for the specific delivery and sustained release of a model 2',3'-dideoxynucleotide to the brain of mice as the initial effort in a search for agents that may prove effective in reversing the complicating nuerol. disorders of AIDS. The unsatd. nucleoside 2',3'-didehydro-2',3'-dideoxythymidine (I), which is effective in protecting ATH8 cells against the cytopathogenicity of HIV-1, was converted to the corresponding N-methyl-1,4-dihydronicotinate deriv., II, in 3 steps. The 5'-O-nicotinate ester, III, obtained by reaction of I with nicotinoyl chloride, was converted in quant. yield to the N-methylpyridinium salt IV on treatment with MeI in acetone. Redn. of the latter with Na2S2O4 gave II in 50% yield. Pseudo-first-order rate consts. for the oxidn. of II to III were obsd. in plasma and in homogenates of mouse liver and brain. None of the chem. delivery system II could be detected in the brain of female BDF/1 mice at 1 h postinjection. The peak level of IV in the brain occurred at 3 h with a half-life of 25 h. Both I and N-methylnicotinic acid were readily identified by HPLC in brain homogenate derived from mice injected (25 mg/kg) with II. TLC showed a low level penetration of mouse brain by I (0.44 .mu.g/g wet tissue)

following injection of the corresponding labeled [methyl-3H]-2',3'-unsatd. nucleoside (25 mg/kg). The data indicate that II crosses the blood-brain barrier to be oxidized by cerebral tissue to the ionic structure IV which is locked therein. The sustained local release of a 2',3'-dideoxynucleoside, such as I, from a chem. delivery system (II) represents a potentially useful approach to the treatment of AIDS dementia complex.

- ST dihydropyridine carrier system dideoxynucleoside brain; nucleoside dideoxy carrier system brain; thymidine dideoxydidehydro carrier system brain; AIDS dideoxynucleoside carrier system brain
- IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, dihydropyridine carrier system for sustained delivery of dideoxynucleosides to brain for)
- IT Nucleosides, biological studies
RL: BIOL (Biological study)
(dideoxy, dihydropyridine carrier system for sustained delivery of, to brain, in AIDS treatment)
- IT 10400-19-8, Nicotinoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, with didehydrodideoxythymidine)
- IT 3056-17-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, with nicotinoyl chloride)
- IT 118869-93-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and quaternization of, with Me iodide)
- IT 118869-94-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and redn. of)
- IT 7775-14-6P, Sodium dithionite
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
- IT 118869-95-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for sustained delivery of dideoxynucleoside to the brain, for AIDS treatment)

L19 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1970:79401 CAPLUS

DN 72:79401

TI Synthesis of some nucleotides derived from 3'-deoxythymidine

AU Russell, Alan F.; Moffatt, J. G.

CS Inst. of Mol. Biol., Palo Alto, CA, USA

SO Biochemistry (1969), 8(12), 4889-96

CODEN: BICHAW; ISSN: 0006-2960

DT Journal

LA English

CC 33 (Carbohydrates)

AB Phosphorylation of 3'-deoxy-3'-iodothymidine gives the corresponding 3'-deoxy-3'-iodothymidine 5'-phosphate in high yield. Activation of the phosphate group can be achieved by formation of the phosphoromorpholidate under anhydrous conditions, and subsequent condensation with tributylammonium pyrophosphate in anhydrous dimethyl sulfoxide gives 3'-deoxy-3'-iodothymidine 5'-triphosphate in modest yield. The latter reaction is complicated by simultaneous dehydrohalogenation giving the related 2',3'-unsatd. nucleoside 5'-triphosphate and by extensive intramol. displacement of iodide ion by phosphate giving a 3',5'-cyclic phosphate with the 2-deoxy-.beta.-D-threo-pentofuranosyl configuration. The same spectrum of products is obtained using 3'-deoxy-3'-iodothymidine 5'-phosphoroimid-azolate prep. from the parent

nucleoside and triimidazolephosphine oxide. The various products are characterized by enzymic and spectroscopic techniques, and redn. of either the iodotriphosphate or the unsatd. triphosphate with H and Pd gives 3'-deoxythymidine 5'-triphosphate. Phosphorylation of 1-(2-deoxy-.beta.-D-threo-pentofuranosyl)thymine with diphenyl phosphorochloridate gives the cryst. 5'-diphenyl phosphate **ester** that can be converted with base into the same 3',5'-cyclic phosphate obtained as a by-product during prepn. of the triphosphates above. A pair of 3',5'-cyclic phosphate triester diastereoisomeric about their phosphorus atoms are intermediates in this cyclization reaction.

ST nucleotides prepn; deoxythymidines iodo; thymidines phosphorylation; phosphorylation thymidines

IT Nucleotides, preparation

RL: PREP (Preparation)

(3'-deoxythymidine derivs.)

IT 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin, nucleoside derivs.

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

IT 611-60-9P 15981-92-7P 16053-52-4P 26194-88-7P 27641-12-9P

27641-15-2P 27641-16-3P 27646-57-7P 27646-58-8P **27646-59-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

L19 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1994:173200 CAPLUS

DN 120:173200

TI Prodrugs of 2',3'-didehydro-3'-deoxythymidine

AU Hasegawa, Tetsuya; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo; Kawaguchi, Takeo

CS Fac. Pharm. Sci., Josai Univ., Saitama, 350-02, Japan

SO Journal of Pharmaceutical Sciences (1993), 82(12), 1232-6

CODEN: JPMSAE; ISSN: 0022-3549


DT Journal

LA English

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 33

GI



I

AB Six **ester** prodrugs of 2',3'-didehydro-3'-deoxythymidine (I) were prepd., and their physicochem. properties evaluated. Marked differences were obsd. All of the prodrugs were chem. stable within the pH range 2-7. Hydrolysis of these esters was obsd. in all cases for 4 rat enzyme systems (plasma, liver, duodenum, and kidney), with I being regenerated. I or the prodrug was administered orally to rats, and the plasma concns. of I and a corresponding prodrug were measured. The half-life of I after i.v.

administration was 35.9 min. The half-life calcd. from the terminal phase and the max. concn. in plasma following oral administration of I were 35.9 min and 48.4 .mu.M, resp. After oral prodrug administration (with water or olive oil as a solvent), though none of the prodrugs was detected in plasma except for 5'-hemisuccinyl deriv. of I and 5'-hemiglutaryl deriv. of I with olive oil as a solvent, retention time of plasma I concn. was extended and the elevated I concn. in plasma decreased.

ST prodrug didehydrodeoxythymidine prepn; dehydrodeoxythymidine prodrug
prepn; hydrolysis didehydrodeoxythymidine prodrug
IT Blood plasma
Kidney
Liver
(didehydrodeoxythymidine prodrugs hydrolysis in)
IT Hydrolysis
Partition
Solubility
(of didehydrodeoxythymidine prodrugs)
IT Drug bioavailability
(of dehydrodeoxythymidine, from prodrugs)
IT Intestine
(duodenum, didehydrodeoxythymidine prodrugs hydrolysis in)
IT 77421-68-2P 122567-97-9P 126209-27-6P 134767-53-6P 152336-78-2P
152336-79-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis and physicochem. properties of, as
didehydrodeoxythymidine prodrug)
IT 3056-17-5, 2',3'-Didehydro-3'-deoxythymidine
RL: BIOL (Biological study)
(prodrugs for, prepn. and hydrolysis and physicochem. properties of)

L19 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1994:116622 CAPLUS

DN 120:116622

TI Prodrugs of 2',3'-Didehydro-3'-deoxythymidine (D4T): Synthesis, Antiviral Activity, and Rapid Pharmacokinetic Evaluation

AU Tortolani, David R.; Russell, John W.; Whiterock, Valerie J.; Hitchcock, Michael J. M.; Ghazzouli, Ismail; Martin, John C.; Mansuri, Muzammil M.; Starrett, John E., Jr.

CS Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Wallingford, CT, 06492-7660., USA

SO Journal of Pharmaceutical Sciences (1994), 83(3), 339-43
CODEN: JPMSAE; ISSN: 0022-3549

DT Journal

LA English

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 33

AB A series of 5'-derivs. and modified pyrimidine analogs of 2',3'-didehydro-3'-deoxythymidine (d4T, stavudine) were synthesized to det. their potential as oral prodrugs of d4T. Utilizing a screen developed for the rapid evaluation of a variety of prodrugs in mice, it was detd. that 5'-acetate provided comparable plasma levels of d4T after oral administration of the prodrug to that when d4T was administered alone. The relative oral bioavailability of methoxy acetate and cyclohexyl carbonate derivs. was 79 and 41%, resp. The dihydropyridine ester did not provide detectable levels of d4T up to 1 h after oral administration of 6. Thiopyrimidine and aminopyrimidine derivs. also failed to provide measurable levels of d4T after oral administration. 5'-Derivs. showed similar activity to that of d4T against HIV and MuLV, as did 5'-benzoyl-4-thio deriv. However, the corresponding 4-thio 5'-alc. deriv. was inactive.

ST stavudine prodrug prepn antiviral bioavailability

IT Virucides and Virustats

(didehydrodeoxythymidine prodrugs as, prepn. and pharmacokinetics of)

IT Drug bioavailability
(of didehydrodeoxythymidine prodrugs)

IT Virus, animal
(human immunodeficiency, treatment of, by didehydrodeoxythymidine prodrugs)

IT Pharmaceutical dosage forms
(prodrugs, of didehydrodeoxythymidine, prepn. and antiviral activity and pharmacokinetics of)

IT 118869-95-7
RL: BIOL (Biological study)
(antiviral activity and bioavailability of, as stavudine prodrug)

IT 3056-17-5, Stavudine
RL: RCT (Reactant); RACT (Reactant or reagent)
(antiviral activity and reactions of)

IT 5983-08-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amination and antiviral activity of, as stavudine prodrug)

IT 77421-68-2P 120826-44-0P 126209-28-7P 152917-61-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antiviral activity of, as stavudine prodrug)

IT 122567-98-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deprotection and antiviral activity of, as stavudine prodrug)

IT 126209-30-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with cyclohexanol)

IT 122567-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and thiation of)

IT 530-62-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with stavudine)

IT 108-93-0, Cyclohexanol, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with stavudine deriv.)

=> s 19 and l11

L20 3 L9 AND L11

=> d 120 1-3

L20 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2003:97550 CAPLUS

DN 138:164674

TI Molecular markers for hepatocellular carcinoma and their use in diagnosis and therapy

IN Debuschewitz, Sabine; Jobst, Juergen; Kaiser, Stephan

PA Germany

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

PI WO 2003010336 A2 20030206 WO 2002-EP8305 20020725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
DE 10136273 A1 20030213 DE 2001-10136273 20010725
PRAI DE 2001-10136273 A 20010725

L20 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2001:454452 CAPLUS
DN 135:313108
TI In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent d4T-5'-(P-bromophenyl methoxyalaninyl phosphate) (sampidine) in mice
AU Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS Drug Discovery Program, Department of Pharmaceutical Sciences, Parker Hughes Institute, St. Paul, MN, 55113, USA
SO Drug Metabolism and Disposition (2001), 29(7), 1035-1041
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1996:365474 CAPLUS
DN 125:58113
TI Preparation of arylthio and dithiobisarylamide compounds as antibacterial and antiviral agents
IN Domagala, John Michael; Elslager, Edward Faith; Gogliotti, Rocco Dean
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9604242 | A1 | 19960215 | WO 1995-US8802 | 19950711 |
| W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, VN | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 5463122 | A | 19951031 | US 1994-286816 | 19940805 |
| US 5734081 | A | 19980331 | US 1995-446917 | 19950601 |
| AU 9530087 | A1 | 19960304 | AU 1995-30087 | 19950711 |
| AU 710806 | B2 | 19990930 | | |
| EP 775110 | A1 | 19970528 | EP 1995-926276 | 19950711 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| JP 10504292 | T2 | 19980428 | JP 1995-506523 | 19950711 |
| RU 2156236 | C2 | 20000920 | RU 1997-103207 | 19950711 |
| PL 181425 | B1 | 20010731 | PL 1995-318540 | 19950711 |
| FI 9700417 | A | 19970131 | FI 1997-417 | 19970131 |

| | | | | |
|---------------------|----|----------|----------------|----------|
| NO 9700495 | A | 19970402 | NO 1997-495 | 19970204 |
| BG 63301 | B1 | 20010928 | BG 1997-101189 | 19970204 |
| PRAI US 1994-286816 | A | 19940805 | | |
| US 1995-446917 | A | 19950601 | | |
| WO 1995-US8802 | W | 19950711 | | |
| OS MARPAT 125:58113 | | | | |

=> d 120 3 all

L20 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1996:365474 CAPLUS
DN 125:58113
TI Preparation of arylthio and dithiobisarylamide compounds as antibacterial and antiviral agents
IN Domagala, John Michael; Elslager, Edward Faith; Gogliotti, Rocco Dean
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C323-62
ICS C07C323-63; C07C323-67; C07D207-16; C07D239-42; C07D295-18; A61K031-165; A61K031-105
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 10, 63

FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9604242 | A1 | 19960215 | WO 1995-US8802 | 19950711 |
| W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, VN | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 5463122 | A | 19951031 | US 1994-286816 | 19940805 |
| US 5734081 | A | 19980331 | US 1995-446917 | 19950601 |
| AU 9530087 | A1 | 19960304 | AU 1995-30087 | 19950711 |
| AU 710806 | B2 | 19990930 | | |
| EP 775110 | A1 | 19970528 | EP 1995-926276 | 19950711 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| JP 10504292 | T2 | 19980428 | JP 1995-506523 | 19950711 |
| RU 2156236 | C2 | 20000920 | RU 1997-103207 | 19950711 |
| PL 181425 | B1 | 20010731 | PL 1995-318540 | 19950711 |
| FI 9700417 | A | 19970131 | FI 1997-417 | 19970131 |
| NO 9700495 | A | 19970402 | NO 1997-495 | 19970204 |
| BG 63301 | B1 | 20010928 | BG 1997-101189 | 19970204 |
| PRAI US 1994-286816 | A | 19940805 | | |
| US 1995-446917 | A | 19950601 | | |
| WO 1995-US8802 | W | 19950711 | | |

OS MARPAT 125:58113

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = monocyclic or bicyclic aryl which can contain up to 3 heteroatoms (e.g., O, S, N); R1, R2 = H, halogen, alkyl, alkoxy, cycloalkyl, OH, CN, NO2, etc.; X = (un)substituted amido, CHO, halocarbonyl, alkylcarbonyl, alkoxy carbonyl, etc.; Y = H, SZ; Z = H, halogen, alkyl, alkylcarbonyl, cycloalkyl, etc; n = 1, 2], useful as antibiotics and antiviral agents, are prepd. and I-contg. formulations presented. Thus, 2,2'-dithiobisbenzoyl chloride was reacted with 4-(aminosulfonyl)aniline, producing 2,2'-dithiobis-4'-[sulfamoylbenzanilide], m.p. 311-312.degree., which demonstrated a EC50 of 0.7 .mu.M in a H9/HIV-1 cell assay.

ST sulfamoylbenzanilide prepn antiviral agent; antibiotic prepn
sulfamoylbenzanilide; arylthio prepn antibacterial agent; HIV
antiviral agent prepn sulfamoylbenzanilide; AIDS treatment prepn
sulfamoylbenzanilide

IT Antibiotics
Bactericides, Disinfectants, and Antiseptics
Virucides and Virustats
(arylthio and dithiobisarylamide compds.)

IT Acquired immune deficiency syndrome
(arylthio and dithiobisarylamide compds. for treatment of)

IT 2752-94-5P 14208-44-7P 19532-46-8P 19532-48-0P 19602-84-7P
19602-86-9P 19602-89-2P 30018-07-6P 37010-19-8P 37038-17-8P
49755-40-0P 49755-48-8P 50383-29-4P 63956-06-9P 89011-97-2P
96835-63-1P 96835-64-2P 121451-38-5P 171744-40-4P 171744-41-5P
171744-42-6P 173590-72-2P 173590-73-3P 173590-74-4P 173590-78-8P
177785-53-4P 177785-54-5P 177785-55-6P 177785-56-7P 177785-57-8P
177785-58-9P 177785-59-0P 177785-60-3P 177785-61-4P 177785-62-5P
177785-63-6P 177785-64-7P 177785-65-8P 177785-66-9P 177785-67-0P
177785-68-1P 177785-69-2P 177785-70-5P 177785-71-6P 177785-72-7P
177785-73-8P 177785-74-9P 177785-75-0P 177785-76-1P 177785-77-2P
177785-78-3P 177785-79-4P 177785-80-7P 177785-81-8P 177785-82-9P
177785-83-0P 177785-84-1P 177785-85-2P 177785-86-3P 177785-87-4P
177785-88-5P 177785-89-6P 177785-90-9P 177785-91-0P 177785-92-1P
177785-93-2P 177785-94-3P 177785-95-4P 177785-96-5P 177785-97-6P
177785-98-7P 177785-99-8P 177786-00-4P 177786-01-5P 177786-02-6P
177786-03-7P 177786-04-8P 177786-05-9P 177786-06-0P 177786-07-1P
177786-08-2P 177786-09-3P 177786-10-6P 177786-11-7P 177786-12-8P
177786-13-9P 177786-14-0P 177786-15-1P 177786-16-2P 177786-17-3P
177786-18-4P 177786-19-5P 177786-20-8P 177786-21-9P 177786-22-0P
177786-23-1P 177786-24-2P 177786-25-3P 177786-26-4P 177786-27-5P
177786-28-6P 177786-29-7P 177786-30-0P 177786-31-1P 177786-32-2P
177786-33-3P 177786-34-4P 177786-35-5P 177786-36-6P 177786-37-7P
177786-38-8P 177786-39-9P 177786-40-2P 177786-41-3P 177786-42-4P
177786-43-5P 177786-44-6P 177786-45-7P 177786-46-8P 177786-47-9P
177786-49-1P 177786-50-4P 177786-51-5P 177786-52-6P 177786-53-7P
177786-54-8P 177786-55-9P 177786-56-0P 177786-57-1P 177786-58-2P
177786-59-3P 177786-60-6P 177786-61-7P 177786-62-8P 177786-63-9P
177786-64-0P 177786-65-1P 177786-66-2P 177786-67-3P 177786-68-4P
177786-69-5P 177786-70-8P 177786-71-9P 177786-72-0P 177786-73-1P
177786-74-2P 177932-76-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylthio and dithiobisarylamide compds. as antibacterial and
antiviral agents)

IT 56-91-7 63-74-1 68-35-9 75-09-2, reactions 79-42-5 90-04-0
95-53-4, reactions 95-64-7 95-76-1 96-27-5 98-18-0 99-09-2
100-01-6, reactions 104-94-9 107-95-9, .beta.-Alanine 108-24-7
108-98-5, Benzenethiol, reactions 110-18-9 110-91-8, Morpholine,
reactions 119-80-2 123-75-1, Pyrrolidine, reactions 138-37-4
144-80-9 147-93-3 328-74-5 371-40-4 393-11-3 443-79-8,
DL-Isoleucine 498-94-2, 4-Piperidinecarboxylic acid 540-37-4
554-00-7 578-54-1 591-19-5 591-54-8, 4-Pyrimidinamine 616-91-1
626-01-7 626-43-7 643-28-7 765-30-0, Cyclopropanamine 769-92-6
873-74-5 1197-18-8 1197-55-3 1538-75-6 1791-13-5 1801-99-6
1953-02-2 2038-03-1, 4-Morpholineethanamine 2516-96-3 2592-95-2
2757-23-5 2812-46-6 2835-68-9 3306-62-5 3483-12-3 3862-73-5
4369-80-6 4892-02-8 5082-74-6, 3-Pyrrolidinemethanol 5183-78-8
5305-59-9 5470-49-5 6919-61-5 7298-84-2 7449-74-3 7720-45-8
7750-45-0 7752-82-1 13363-59-2 13616-79-0 14597-58-1
14984-58-8 16588-15-1 16874-08-1 16874-17-2 18239-19-5
18239-23-1 19532-69-5 19532-70-8 19602-82-5 20557-42-0

20859-02-3 27738-89-2 27757-85-3, 2-Thiophenemethanamine 32677-01-3
 34297-27-3 39235-27-3 42807-86-3 50479-22-6 51537-21-4
 53448-09-2 53668-35-2 69320-89-4 75844-69-8 81223-41-8
 92906-21-3 147027-69-8 147027-78-9 147081-44-5 161879-13-6
 162089-06-7 171744-39-1 177785-39-6 177785-41-0 177785-42-1
 177785-43-2 177785-44-3 177785-45-4 177785-46-5 177785-47-6
 177785-48-7

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of arylthio and dithiobisarylamide compds. as antibacterial and
 antiviral agents)

IT 13363-60-5P 18239-20-8P 18239-22-0P 18394-74-6P 147027-70-1P
 147027-74-5P 177785-38-5P 177785-49-8P 177785-50-1P 177785-51-2P
 177785-52-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of arylthio and dithiobisarylamide compds. as antibacterial and
 antiviral agents)

=> s 19 and 114

L21 0 L9 AND L14

=> s 110 and 111

L22 2 L10 AND L11

=> d 122 1-2

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 2001:454452 CAPLUS

DN 135:313108

TI In vivo pharmacokinetics and metabolism of anti-human immunodeficiency
 virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine)
 in mice

AU Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.

CS Drug Discovery Program, Department of Pharmaceutical Sciences, Parker
 Hughes Institute, St. Paul, MN, 55113, USA

SO Drug Metabolism and Disposition (2001), 29(7), 1035-1041

CODEN: DMDSAI; ISSN: 0090-9556

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1998:293427 CAPLUS

DN 129:8597

TI Embedding and encapsulation of controlled release particles

IN Van Lengerich, Bernhard H.

PA Van Lengerich, Bernhard H., USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 9818610 | A1 | 19980507 | WO 1997-US18984 | 19971027 |
| | W: AU, CA, JP, NO, PL, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9749915 | A1 | 19980522 | AU 1997-49915 | 19971027 |
| | AU 744156 | B2 | 20020214 | | |

EP 935523 A1 19990818 EP 1997-912825 19971027
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2002511777 T2 20020416 JP 1998-520558 19971027
 NO 9902036 A 19990428 NO 1999-2036 19990428
 PRAI US 1996-29038P P 19961028
 US 1997-52717P P 19970716
 WO 1997-US18984 W 19971027
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 122 2 all

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1998:293427 CAPLUS

DN 129:8597

TI Embedding and encapsulation of controlled release particles

IN Van Lengerich, Bernhard H.

PA Van Lengerich, Bernhard H., USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM B29C047-04

ICS B01J013-04; A01N025-26

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 5

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9818610 | A1 | 19980507 | WO 1997-US18984 | 19971027 |
| | W: AU, CA, JP, NO, PL, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9749915 | A1 | 19980522 | AU 1997-49915 | 19971027 |
| | AU 744156 | B2 | 20020214 | | |
| | EP 935523 | A1 | 19990818 | EP 1997-912825 | 19971027 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002511777 | T2 | 20020416 | JP 1998-520558 | 19971027 |
| | NO 9902036 | A | 19990428 | NO 1999-2036 | 19990428 |
| PRAI | US 1996-29038P | P | 19961028 | | |
| | US 1997-52717P | P | 19970716 | | |
| | WO 1997-US18984 | W | 19971027 | | |

AB Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The addnl. component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temp. of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixt. The mixt. is extruded through a die without substantial

or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, glycerol monostearate, and vegetable oil.

- ST encapsulation controlled release particle
- IT Drug delivery systems
 - (controlled-release; embedding and encapsulation of controlled release particles)
- IT Antitumor agents
- IT Antiviral agents
- IT Encapsulation
 - (embedding and encapsulation of controlled release particles)
- IT Estrogens
- IT Polyoxyalkylenes, biological studies
- IT Tuberculin
- IT RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 - (embedding and encapsulation of controlled release particles)
- IT Antibiotics
- IT Antioxidants
- IT Detergents
- IT Emulsifying agents
- IT Extrusion, nonbiological
- IT Fats and Glyceridic oils, biological studies
- IT Fatty acids, biological studies
- IT Flavor
- IT Fungicides
- IT Glass transition
- IT Heat treatment
- IT Herbicides
- IT Hydrocolloids
- IT Insecticides
- IT Lipids, biological studies
- IT Paraffin waxes, biological studies
- IT Peptides, biological studies
- IT Perfumes
- IT Pesticides
- IT Plasticizers
- IT Polyolefins
- IT Polyurethanes, biological studies
- IT Proteins, general, biological studies
- IT Rodenticides
- IT Steroids, biological studies
- IT Surfactants
- IT Waxes
- IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (embedding and encapsulation of controlled release particles)
- IT Antibodies
- IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (monoclonal; embedding and encapsulation of controlled release particles)
- IT Drug delivery systems
 - (particles; embedding and encapsulation of controlled release particles)
- IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephentytoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2,

Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4,
 Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate
 50-63-5, Chloroquine phosphate 50-78-2, Acetylsalicylic acid 50-81-7,
 Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride
 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8,
 Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine
 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies
 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies
 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine
 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9,
 Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepe
 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5,
 Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1,
 Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone,
 biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1,
 Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium
 salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-64-8,
 Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1,
 Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan
 56-29-1, Hexobarbital 56-47-3, Desoxycorticosterone acetate 56-53-1,
 Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol
 56-84-8, L-Aspartic acid, biological studies 56-87-1, L-Lysine,
 biological studies 57-13-6, Urea, biological studies 57-22-7,
 Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin
 57-42-1, Meperidine 57-43-2, Amobarbital 57-47-6,
 Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol
 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone,
 biological studies 57-92-1, Streptomycin, biological studies 57-96-5,
 Sulfinpyrazone 58-00-4, Apomorphine 58-08-2, Caffeine, biological
 studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0
 58-25-3, Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyridamole
 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9,
 Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9,
 Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride
 58-85-5, Biotin 58-89-9, Lindane 58-93-5, Hydrochlorothiazide
 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid,
 biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin,
 biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid
 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7,
 Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4,
 Tyrosine, biological studies 60-54-8, Tetracycline 60-56-0,
 Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1,
 Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine
 hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine
 hydrochloride 61-90-5, Leucine, biological studies 62-31-7, Dopamine
 hydrochloride 62-44-2, Phenacetin 62-67-9, Nalorphine 62-90-8,
 Nandrolone phenpropionate 63-68-3, Methionine, biological studies
 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine
 hydrochloride 63-98-9, Phenacetamide 64-31-3, Morphine sulfate
 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8,
 Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8,
 Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone
 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 67-97-0,
 Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone
 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole
 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4,
 Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1,
 Histidine, biological studies 71-58-9, Medroxyprogesterone acetate
 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8
 72-14-0, Sulfathiazole 72-17-3, Sodium lactate 72-18-4, Valine,
 biological studies 72-19-5, L-Threonine, biological studies 72-33-3,
 Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan,

biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-44-4, Carisoprodol 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-22-0, Tetrahydrozoline 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Phenoxymethylpenicillin 87-33-2, ISDN 89-57-6, 5-Aminosalicylic acid 90-33-5, Hymecromone 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripeleminamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzene 103-86-6, Hydroxyamphetamine 103-90-2, Acetaminophen 104-28-9, Cinoxate 104-31-4, Benzonatate 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital 115-77-5, biological studies 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

IT 121-75-5, Malathion 123-31-9, 1,4-Benzenediol, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscipine 129-20-4, Oxyphenbutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clisoquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-47-0 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital sodium 144-14-9, Anileridine 144-48-9, Iodoacetamide 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-24-0, Diphenhydramine hydrochloride 147-52-4, Nafcillin 147-85-3, Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 152-97-6, Fluocortolone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrin 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]- 343-55-5, Dicloxacillin sodium

345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide
 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 359-83-1,
 Pentazocine 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide
 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9,
 Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone
 389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene
 426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2,
 Phenprocoumon 437-74-1, Xantinol nicotinate 439-14-5, Diazepam
 440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole
 446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone
 471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin
 479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine
 511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate
 514-65-8, Biperiden 518-47-8, Fluorescein sodium 519-37-9, Etofylline
 520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6,
 Propranolol 527-07-1, Sodium gluconate 532-03-6, Methocarbamol
 533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide
 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0,
 Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol
 549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaïne
 hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2,
 Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide
 hydrochloride 555-30-6, Methyldopa 557-34-6, Zinc acetate 562-10-7
 564-25-0, Doxycycline 577-11-7, Docusate sodium 579-56-6, Isoxsuprine
 hydrochloride 587-61-1, Propylidone 590-63-6, Bethanechol chloride
 595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1,
 Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1,
 Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine
 620-61-1, Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate
 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 638-23-3
 642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 652-67-5
 672-87-7, Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine
 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3,
 Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine
 777-11-7, Haloprogin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine
 hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7,
 Lincomycin hydrochloride 865-21-4, Vinblastine 894-71-3, Nortriptyline
 hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton
 969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafcillin sodium
 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride
 1077-28-7, Thiocetic acid 1094-08-2, Ethopropazine hydrochloride
 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9,
 Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin
 1151-11-7, Iodate calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin
 sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Iodate sodium
 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride
 1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1309-48-4,
 Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid
 1321-23-9, Chloroxylenol 1343-97-1, Selenium sulfate 1393-48-2,
 Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3,
 Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2,
 Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin
 sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin
 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9,
 Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin
 calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide
 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide
 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3,
 Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene
 hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8,
 Phenmetrazine hydrochloride 1808-12-4, Bromodiphenhydramine
 hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3,

Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3, Meclocycline

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

IT 2022-85-7, Flucytosine 2030-63-9; Clofazimine 2062-78-4, Pimozide 2098-66-0, Cyproterone 2179-37-5, Bencyclane 2192-20-3, Hydroxyzine hydrochloride 2315-02-8, Oxymetazoline hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 2955-38-6, Prazepam 2998-57-4, Estramustine 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatadine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 6890-40-0, Histamine phosphate 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, .beta.-Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts, biological studies 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts, biological studies 7440-39-3, Barium, biological studies 7440-69-9, Bismuth, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride (KCl), biological studies 7491-74-9, Piracetam 7553-56-2, Iodine, biological studies 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide (KI), biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide, biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7778-49-6, Potassium citrate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1, Ergoloid mesylates 9001-01-8, Kallidinogenase 9001-73-4, Papain 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9002-86-2, Pvc 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8, Pvp 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-53-9, Dextrin 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanazolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12619-70-4, Cyclodextrin 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin

13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3, Dihydroxyaluminum aminoacetate 14009-24-6, Drotaverine 14028-44-5, Amoxapine 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15078-28-1, Nitroprusside 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalixin 15687-27-1 15687-41-9, Oxyfedrine 16482-55-6, Dihydroxyaluminum sodium carbonate 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrel sulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4 22916-47-8 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probuco 23593-75-1, Clotrimazole 23869-24-1, O-(.beta.-Hydroxyethyl)-rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25086-89-9, Vinyl acetate-N-vinylpyrrolidinone copolymer 25155-18-4, Methylbenzethonium chloride 25167-80-0, Chlorophenol 25301-02-4, Tyloxapol 25322-68-3 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25717-80-0, Molsidomine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26652-09-5, Ritodrine 26675-46-7, Isoflurane 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepine 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenopropfen 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36688-78-5 36791-04-5 37270-89-6, Heparin calcium 37517-28-5, Amikacin 37517-30-9, Acebutolol 38194-50-2, Sulindac 38260-01-4, Trientine hydrochloride 38304-91-5, Minoxidil 38363-40-5, Penbutolol 38396-39-3, Bupivacaine 38821-53-3, Cephradine 39562-70-4, Nitrendipine 40828-46-4, Suprofen 41859-67-0, Bezafibrate 42200-33-9, Nadolol 42399-41-7, Diltiazem 42540-40-9, Cefamandole nafate 49562-28-9, Fenofibrate 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-69-6, Amcinonide 51481-61-9, Cimetidine 51781-06-7, Carteolol 52468-60-7, Flunarizine 53164-05-9, Acemetacin 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide 54182-58-0, Sucralfate 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-74-1, Praziquantel 55837-25-7, Buflomedil 55837-27-9, Piretanide

56392-17-7, Metoprolol tartrate 57109-90-7, Dipotassium chlorazepate
 57432-61-8, Methylergonovine maleate 57435-86-6, Premazepam
 58551-69-2, Carboprost tromethamine 59277-89-3, Acyclovir 59865-13-3,
 Cyclosporine 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60833-22-9,
 Pyridoxal 5'-phosphate glutamate 61177-45-5, Clavulanate potassium
 61489-71-2, Menotropin 61563-18-6, Soquinolol 62571-86-2, Captopril
 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 63659-18-7, Betaxolol
 64024-15-3, Pentazocine hydrochloride 64544-07-6, Cefuroxime axetil
 65277-42-1, Ketoconazole 65666-07-1, Silymarin 65899-73-2, Tioconazole
 66108-95-0, Iohexol 66357-35-5, Ranitidine 66711-21-5, Apraclonidine
 66734-13-2, Alclometasone dipropionate 68844-77-9, Astemizole
 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 74978-16-8, Magaldrate
 75330-75-5, Lovastatin 76095-16-4, Enalapril maleate 76420-72-9,
 Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril
 76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam
 78266-06-5, Mebrofenin 79350-37-1, Cefixime 81103-11-9, Clarithromycin
 83200-10-6, Anipamil 83905-01-5, Azithromycin 85721-33-1,
 Ciprofloxacin 92665-29-7, Cefprozil 102188-40-9, Acromycin
 150977-36-9, Bromelain

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses)
 (embedding and encapsulation of controlled release particles)

IT 9001-92-7, Protease

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, HIV; embedding and encapsulation of controlled
 release particles)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Carr; US 5183690 A 1993 CAPLUS
- (2) Chan; US 5075058 A 1991
- (3) Katzen; US 3786123 A 1974 CAPLUS
- (4) Katzen; US 3962416 A 1976 CAPLUS
- (5) McMahon; US 5466460 A 1995 CAPLUS

=> s l10 and l14

L23 1 L10 AND L14

=> d l23 1 all

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 1998:618371 CAPLUS

DN 129:255004

TI Prophylactic and therapeutic methods for ocular degenerative diseases and
 inflammations, and histidine compositions therefor

IN Thomas, Peter G.

PA Cytos Pharmaceuticals LLC, USA

SO U.S., 10 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A01N043-50

ICS C07D233-60

NCL 514399000

CC 1-12 (Pharmacology)

Section cross-reference(s): 62, 63

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | US 5811446 | A | 19980922 | US 1997-839805 | 19970418 |
| | WO 9847366 | A1 | 19981029 | WO 1998-US7319 | 19980417 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9873583 A1 19981113 AU 1998-73583 19980417

PRAI US 1997-839805 19970418

WO 1998-US7319 19980417

AB Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods.

ST histidine pharmaceutical eye degenerative disease inflammation

IT Ulcer

(Mooren's, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease

(Terrein's marginal degeneration, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Granulomatous disease

(Wegener's granulomatosis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Burn

(acid and alkali, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Glycosides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Fibronectins

Vitronectin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(and analogs; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Tear (ocular fluid)

(artificial; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Dysentery

(bacillary, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease

(blepharitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Acids, biological studies

Bases, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(chem. burn, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease

(conjunctivitis, allergic and others, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and

inflammations)

IT Eye
(cornea, haze; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye
(cornea, infiltration and thinning, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
Eye, disease
Eye, disease
(cornea, ulcer, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Autoimmune disease
Food allergy
Leukemia
Myasthenia gravis
Psoriasis
Rheumatoid arthritis
Syphilis
(corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Excimer lasers
(corneal procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Antiulcer agents
(corneal ulcer; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Amyloidosis
(corneal; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(creams; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drugs
(cytoplegics and miotics; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(degeneration; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(dellen, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(diabetic retinopathy; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(emulsions; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Human herpesvirus
(epithelial keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Edema
Infection
Lasers
(eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(eye liners; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(eye; histidine compns. and methods for ocular degenerative diseases

and inflammations)

IT Sexually transmitted diseases
(gonorrhea, corneal disorder from, eye inflammation related to;
histidine compns. and methods for ocular degenerative diseases and
inflammations)

IT Human herpesvirus 3
(herpes zoster from, keratitis and iridocyclitis, eye
inflammation related to; histidine compns. and methods for ocular
degenerative diseases and inflammations)

IT Anti-inflammatory agents
Antibacterial agents
Antibiotics
Antiglaucoma agents
Antioxidants
Antiviral agents
Eye, disease
Glaucoma (disease)
Wound healing promoters
(histidine compns. and methods for ocular degenerative diseases and
inflammations)

IT Corticosteroids, biological studies
Glycoproteins, general, biological studies
Sulfonamides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(histidine compns. and methods for ocular degenerative diseases and
inflammations)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(hydroxy; histidine compns. and methods for ocular degenerative
diseases and inflammations)

IT Chlamydia trachomatis
(infection with, trachoma, eye inflammation related to; histidine
compns. and methods for ocular degenerative diseases and inflammations)

IT Adenoviridae
Arbovirus
Bacteria (Eubacteria)
Borrelia burgdorferi
Corynebacterium diphtheriae
Cytomegalovirus
DNA viruses
Fungi
Haemophilus
Human enterovirus 70
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human poliovirus
Influenza virus
Measles virus
Moraxella
Mumps virus
Neisseria gonorrhoeae
Neisseria meningitidis
Papillomavirus
Parasite
Pseudomonas

- RNA viruses
- Rabies virus
- Rhinovirus
- Serratia marcescens
- Staphylococcus
- Staphylococcus aureus
- Staphylococcus epidermidis
- Streptococcus
 - (infection, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (injections, i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (injections, intraocular; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (keratopathy, calcific band, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Ablation
 - (laser-assisted photoablative surgical procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (liqs.; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (macula, degeneration, age-related; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Cosmetics
 - (mascaras; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Angiogenesis
 - (neovascularization, retinal, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Anti-inflammatory agents
 - (nonsteroidal; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ointments, creams; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ointments, eye; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Surgery
 - (ophthalmic procedures, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ophthalmic, ocular inserts; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (oral; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Carboxylic acids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oxo; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Artery, disease
 (polyarteritis nodosa; corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Radicals, biological studies
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (radical-mediated eye disease; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
 Eye, disease
 Eye, disease
 (retina, injury, photic or ischemia-induced; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
 (retina, ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
 (retina, neovascularization, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Ischemia
 (retinal injury from; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Anti-ischemic agents
 (retinal ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
 Eye, disease
 (retinitis, cytomegalovirus, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
 (scleritis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
 (solns., i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
 (solns., ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cataract
 (surgery, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
 (suspensions; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Lupus erythematosus
 (systemic, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
 (tablets; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
 (topical; histidine compns. and methods for ocular degenerative

diseases and inflammations)

IT Injury
(trauma, eye, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Intestine, disease
(ulcerative colitis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(uveitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Infection
(viral, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye
(vitreous humor, age- or disease-based posterior vitreous detachment; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 71-00-1, L-Histidine, biological studies 351-50-8, D-Histidine 4998-57-6, Histidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compns. therefor)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological studies 51-83-2, Carbachol 53-03-2, Prednisone 53-86-1, Indomethacin 54-42-2, Idoxuridine 56-75-7, Chloramphenicol **57-47-6**, Physostigmine 59-02-9, .alpha.-Tocopherol 59-42-7, Phenylephrine 59-66-5, Acetazolamide 69-53-4, Ampicillin 70-00-8, Trifluridine 70-18-8, Glutathione, biological studies 92-13-7, Pilocarpine 114-07-8, Erythromycin 127-40-2, Lutein 144-68-3, Zeaxanthin 378-44-9, Betamethasone 426-13-1, Fluorometholone 472-61-7, Astaxanthin 514-78-3, Canthaxanthin 616-91-1, Acetyl cysteine 738-70-5, Trimethoprim 768-94-5, Amantadine 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 4697-36-3, Carbenicillin 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine 7235-40-7, .beta.-Carotene 7761-88-8, Silver nitrate, biological studies 7783-00-8, Selenious acid 9054-89-1, Superoxide dismutase 11111-12-9, Cephalosporin 13292-46-1, Rifampin 13392-28-4, Rimantadine 13410-01-0, Sodium selenate 15307-86-5, Diclofenac 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 25953-19-9, Cefazolin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 30516-87-1, Azidothymidine 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 51481-65-3, Mezlocillin 56272-24-3, Histidine hydrochloride 59277-89-3, Acyclovir 68767-14-6, Loxoprofen 70458-96-7, Norfloxacin 74103-06-3, Ketorolac 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82768-44-3 85721-33-1, Ciprofloxacin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 9001-03-0, Carbonic anhydrase 9001-12-1, Collagenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histidine compns. and methods for ocular degenerative diseases and inflammations)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Babizhayev; 1989 CAPLUS

(2) Babizhayev; Biochimica et Biophysica Acta 1989, V1004, P363 CAPLUS
(3) Santen; 1983 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T
L3 5 S STAVUDINE
L4 42 S PARAOXON
L5 0 S PHYOSTIGMINE
L6 0 S PHYOSTIGMINE
L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

L8 1300 S L3
L9 2913 S L4
L10 4718 S L7
E HIV
L11 50075 S E3 OR E7
E HERPES
L12 21343 S E3
L13 17244 S HHV OR HSV OR HCMV OR CMV
L14 29657 S L12 OR L13
L15 7547 S PHOSPHATE ESTER
L16 2 S L8 AND L15
E ESTER
L17 518186 S E3
L18 2414368 S S
L19 54 S L17 AND L8
L20 3 S L9 AND L11
L21 0 S L9 AND L14
L22 2 S L10 AND L11
L23 1 S L10 AND L14

=> d 123

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 1998:618371 CAPLUS

DN 129:255004

TI Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor

IN Thomas, Peter G.

PA Cytos Pharmaceuticals LLC, USA

SO U.S., 10 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | US 5811446 | A | 19980922 | US 1997-839805 | 19970418 |
| | WO 9847366 | A1 | 19981029 | WO 1998-US7319 | 19980417 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9873583 A1 19981113 AU 1998-73583 19980417
PRAI US 1997-839805 19970418
WO 1998-US7319 19980417
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> e antiviral

| | | |
|-----|-----------|----------------|
| E1 | 5 | ANTIVIR/BI |
| E2 | 1 | ANTIVIRA/BI |
| E3 | 38409 --> | ANTIVIRAL/BI |
| E4 | 1 | ANTIVIRALE/BI |
| E5 | 2 | ANTIVIRALEN/BI |
| E6 | 100 | ANTIVIRALLY/BI |
| E7 | 789 | ANTIVIRALS/BI |
| E8 | 1 | ANTIVIREMIC/BI |
| E9 | 111 | ANTIVIRIAL/BI |
| E10 | 2 | ANTIVIRIALS/BI |
| E11 | 1 | ANTIVIRIL/BI |
| E12 | 15 | ANTIVIRIN/BI |

=> s e3-e9

| | | |
|-----|-------|---|
| | 38409 | ANTIVIRAL/BI |
| | 1 | ANTIVIRALE/BI |
| | 2 | ANTIVIRALEN/BI |
| | 100 | ANTIVIRALLY/BI |
| | 789 | ANTIVIRALS/BI |
| | 1 | ANTIVIREMIC/BI |
| | 111 | ANTIVIRIAL/BI |
| L24 | 38629 | (ANTIVIRAL/BI OR ANTIVIRALE/BI OR ANTIVIRALEN/BI OR ANTIVIRALLY/ BI OR ANTIVIRALS/BI OR ANTIVIREMIC/BI OR ANTIVIRIAL/BI) |

=> s l24 and l9

L25 2 L24 AND L9

=> d l25 1-2

L25 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:706699 CAPLUS
DN 138:66452
TI Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That
Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide
AU Van Lenten, Brian J.; Wagner, Alan C.; Anantharamaiah, G. M.; Garber,
David W.; Fishbein, Michael C.; Adhikary, Lopa; Nayak, Debi P.; Hama,
Susan; Navab, Mohamad; Fogelman, Alan M.
CS Deo, Ned, University of California, Los Angeles, CA, USA
SO Circulation (2002), 106(9), 1127-1132
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1996:365474 CAPLUS
DN 125:58113
TI Preparation of arylthio and dithiobisarylamide compounds as antibacterial

and **antiviral** agents
IN Domagala, John Michael; Elslager, Edward Faith; Gogliotti, Rocco Dean
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9604242 | A1 | 19960215 | WO 1995-US8802 | 19950711 |
| | W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5463122 | A | 19951031 | US 1994-286816 | 19940805 |
| | US 5734081 | A | 19980331 | US 1995-446917 | 19950601 |
| | AU 9530087 | A1 | 19960304 | AU 1995-30087 | 19950711 |
| | AU 710806 | B2 | 19990930 | | |
| | EP 775110 | A1 | 19970528 | EP 1995-926276 | 19950711 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 10504292 | T2 | 19980428 | JP 1995-506523 | 19950711 |
| | RU 2156236 | C2 | 20000920 | RU 1997-103207 | 19950711 |
| | PL 181425 | B1 | 20010731 | PL 1995-318540 | 19950711 |
| | FI 9700417 | A | 19970131 | FI 1997-417 | 19970131 |
| | NO 9700495 | A | 19970402 | NO 1997-495 | 19970204 |
| | BG 63301 | B1 | 20010928 | BG 1997-101189 | 19970204 |
| PRAI | US 1994-286816 | A | 19940805 | | |
| | US 1995-446917 | A | 19950601 | | |
| | WO 1995-US8802 | W | 19950711 | | |
| OS | MARPAT 125:58113 | | | | |

=> s 110 and 124
L26 8 L10 AND L24

=> d 126 1-8

L26 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2003:319255 CAPLUS
DN 138:343854
TI Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
IN Dugger, Harry A.
PA USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 2003077227 | A1 | 20030424 | US 2002-230060 | 20020829 |
| | WO 9916417 | A1 | 19990408 | WO 1997-US17899 | 19971001 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, | | | | |

GN, ML, MR, NE, SN, TD, TG
 EP 1029536 A1 20000823 EP 2000-109347 19971001
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 EP 1036561 A1 20000920 EP 2000-109357 19971001
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 PRAI WO 1997-US17899 A2 19971001
 US 2000-537118 A2 20000329
 EP 1997-911621 A3 19971001

L26 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:154686 CAPLUS
 DN 138:198554
 TI Drug interaction assay chip
 IN Diamond, Scott L.; Sevrain, Christophe J.-P.
 PA Morewood Molecular, Inc., USA; University of Pennsylvania-Center for
 Technology
 SO PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2003016870 | A1 | 20030227 | WO 2002-US26395 | 20020819 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2003059846 A1 20030327 US 2002-224529. 20020819 PRAI US 2001-313366P P 20010817 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L26 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:748713 CAPLUS
 DN 137:268439
 TI Nonaqueous fluorinated drug delivery suspensions
 IN Meadows, David Louis
 PA Allergan, Inc., USA
 SO U.S., 12 pp., Cont.-in-part of U. S. Ser. No. 853,827, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|------|----------|-----------------|----------|
| US 6458376 | B1 | 20021001 | US 1993-179508 | 19931230 |
| US 5173298 | A | 19921222 | US 1990-588697 | 19900927 |
| US 5518731 | A | 19960521 | US 1994-260482 | 19940614 |
| US 5620699 | A | 19970415 | US 1995-556277 | 19951113 |
| PRAI US 1990-588697 | A2 | 19900927 | | |
| US 1992-853827 | B2 | 19920319 | | |
| US 1994-260482 | A3 | 19940614 | | |

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:136991 CAPLUS
DN 134:198075
TI Triglyceride-free compositions and methods for enhanced absorption of
 hydrophilic therapeutic agents
IN Patel, Mahesh V.; Chen, Feng-Jing
PA Lipocine, Inc., USA
SO PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001012155 | A1 | 20010222 | WO 2000-US18807 | 20000710 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |
| | CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, | | | | |
| | HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, | | | | |
| | LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, | | | | |
| | SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, | | | | |
| | ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, | | | | |
| | DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, | | | | |
| | CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6309663 | B1 | 20011030 | US 1999-375636 | 19990817 |
| | EP 1210063 | A1 | 20020605 | EP 2000-947184 | 20000710 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |
| | IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | JP 2003506476 | T2 | 20030218 | JP 2001-516502 | 20000710 |
| | US 2001024658 | A1 | 20010927 | US 2000-751968 | 20001229 |
| | US 6458383 | B2 | 20021001 | | |
| PRAI | US 1999-375636 | A | 19990817 | | |
| | WO 2000-US18807 | W | 20000710 | | |

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2000:259972 CAPLUS
DN 132:293042
TI Encapsulation of sensitive liquid components into a matrix to obtain
 discrete shelf-stable particles
IN Van Lengerich, Bernhard H.
PA General Mills, Inc., USA
SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2000021504 | A1 | 20000420 | WO 1999-US20905 | 19991006 |
| | W: | | | | |
| | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, | | | | |
| | DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, | | | | |
| | JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, | | | | |
| | MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, | | | | |
| | TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, | | | | |
| | MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, | | | | |
| | DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, | | | | |

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2345815 AA 20000420 CA 1999-2345815 19991006
 AU 9963872 A1 20000501 AU 1999-63872 19991006
 EP 1119345 A1 20010801 EP 1999-951433 19991006
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002527375 T2 20020827 JP 2000-575480 19991006
 NO 2000004784 A 20000925 NO 2000-4784 20000925
 PRAI US 1998-103700P P 19981009
 US 1998-109696P P 19981124
 US 1999-233443 A 19990120
 US 1998-79060P P 19980323
 WO 1999-US4267 W 19990323
 WO 1999-US20905 W 19991006

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:618371 CAPLUS
 DN 129:255004
 TI Prophylactic and therapeutic methods for ocular degenerative diseases and
 inflammations, and histidine compositions therefor
 IN Thomas, Peter G.
 PA Cytos Pharmaceuticals LLC, USA
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 5811446 | A | 19980922 | US 1997-839805 | 19970418 |
| | WO 9847366 | A1 | 19981029 | WO 1998-US7319 | 19980417 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9873583 | A1 | 19981113 | AU 1998-73583 | 19980417 |
| PRAI | US 1997-839805 | | 19970418 | | |
| | WO 1998-US7319 | | 19980417 | | |

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:293427 CAPLUS
 DN 129:8597
 TI Embedding and encapsulation of controlled release particles
 IN Van Lengerich, Bernhard H.
 PA Van Lengerich, Bernhard H., USA
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------------------|------|----------|-----------------|----------|
| PI | WO 9818610 | A1 | 19980507 | WO 1997-US18984 | 19971027 |
| | W: AU, CA, JP, NO, PL, US | | | | |

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AU 9749915 A1 19980522 AU 1997-49915 19971027
 AU 744156 B2 20020214
 EP 935523 A1 19990818 EP 1997-912825 19971027

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

JP 2002511777 T2 20020416 JP 1998-520558 19971027
 NO 9902036 A 19990428 NO 1999-2036 19990428
 PRAI US 1996-29038P P 19961028
 US 1997-52717P P 19970716
 WO 1997-US18984 W 19971027

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:440981 CAPLUS
 DN 127:144786
 TI Rabies virus infection of IMR-32 human neuroblastoma cells and effect of
 neurochemical and other agents
 AU Lentz, Thomas L.; Fu, Yiguang; Lewis, Peter
 CS Dep. Cell Biol., Yale Univ. School Med., New Haven, CT, 06520-8002, USA
 SO Antiviral Research (1997), 35(1), 29-39
 CODEN: ARSRDR; ISSN: 0166-3542
 PB Elsevier
 DT Journal
 LA English

=> d 126 1 3 4 5 6 7 8 all

L26 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:319255 CAPLUS
 DN 138:343854
 TI Buccal sprays or capsules containing drugs for treating disorders of the
 central nervous system
 IN Dugger, Harry A.
 PA USA
 SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K009-00
 ICS A61L009-04
 NCL 424043000
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 8

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 2003077227 | A1 | 20030424 | US 2002-230060 | 20020829 |
| | WO 9916417 | A1 | 19990408 | WO 1997-US17899 | 19971001 |
| | W: | | | | |
| | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, | | | | |
| | DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, | | | | |
| | LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, | | | | |
| | PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, | | | | |
| | UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, | | | | |
| | GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, | | | | |
| | GN, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1029536 | A1 | 20000823 | EP 2000-109347 | 19971001 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |
| | IE, SI, LT, LV, FI, RO | | | | |
| | EP 1036561 | A1 | 20000920 | EP 2000-109357 | 19971001 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRAI WO 1997-US17899 A2 19971001
US 2000-537118 A2 20000329
EP 1997-911621 A3 19971001

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aq. polar solvent, active compd., and optional flavoring agent; formulation B: aq. polar solvent, active compd., optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compd., and optional flavoring agent; and formulation D: non-polar solvent, active compd., optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

ST buccal spray central nervous system disease; capsule central nervous system disease

IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C2-26; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Alcohols, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C2-8; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Alcohols, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C7-18; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Hydrocarbons, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C7-18; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Prostaglandins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Antihistamines

(H2; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Drug delivery systems

(aerosols; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Benzodiazepine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Mental disorder

(attention deficit disorder; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Adrenoceptor antagonists

Alzheimer's disease

Antibiotics

Anticonvulsants

Antidepressants

Antiparkinsonian agents

Antipsychotics

Antiviral agents

Anxiolytics

Cholinergic antagonists

Flavoring materials

Fungicides
 Hypnotics and Sedatives
 Molecular weight distribution
 Neurotransmitter agonists
 Neurotransmitter antagonists
 Polar solvents
 Propellants (sprays and foams)
 Sweetening agents
 Tranquillizers
 (buccal sprays or capsule contg. drugs for treating disorders of
 central nervous system)
 IT Esters, biological studies
 Hormones, animal, biological studies
 Neurotransmitters
 Peptides, biological studies
 Polyoxyalkylenes, biological studies
 Prostaglandins
 Sulfonylureas
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (buccal sprays or capsule contg. drugs for treating disorders of
 central nervous system)
 IT Drug delivery systems
 (buccal; buccal sprays or capsule contg. drugs for treating disorders
 of central nervous system)
 IT Drug delivery systems
 (capsules; buccal sprays or capsule contg. drugs for treating disorders
 of central nervous system)
 IT Nervous system
 (central, disease; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)
 IT Essential oils
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (citrus; buccal sprays or capsule contg. drugs for treating disorders
 of central nervous system)
 IT Fatty acids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (esters, C2-24; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)
 IT Echinacea
 Valerian (Valeriana)
 (exts.; buccal sprays or capsule contg. drugs for treating disorders of
 central nervous system)
 IT Flavoring materials
 (fruit flavors; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)
 IT Mouth
 (mucosa; buccal sprays or capsule contg. drugs for treating disorders
 of central nervous system)
 IT Sleep
 (narcolepsy; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)
 IT Cytoprotective agents
 (neuroprotectants; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)
 IT Essential oils
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (peppermint; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)
 IT Alcohols, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polyhydric, C2-8; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)

IT Essential oils
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (spearmint; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Drug delivery systems
 (sprays; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Brain, disease
 (stroke; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Diet
 (supplements; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta., 1A; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta., 1B; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT 50-06-6, Phenobarbital, biological studies 50-28-2, Estradiol, biological studies 50-47-5, Desipramine 50-48-6 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-67-9, Serotonin, biological studies 51-30-9, Isoproterenol Hydrochloride 51-41-2, Norepinephrine 51-43-4, Epinephrine 51-45-6, Histamine, biological studies 51-61-6, Dopamine, biological studies 51-64-9, Dextroamphetamine 51-71-8, Phenelzine 51-84-3, Acetylcholine, biological studies 52-86-8, Haloperidol 56-12-2, GABA, biological studies 56-40-6, Glycine, biological studies 56-65-5, ATP, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies 57-41-0, Phenytoin 57-47-6, Physostigmine 57-83-0, Progesterone, biological studies 57-94-3, Tubocurarine 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-92-7, Levodopa, biological studies 59-99-4, Neostigmine 60-87-7, Promethazine 64-17-5, Ethanol, biological studies 67-52-7D, 2,4,6(1H,3H,5H)-Pyrimidinetrione, derivs. 68-88-2, Hydroxyzine 72-69-5 74-98-6, Propane, biological studies 75-28-5, Isobutane 77-19-0, Dicycloverine 77-67-8, Ethosuximide 78-78-4, Isopentane 95-25-0, Chlorzoxazone 96-88-8, Mepivacaine 106-97-8, N-Butane, biological studies 109-66-0, N-Pentane, biological studies 113-45-1, Methylphenidate 114-07-8, Erythromycin 125-33-7, Primidone 127-48-0, Trimethadione 137-58-6, Lidocaine 147-24-0, Diphenhydramine hydrochloride 155-09-9, Tranlycypromine 298-46-4, Carbamazepine 300-62-9, Amphetamine 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 312-48-1, Edrophonium 321-64-2, Tacrine 322-35-0, Benserazide 357-70-0, Galantamine 363-24-6, Dinoprostone 438-60-8, Protriptyline 439-14-5, Diazepam 463-82-1, Neopentane 511-12-6, Dihydroergotamine 523-87-5, Dimenhydrinate 569-65-3, Meclizine 721-50-6, Prilocaine 768-94-5, Amantadine 1622-61-3, Clonazepam 1668-19-5, Doxepin 1744-22-5, Riluzole 2078-54-8, Propofol 2152-34-3, Pemoline 3239-45-0, Dexfenfluramine hydrochloride 3313-26-6, Thiothixene 5588-33-0, Mesoridazine 5786-21-0, Clozapine 10102-43-9, Nitric oxide, biological studies 10238-21-8, Glyburide 10262-69-8, Maprotiline 10457-90-6, Bromperidol 14028-44-5, Amoxapine 14611-51-9, Selegiline 15500-66-0, Pancuronium 15676-16-1, Sulpiride 17780-72-2, Clorgyline 19794-93-5, Trazodone 19982-08-2, Memantine 22232-71-9, Mazindol 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23887-31-2, Clorazepate 25322-68-3, Polyethylene glycol 25614-03-3, Bromocriptine 27262-47-1, Levobupivacaine 27848-84-6, Nicergoline 28721-07-5, Oxcarbazepine 28860-95-9, Carbidopa 30516-87-1, Zidovudine

34911-55-2, Bupropion 36505-84-7, Buspirone 43200-80-2, Zopiclone
 47931-85-1, Salmon Calcitonin 50700-72-6, Vecuronium 51022-70-9,
 Albuterol sulfate 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine
 59729-33-8, Citalopram 60142-96-3, Gabapentin 60205-81-4, Ipratropium
 61869-08-7, Paroxetine 63798-73-2, Cyclosporine 64228-79-1, Atracurium
 64840-90-0, Eperisone 66085-59-4, Nimodipine 66104-22-1, Pergolide
 68291-97-4, Zonisamide 68399-58-6, Pipecuronium 68506-86-5, Vigabatrin
 68693-11-8, Modafinil 70059-30-2, Cimetidine hydrochloride 71320-77-9,
 Moclobemide 71675-85-9, Amisulpride 72432-10-1, Aniracetam
 76584-70-8 76824-35-6, Famotidine 77191-36-7, Nefiracetam
 77337-76-9, Acamprosate 78755-81-4, Flumazenil 79517-01-4, Sandostatin
 79617-96-2, Sertraline 81409-90-7, Cabergoline 82626-48-0, Zolpidem
 83015-26-3, Atomoxetine 83366-66-9, Nefazodone 84057-84-1, Lamotrigine
 84057-95-4, Ropivacaine 85650-52-8, Mirtazapine 90293-01-9, Bifemelane
 91374-21-9, Ropinirole 93107-08-5, Ciprofloxacin hydrochloride
 93413-69-5, Venlafaxine 96946-41-7, Cisatracurium 97240-79-4,
 Topiramate 99571-64-9, Oxitropium 99614-01-4, Ondansetron
 hydrochloride 102767-28-2, Levetiracetam 103628-46-2, Sumatriptan
 103628-48-4, Sumatriptan succinate 103878-84-8, Lazabemide
 104632-26-0, Pramipexole 106266-06-2, Risperidone 106650-56-0,
 Sibutramine 106861-44-3, Mivacurium chloride 111974-69-7, Quetiapine
 113775-47-6, Dexmedetomidine 115103-54-3, Tiagabine 116539-59-4,
 Duloxetine 120014-06-4, Donepezil 120444-71-5, Deramciclane
 121679-13-8, Naratriptan 123441-03-2, Rivastigmine 128196-01-0,
 Escitalopram 128298-28-2, Remacemide 129722-12-9, Aripiprazole
 130929-57-6, Entacapone 132539-06-1, Olanzapine 133107-64-9, Insulin
 lispro 133454-47-4, Iloperidone 133737-32-3, Pagoclone 133814-18-3,
 Doxacurium 134308-13-7, Tolcapone 135354-02-8, Xaliproden
 138729-47-2, Esopiclone 139264-17-8, Zolmitriptan 142852-51-5, TAK147
 143322-58-1, Eletriptan 143558-00-3, Rocuronium 144034-80-0,
 Rizatriptan 146939-27-7, Ziprasidone 148553-50-8, Pregabalin
 151319-34-5, Zaleplon 154323-57-6, Almotriptan 156137-99-4,
 Rapacuronium bromide 214415-55-1 325715-02-4, Indiplon 515132-12-4
 516482-86-3, Sermorelin acetate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (buccal sprays or capsule contg. drugs for treating disorders of
 central nervous system)

IT 9000-81-1, Acetylcholinesterase

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors; buccal sprays or capsule contg. drugs for treating
 disorders of central nervous system)

L26 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2002:748713 CAPLUS

DN 137:268439

TI Nonaqueous fluorinated drug delivery suspensions

IN Meadows, David Louis

PA Allergan, Inc., USA

SO U.S., 12 pp., Cont.-in-part of U. S. Ser. No. 853,827, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-10

ICS A61K047-24; A61P027-02

NCL 424427000

CC 63-6 (Pharmaceuticals)

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | US 6458376 | B1 | 20021001 | US 1993-179508 | 19931230 |
| | US 5173298 | A | 19921222 | US 1990-588697 | 19900927 |
| | US 5518731 | A | 19960521 | US 1994-260482 | 19940614 |

| | | | | | |
|------|----------------|----|----------|----------------|----------|
| | US 5620699 | A | 19970415 | US 1995-556277 | 19951113 |
| PRAI | US 1990-588697 | A2 | 19900927 | | |
| | US 1992-853827 | B2 | 19920319 | | |
| | US 1994-260482 | A3 | 19940614 | | |

AB Nonaq. pharmaceutical compns. for use in aq. physiol. systems are disclosed comprising drug delivery suspension of nonaq. perfluorocarbon or fluorinated silicone liq. carriers. The suspended drug may be water labile or water stable and therapeutic or diagnostic compds. which will remain stable and pharmaceutically effective for extended periods. The pharmaceutical compns. have improved bioavailability, are capable of low dose vol. delivery, and do not degrade the incorporated therapeutic or diagnostic compds. making them well suited for multi-dose packaging and administration. For example, 5 g of poly(Me vinyl ether/maleic anhydride) was completely dissolved in a soln. contg. 100 mg dipivefrin in .95 mL of acetonitrile. This polymer stock was then added to a roto-evaporator operating at 40.degree., and the acetonitrile was completely removed. The drug/polymer stock mixt. was roto-evapd. to dryness and the residue was first ground in a mortar and pestle and placed in a roller bottle contg. glass beads with a nonaq. diluent [preferably perfluoro(decahydronaphthalene), PFD]. The suspension was ball milled for approx. 3 days to reach the desired 2-200 .mu.m size range.

ST fluorinated silicone perfluorocarbon liq carrier ophthalmic suspension

IT Diagnosis
(agents; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epithelial cell growth factors; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Polysiloxanes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluorine-contg., liq. carriers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Perfluorocarbons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liq. carriers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Nervous system agents
(miotics; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Anesthetics
Anti-inflammatory agents
Antibacterial agents
Antiglaucoma agents
Antihistamines
Antiviral agents
Cholinergic antagonists
Drug delivery systems
Fungicides
Immunosuppressants
Parasitocides
Surfactants
(nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligopeptides; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Perfluoro compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perfluoroalkyl ethers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Ethers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (perfluoroalkyl; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Fluoropolymers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polysiloxane-, liq. carriers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Drug delivery systems
 (suspensions, ophthalmic; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Eye
 (targeting to; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 9001-03-0, Carbonic anhydrase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 9011-16-9, Poly(methyl vinyl ether/maleic anhydride)
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (matrix; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 92-13-7, Pilocarpine
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 51-34-3, Scopolamine 51-43-4, Epinephrine 51-83-2, Carbachol 52-21-1, Prednisolone acetate 54-42-2, Idoxuridine 56-94-0, Demecarium bromide 57-62-5, Chlortetracycline 57-64-7, Eserine salicylate 59-42-7, Phenylephrine 60-54-8, Tetracycline 61-33-6, biological studies 87-00-3, Homatropine 114-07-8, Erythromycin 302-79-4, Tretinoin 306-91-2, Perfluoroperhydrophenanthrene 306-92-3, Perfluoro(decahydro-1-methylnaphthalene) 306-94-5, Perfluoro(decahydronaphthalene) 311-89-7, Perfluorotributylamine 312-93-6, Dexamethasone-21-phosphate 335-27-3, Perfluoro(1,3-dimethylcyclohexane) 355-02-2, Perfluoromethylcyclohexane 374-60-7 378-44-9, Betamethasone 423-02-9, Perfluoroisopropylcyclohexane 423-03-0 426-13-1, Fluorometholone 512-15-2, Cyclopentolate 513-10-0, Echothiophate iodide 518-47-8, Sodium fluorescein 807-38-5, Fluocinolone 827-61-2, Aceclidine 1043-21-6, Pirenoxine 1404-04-2, Neomycin 1405-87-4, Bacitracin 1405-97-6, Gramacidin 1406-11-7, Polymyxin 2391-15-3 2668-66-8, Medrysone 15687-27-1, Ibuprofen 25953-19-9, Cefazolin 27912-14-7, Levo-bunolol hydrochloride 32986-56-4, Tobramycin 52365-63-6, Dipivefrin 54471-59-9, Perfluoro(decahydrodimethylnaphthalene) 60096-00-6 64221-86-9, Imipenem 67711-54-0 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 73196-05-1 75108-51-9 85721-33-1, Ciprofloxacin 118183-26-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nonaq. fluorinated drug delivery suspensions for targeting to eye)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; WO 810002 1981
- (2) Anon; JP 5721312 1982
- (3) Anon; EP 0089815 1983 CAPLUS
- (4) Anon; EP 0091313 1983 CAPLUS
- (5) Anon; WO 8400686 1984 CAPLUS
- (6) Anon; EP 0288659 1988 CAPLUS
- (7) Anon; EP 0322249 1988 CAPLUS
- (8) Anon; WO 9118613 1991 CAPLUS

(9) Borgarello; US 4942179 A 1990 CAPLUS
 (10) Chabert; US 3989843 A 1976 CAPLUS
 (11) Clark; US 3911138 A 1975 CAPLUS
 (12) Clark; US 4490351 A 1984 CAPLUS
 (13) Haidt; US 4452818 A 1984 CAPLUS
 (14) Higuchi; US 3968245 A 1976 CAPLUS
 (15) Kaswan; US 4649047 A 1987 CAPLUS
 (16) Kaufman; US 4865846 A 1989 CAPLUS
 (17) Kaufman; US 4882150 A 1989 CAPLUS
 (18) Lucas; US 4035506 A 1977 CAPLUS
 (19) Moore; US 4105798 A 1978 CAPLUS
 (20) Sheil; US 4115544 A 1978 CAPLUS
 (21) Wheeler; US 4426374 A 1984 CAPLUS
 (22) White; US 4366169 A 1982 CAPLUS
 (23) Wretlind; US 4168308 A 1979 CAPLUS
 (24) Yokoyama; US 3962439 A 1976 CAPLUS
 (25) Yuhas; US 4889525 A 1989

L26 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2001:136991 CAPLUS

DN 134:198075

TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

IN Patel, Mahesh V.; Chen, Feng-Jing

PA Lipocine, Inc., USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-00

ICS A61K009-14; A61K009-16; A61K009-20; A61K009-22; A61K009-28;
 A61K009-48

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|------|-----------------|------|----------|--|----------|--|
| PI | WO 2001012155 | A1 | 20010222 | WO 2000-US18807 | 20000710 | |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | |
| | US 6309663 | B1 | 20011030 | US 1999-375636 | 19990817 | |
| | EP 1210063 | A1 | 20020605 | EP 2000-947184 | 20000710 | |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | |
| | JP 2003506476 | T2 | 20030218 | JP 2001-516502 | 20000710 | |
| | US 2001024658 | A1 | 20010927 | US 2000-751968 | 20001229 | |
| | US 6458383 | B2 | 20021001 | | | |
| PRAI | US 1999-375636 | A | 19990817 | | | |
| | WO 2000-US18807 | W | 20000710 | | | |

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the compn., or can

be co-administered with the compn. as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a compn. contg. Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

- ST hydrophilic drug surfactant absorption enhancement
- IT Lysophospholipids
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (C18; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Diglycerides
 - Glycerides, biological studies
 - Monoglycerides
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (C8-10 monoglycerides and diglycerides; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Glycerides, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (C8-10, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Glycerides, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (C8-18 and C18-unsatd. mono- and di-, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Antibodies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (Fc fragment, fusion protein with TNF receptor; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Lung
 - Mucous membrane
 - (administration by; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (aerosols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Phenols, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (alkyl, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Fats and Glyceridic oils, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (almond, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Antiarthritis
 - (anti-gout agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (beads; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Natural products, pharmaceutical
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (belladonna; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (buccal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Gelatins, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gonadotropins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chronic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Analgesics

Anthelmintics

Anti-inflammatory agents

Antianginal agents

Antiarrhythmics

Antiasthmatics

Antibacterial agents

Anticoagulants

Anticonvulsants

Antidepressants

Antidiabetic agents

Antifoaming agents

Antihistamines

Antihypertensives

Antimalarials

Antimigraine agents

Antiparkinsonian agents

Antipsychotics

Antitumor agents

Antitussives

Antiviral agents

Anxiolytics

Blood serum

Buffers

Chelating agents

Compression

Diuretics

Drug delivery systems

Encapsulation

Extrusion, nonbiological

Flavoring materials

Fungicides

Hypnotics and Sedatives

Immunosuppressants

Inotropics

Molding

Muscarinic antagonists

Muscle relaxants

Nervous system stimulants

Nutrients

Peptidomimetics

Plasticizers

Preservatives

Protozoacides

Solubilizers

Spheronization

Surfactants

Vaccines

(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Acrylic polymers, biological studies

Alcohols, biological studies

Amides, biological studies

Amino acids, biological studies

Carbohydrates, biological studies

Corticosteroids, biological studies

Cytokines
 Diglycerides
 Elastins
 Enkephalins
 Esters, biological studies
 Fatty acids, biological studies
 Genetic element
 Glycerides, biological studies
 Glycosides
 Interleukin 2
 Interleukin 3
 Lecithins
 Lysophosphatidic acids
 Lysophosphatidylcholines
 Lysophosphatidylethanolamines
 Lysophosphatidylserines
 Macromolecular compounds
 Nucleic acids
 Nucleosides, biological studies
 Nucleotides, biological studies
 Oligonucleotides
 Peptides, biological studies
 Phosphatidic acids
 Phosphatidylcholines, biological studies
 Phosphatidylethanolamines, biological studies
 Phosphatidylglycerols
 Phosphatidylserines
 Phospholipids, biological studies
 Platelet-derived growth factors
 Polyoxyalkylenes, biological studies
 Proteins, general, biological studies
 Sex hormones
 Shellac
 Sterols
 Sulfonic acids, biological studies
 Tannins
 Toxoids

Tumor necrosis factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for enhanced absorption of hydrophilic drugs using combination
 of surfactants)

- IT Drug delivery systems
 (controlled-release; compns. for enhanced absorption of hydrophilic
 drugs using combination of surfactants)
- IT Glycerides, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (corn, ethoxylated; compns. for enhanced absorption of hydrophilic
 drugs using combination of surfactants)
- IT Bath preparations
 (douches; compns. for enhanced absorption of hydrophilic drugs using
 combination of surfactants)
- IT Drug delivery systems
 (drops; compns. for enhanced absorption of hydrophilic drugs using
 combination of surfactants)
- IT Drug delivery systems
 (elixirs; compns. for enhanced absorption of hydrophilic drugs using
 combination of surfactants)
- IT Drug delivery systems
 (emulsions; compns. for enhanced absorption of hydrophilic drugs using
 combination of surfactants)
- IT Castor oil
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ethoxylated, Emalex C40; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Corn oil
Ethers, biological studies
Palm kernel oil
Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Tumor necrosis factor receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fusion protein with antibody Fc fragment; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drugs
(gastrointestinal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(gels; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(granules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(hepatitis A; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(hepatitis B; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(influenza; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Enzymes, biological studies
Thyroid hormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Skin preparations (pharmaceutical)
(keratolytics; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipid regulating agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(lotions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lysophosphatides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lysophosphatidylglycerols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(measles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mucoadhesive; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines

(mumps; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(nasal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Surfactants
(nonionic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(ointments, creams; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(ointments; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(oral; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(particles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(pastes; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(pellets; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antioxidants
(pharmaceutical; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection
(plague, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Phosphatidylethanolamines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction products, with PEG and PVP; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(rectal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, carnitine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(solns.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(sprays; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Monoglycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(succinylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems

(suppositories, vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(suppositories; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(suspensions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(sustained-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(syrups; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thioglycosides, alkyl esters; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Haemophilus influenzae
(type b, conjugated vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Human poliovirus
(vaccine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Japanese encephalitis virus
Mycobacterium BCG
Neisseria meningitidis
Rabies
Rotavirus
Streptococcus pneumoniae
Typhoid fever
(vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Human herpesvirus 3
(varicella from, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection
(variola, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, ethoxylated, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fever and Hyperthermia
(yellow, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Adrenoceptor antagonists

(.beta.-; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses).

(.beta.-; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9011-29-4, Nikkol GS 6

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Nikkol GS 460; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9005-25-8, Starch, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 59277-89-3, Acyclovir

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 63585-09-1, Foscarnet sodium

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, acyl esters 50-56-6, Oxytocin, biological studies 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 51-15-0, Pralidoxime chloride 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 51-60-5, Neostigmine methyl sulfate 52-24-4, Thiotepea 53-79-2, Puromycin 56-81-5, Glycerol, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-55-6, Propylene glycol, biological studies 57-55-6D, Propylene glycol, ethers 57-64-7, Physostigmine salicylate 57-88-5, Cholesterol, biological studies 57-94-3, Tubocurarine chloride 59-05-2, Methotrexate 60-00-4, EDTA, biological studies 60-00-4D, EDTA, conjugates with antipain and chitosan 60-31-1, Acetylcholine chloride 60-33-3, Linoleic acid, biological studies 62-31-7, Dopamine hydrochloride 63-91-2, Phenylalanine, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-28-1, Phentolamine mesylate 65-85-0, Benzoic acid, biological studies 66-71-7, 1,10-Phenanthroline 67-42-5, EGTA 68-11-1, Thioglycolic acid, biological studies 68-19-9, Vitamin B12 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-79-4D, Maltose, alkyl esters 69-93-2, Uric acid, biological studies 70-51-9, Deferoxamine 71-27-2, Suxamethonium chloride 74-89-5, Methanamine, biological studies 75-75-2, Methanesulfonic acid 77-19-0, Dicyclomine 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, glycerides 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-10-7D, Acrylic acid, polymers 81-24-3, Taurocholic acid 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 87-69-4, Tartaric acid, biological studies 87-69-4D, Tartaric acid, glycerides 89-57-6, Mesalamine 89-65-6, Isoascorbic acid 101-26-8, Pyridostigmine bromide 102-71-6, Triethanolamine, biological studies 104-15-4, p-Toluenesulfonic acid, biological studies 107-15-3, Ethylenediamine, biological studies 107-21-1, Ethylene glycol, biological studies 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 111-62-6, Ethyl oleate 112-80-1, Oleic acid, biological studies 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-77-5, Pentaerythritol, biological studies 121-44-8, Triethylamine, biological

studies 122-20-3, Triisopropanolamine 124-04-9, Adipic acid, biological studies 124-07-2, Caprylic acid, biological studies 128-13-2, Ursodeoxycholic acid 129-06-6, Warfarin sodium 131-49-7, Diatrizoate meglumine 138-36-3, p-Bromobenzenesulfonic acid 140-64-7, Pentamidine isethionate 141-22-0, Ricinoleic acid 141-43-5, Ethanolamine, biological studies 142-62-1, Caproic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 143-07-7D, Lauric acid, Macrogol glycerides 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Oxalic acid, biological studies 145-42-6, Sodium taurocholate 147-94-4, Cytarabine 148-24-3, 8-Quinolinol, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 151-41-7, Lauryl sulfate 154-21-2, Lincomycin 155-97-5, Pyridostigmine 299-42-3, Ephedrine 334-48-5, Capric acid 360-65-6, Glycodeoxycholic acid 434-13-9, Lithocholic acid 463-40-1, Linolenic acid 463-79-6, Carbonic acid, biological studies 471-34-1, Calcium carbonate, biological studies 474-25-9, Chenodeoxycholic acid 475-31-0, Glycocholic acid 516-35-8, Taurochenodeoxycholic acid 516-50-7, Taurodeoxycholic acid 526-95-4, Gluconic acid 541-15-1D, Carnitine, fatty acid ester salts 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 577-11-7, Sodium docusate 616-91-1, N-Acetylcysteine 640-79-9, Glycochenodeoxycholic acid 665-66-7, Amantadine hydrochloride 737-31-5, Diatrizoate sodium 863-57-0, Sodium glycocholate 865-21-4, Vinblastin 1002-62-6, Sodium caprate 1115-70-4, Metformin hydrochloride 1264-72-8, Colistin sulfate 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1319-82-0, Aminocaproic acid 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene glycol monooleate 1335-30-4, Aluminum silicate 1336-21-6, Ammonium hydroxide 1338-39-2, Span 20 1338-41-6, Sorbitan monostearate 1338-43-8, Span 80 1397-89-3, Amphotericin B 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-20-5, Polymixin B sulfate 1405-37-4, Capreomycin sulfate 1405-87-4, Bacitracin 1492-18-8, Leucovorin calcium 1501-84-4, Rimantadine hydrochloride 1684-40-8, Tacrine hydrochloride 1695-77-8, Spectinomycin 1935-18-8, Palmitoyl carnitine 2016-88-8, Amiloride hydrochloride 2364-67-2, Palmitoyl carnitine 2466-77-5, Lauroyl carnitine 2646-38-0, Sodium chenodeoxycholate 2898-95-5, Sodium ursodeoxycholate 3056-17-5, Stavudine 3485-62-9, Clidinium bromide 3778-73-2, Isofosfamide 3858-83-1, P-Aminobenzamidine 4291-63-8, Cladribine 5534-95-2, Pentagastrin 6303-21-5D, Phosphinic acid, dipeptide derivs. 6493-05-6, Pentoxifylline 7087-68-5, Diisopropylethylamine 7481-89-2, Zalcitabine 7585-39-9D, .beta.-Cyclodextrin, ethers with propanediol 7647-01-0, Hydrochloric acid, biological studies 7648-98-8, Ambenonium 7664-38-2, Phosphoric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 7664-93-9D, Sulfuric acid, alkyl esters, salts, biological studies 7697-37-2, Nitric acid, biological studies 8007-43-0, Sorbitan sesquioleate 8068-28-8, Colistimethate sodium 9001-28-9, Factor IX 9002-01-1, Streptokinase 9002-60-2, Corticotropin, biological studies 9002-92-0, Brij 35 9002-96-4 9003-01-4D, Polyacrylic acid, conjugates with bacitracin 9003-39-8D, Polyvinylpyrrolidone, reaction products with phosphatidylethanolamine 9004-10-8, Insulin, biological studies 9004-17-5, Insulin protamine zinc 9004-32-4D, Carboxymethyl cellulose, conjugates with pepstatin 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, ethers, biological studies 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-81-3 9004-95-9, Polyethylene glycol cetyl ether 9004-96-0, Crodet O40 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Kessco PEG 300DL 9005-07-6, Kessco PEG 1540DO 9005-08-7 9005-32-7, Alginic acid 9005-63-4D, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, Plurol Oleique 9007-92-5, Glucagon,

biological studies 9011-21-6 9012-76-4, Chitosan 9012-76-4D,
 Chitosan, conjugates with antipain and EDTA 9015-68-3, Asparaginase
 9034-40-6, Gonadotropin releasing hormone 9035-81-8, Trypsin inhibitor
 9036-19-5 9039-53-6, Urokinase 9041-08-1, Enoxaparin sodium
 9041-93-4, Bleomycin sulfate 9050-31-1, Hydroxypropylmethyl cellulose
 phthalate 9062-90-2 9063-46-1 9076-44-2, Chymostatin 9078-38-0,
 Soybean trypsin inhibitor 9087-70-1, Pancreatic trypsin inhibitor
 10034-85-2, Hydriodic acid 10035-10-6, Hydrobromic acid, biological
 studies 10041-19-7D, derivs. 10043-35-3, Boric acid, biological
 studies 10596-23-3 11000-17-2, Vasopressin 11061-68-0, Human insulin
 11140-04-8, Imwitor 988 12584-58-6, Porcine insulin 12629-01-5, Human
 growth hormone 13265-10-6, Methscopolamine 13284-86-1, Sodium
 lithocholate 13780-71-7D, Boronic acid, .alpha.-aminoalkyl derivs.
 14440-80-3, Stearoyl-2-lactylate 14605-22-2, Tauroursodeoxycholic acid
 15500-66-0, Pancuronium bromide 15663-27-1, Cisplatin 15686-71-2,
 Cephalexin 15826-37-6, Cromolyn sodium 16679-58-6, Desmopressin
 16960-16-0, Cosyntropin 17438-29-8 18323-44-9, Clindamycin
 18883-66-4, Streptozocin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compsn. for enhanced absorption of hydrophilic drugs using combination
 of surfactants)

IT 20537-88-6, Amifostine 21215-62-3, Calcitonin human 21645-51-2,
 Aluminum hydroxide, biological studies 21679-14-1, Fludarabine
 22254-24-6, Ipratropium bromide 22882-95-7, Isopropyl linoleate
 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 24356-60-3,
 Cephapirin sodium 24938-16-7, Eudragit E 25126-32-3, Sincalide
 25168-73-4, Sucrose monostearate 25212-88-8, Eudragit L100-55 25322-68
 -3, Polyethylene glycol 25339-99-5, Sucrose monolaurate 25496-72-4,
 Monoolein 25597-07-3, Myristoylcarnitine 25637-84-7, Glyceryl dioleate
 25637-97-2, Sucrose dipalmitate 26264-14-2D, Propanediol, ethers with
 .beta.-cyclodextrin 26266-57-9, Sorbitan monopalmitate 26266-58-0,
 Sorbitan trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6,
 Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 26589-39-9,
 Eudragit S 26658-19-5, Sorbitan tristearate 26839-75-8, Timolol
 27164-46-1, Cefazolin sodium 27195-16-0, Sucrose distearate
 27214-38-6, Nikkol MGM 27215-38-9, Imwitor 312 27638-00-2, Glyceryl
 dilaurate 29122-68-7, Atenolol 30516-87-1, Zidovudine 31694-55-0D,
 C8-10-esters 33434-24-1, Eudragit RL 33515-09-2, Gonadorelin
 33564-30-6, Cefoxitin sodium 34787-01-4, Ticarcillin 36354-80-0,
 Glyceryl dicaprylate 36791-04-5, Ribavirin 37220-82-9, Peceol
 37321-62-3, Lauroglycol 37330-34-0, Bowman-Birk inhibitor 37330-34-0D,
 Bowman-Birk inhibitor, conjugates with polyacrylic acid 37691-11-5,
 Antipain 37691-11-5D, Antipain, conjugates with chitosan and EDTA
 38916-34-6, Somatostatin 39324-30-6, Pepstatin 39324-30-6D, Pepstatin,
 conjugates with CM-cellulose 39366-43-3, Magnesium aluminum hydroxide
 39438-11-4, Sorbitan monocaprate 41575-94-4, Carboplatin 42057-22-7,
 Mezlocillin sodium 42540-40-9, Cefamandole nafate 42766-91-6, Nikkol
 DHC 42907-92-6, Sodium tauro-24,25-dihydrofusidate 47931-85-1,
 Calcitonin salmon 50700-72-6, Vecuronium bromide 51192-09-7, Tagat O2
 51384-51-1, Metoprolol 51822-44-7, Eudragit L 51938-44-4, Sorbitan
 sesquistearate 52504-24-2, Softigen 767 52581-71-2, Volpo 3
 52907-01-4, Cellulose acetate trimellitate 53168-42-6, Myvacet 9-45
 53237-50-6 53910-25-1, Pentostatin 53988-07-1, Glyceryl dicaprate
 54063-53-5, Propafenone 54392-26-6, Sorbitan monoisostearate
 54910-89-3, Fluoxetine 55123-66-5, Leupeptin 56180-94-0, Acarbose
 57107-95-6 57171-56-9 57248-88-1, Pamidronate disodium 58561-47-0,
 Softigen 701 58970-76-6, Bestatin 59227-89-3, 1-Dodecylazacycloheptan-
 2-one 59703-84-3, Piperacillin sodium 59721-29-8, Camostat mesylate
 60177-36-8, Sorbitan monocaprylate 61270-78-8, Cefonicid sodium
 61489-71-2, Menotropin 61869-08-7, Paroxetine 62013-04-1,
 Dirithromycin 62288-83-9, Desmopressin acetate 62893-19-0,
 Cefoperazone 63527-52-6, Cefotaxime 64228-81-5, Atracurium besylate

64480-66-6, Glycoursodeoxycholic acid 64544-07-6, Cefuroxime axetil
66376-36-1, Alendronate 66419-50-9, Bovine growth hormone 67352-02-7
67655-94-1, Amastatin 68099-86-5, Bepridil hydrochloride 68401-81-0,
Ceftizoxime 68795-69-7, Propylene glycol monocaprates 68958-64-5
69049-74-7, Nedocromil sodium 69070-98-0 69227-93-6, Lauryl
.beta.-maltopyranoside 69655-05-6, Didanosine 70458-92-3, Pefloxacin
70458-96-7, Norfloxacin 71486-22-1, Vinorelbine 73384-59-5,
Ceftriaxone 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium
74381-53-6, Leuprolide acetate 76420-72-9, Enalaprilat 76470-66-1,
Loracarbef 78110-38-0, Aztreonam 79350-37-1, Cefixime 79517-01-4,
Octreotide acetate 79665-92-2 79665-93-3 81161-17-3, Esmolol
hydrochloride 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
83869-56-1, Granulocyte-macrophage colony stimulating factor 83905-01-5,
Azithromycin 85721-33-1, Ciprofloxacin 87679-37-6, Trandolapril
88669-04-9, Trospromycin 89703-10-6, FK-448 89987-06-4, Tiludronate
93790-70-6, Cholylsarcosine 93790-72-8, N-Methyltaurocholic acid
93792-59-7, Hydroxypropylmethyl cellulose succinate 94749-08-3,
Salmeterol xinafoate 98079-51-7, Lomefloxacin 100986-85-4,
Levofloxacin 104227-87-4, Famciclovir 105287-09-0, Aquateric
105462-24-6, Risedronic acid 106392-12-5, Polyoxyethylene-
polyoxypropylene block copolymer 106819-53-8, Doxacurium chloride
106861-44-3, Mivacurium chloride 107648-80-6, Cefepime hydrochloride
110871-86-8, Sparfloxacin 113189-02-9, Antihemophilic factor
113852-37-2, Cidofovir 116094-23-6, Insulin aspart 119914-60-2,
Grepafloxacin 121368-58-9, Olpadronate 121548-04-7, Gelucire 44/14
121548-05-8, Gelucire 50/13 124832-26-4, Valaciclovir 126467-48-9,
Porcine somatotropin 127759-89-1, Lobucavir 127829-97-4, Solulan C 24
133107-64-9, Insulin lispro 134678-17-4, Lamivudine 137862-53-4,
Valsartan 138636-14-3, Eudragit NE 139110-80-8, Zanamivir
139639-23-9, Tissue type plasminogen activator 141644-88-4, Hydrotalcite
142368-40-9, Imwitor 375 143003-46-7, Alglucerase 143011-72-7,
Granulocyte colony stimulating factor 146961-76-4, Alatrofloxacin
147059-72-1, Trovafloxacin 148046-81-5, Gelucire 33/01 148553-50-8,
Pregabalin 150372-93-3, Glycerol L 151126-32-8, Pramlintide
154361-50-9, Capecitabine 156259-68-6, Capmul MCM 157810-81-6,
Indinavir sulfate 160337-95-1, Insulin glargine 169148-63-4, Insulin
detemir 173146-27-5, Denileukin diftitox 191588-94-0, TNK-tPA
211365-88-7, Nikkol BPS 30

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination
of surfactants)

IT 9001-92-7, Proteinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; compns. for enhanced absorption of hydrophilic drugs using
combination of surfactants)

IT 9003-98-9, Dornase 11096-26-7, Epoetin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; compns. for enhanced absorption of hydrophilic drugs using
combination of surfactants)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cho; US 5858398 A 1999 CAPLUS

L26 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2000:259972 CAPLUS

DN 132:293042

TI Encapsulation of sensitive liquid components into a matrix to obtain
discrete shelf-stable particles

IN Van Lengerich, Bernhard H.

PA General Mills, Inc., USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent
 LA English
 IC ICM A61K009-10
 CC 17-13 (Food and Feed Chemistry)
 Section cross-reference(s): 63

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2000021504 | A1 | 20000420 | WO 1999-US20905 | 19991006 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2345815 | AA | 20000420 | CA 1999-2345815 | 19991006 |
| | AU 9963872 | A1 | 20000501 | AU 1999-63872 | 19991006 |
| | EP 1119345 | A1 | 20010801 | EP 1999-951433 | 19991006 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002527375 | T2 | 20020827 | JP 2000-575480 | 19991006 |
| | NO 2000004784 | A | 20000925 | NO 2000-4784 | 20000925 |
| PRAI | US 1998-103700P | P | 19981009 | | |
| | US 1998-109696P | P | 19981124 | | |
| | US 1999-233443 | A | 19990120 | | |
| | US 1998-79060P | P | 19980323 | | |
| | WO 1999-US4267 | W | 19990323 | | |
| | WO 1999-US20905 | W | 19991006 | | |
| AB | A liq. encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liq. plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liq. plasticizer and the encapsulation of the active encapsulant is accomplished at a low temp. and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liq. content of the liq. encapsulant component provides substantially all or completely all of the liq. plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixt. or dough. Removal of liq. plasticizer prior to extrusion is not needed to adjust the viscosity of the mixt. for formability. Release of an active component from the matrix may be delayed or controlled over time so that the active component is delivered when and where it is needed to perform its intended function. Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. | | | | |
| ST | encapsulation food liq component matrix preservation | | | | |
| IT | Polymers; biological studies | | | | |
| | RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses) (amphiphilic; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles) | | | | |
| IT | Nitro compounds | | | | |
| | Nitro compounds | | | | |
| | Nitroso compounds | | | | |
| | RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses) (arom.; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles) | | | | |

IT Antitoxins
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (botulism; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Bakery products
 (cakes; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Natural products, pharmaceutical
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (cascara sagrada; encapsulation of sensitive liq. components into
 matrix to obtain discrete shelf-stable particles)

IT Temperature effects, biological
 (cold; encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)

IT Bakery products
 (cookies; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Bakery products
 (crackers; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Puddings
 (custard; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Natural products, pharmaceutical
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (digitalis; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Toxins
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (diphtheria, antitoxins; encapsulation of sensitive liq. components
 into matrix to obtain discrete shelf-stable particles)

IT Antibiotics
 Antioxidants
 Antitumor agents
 Antivenoms
Antiviral agents
 Beverages
 Cholera
 Detergents
 Dough
 Drug delivery systems
 Durum wheat
 Emulsifying agents
 Encapsulation
 Flavor
 Flavoring materials
 Food additives
 Food functional properties
 Food preservation
 Food viscoelasticity
 Food viscosity
 Health food
 Hepatitis virus
 Human poliovirus
 Hydrocolloids
 Ice cream
 Lactobacillus acidophilus
 Microorganism
 Pertussis
 Pigments, biological
 Plasticizers
 Puddings

Rauvolfia serpentina
 Soups
 Surfactants
 Thyroid gland
 Vaccines
 Virus
 Wheat flour
 (encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)
 IT Edible oils
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)
 IT Amino acids, biological studies
 Castor oil
 Cod liver oil
 Dipeptides
 Enzymes, biological studies
 Estrogens
 Fats and Glyceridic oils, biological studies
 Glucocorticoids
 Glutens
 Hormones, plant
 Lanolin
 Mineral elements, biological studies
 Paraffin waxes, biological studies
 Pentosans
 Peptides, biological studies
 Phospholipids, biological studies
 Polyolefins
 Polyurethanes, biological studies
 Pumice
 Steroids, biological studies
 Tetracyclines
 Trace elements, biological studies
 Tuberculin
 Vitamins
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)
 IT Fatty acids, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (essential; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)
 IT Belladonna (Atropa belladonna)
 Chrysanthemum
 (ext.; encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)
 IT Microorganism
 (food; encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)
 IT Temperature effects, biological
 (heat; encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)
 IT Food
 (infant; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)
 IT Natural products, pharmaceutical
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (ipecac; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Carbohydrates, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (low-mol. wt.; encapsulation of sensitive liq. components into matrix
 to obtain discrete shelf-stable particles)

IT Nutrients
 (micronutrients; encapsulation of sensitive liq. components into matrix
 to obtain discrete shelf-stable particles)

IT Antibodies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (monoclonal; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Aromatic compounds
 Aromatic compounds
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (nitro; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Peptides, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (oligopeptides; encapsulation of sensitive liq. components into matrix
 to obtain discrete shelf-stable particles)

IT Natural products, pharmaceutical
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (opium; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Mucopolysaccharides, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (polysulfate; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Breakfast cereal
 (ready-to-eat; encapsulation of sensitive liq. components into matrix
 to obtain discrete shelf-stable particles)

IT Food
 (salads; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Durum wheat
 (semolina; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Food
 (snack; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Food
 (sports bars; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Tannins
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (sulfated; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Carboxylic acids, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (thiocarboxylic; encapsulation of sensitive liq. components into matrix
 to obtain discrete shelf-stable particles)

IT Fatty acids, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (unsatd.; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Measles virus
 Rabies
 Rubella virus
 (vaccine; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT Fever and Hyperthermia
 (yellow, vaccine; encapsulation of sensitive liq. components into

matrix to obtain discrete shelf-stable particles)

IT Milk preparations
(yogurt; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 9005-25-8D, Starch, hydrolyzates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-09-9 50-12-4, Mephentyoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptylin 50-49-7 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate 50-63-5, Chloroquine phosphate 50-78-2, Aspirin 50-81-7, L-Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-52-5, Propyl thiouracil 51-55-8, Atropine, biological studies 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-74-1, Histamine phosphate 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5, Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1, L-Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1, Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-47-7, Pyridoxal phosphate 54-64-8, Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan 56-47-3, Deoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-54-2 56-75-7, Chloramphenicol 56-84-8, L-Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-92-1, biological studies 57-96-5, Sulfipyrazone 58-00-4, Apomorphine 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyrindamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride 58-61-7D, Adenosine, derivs. 58-85-5 58-89-9, Lindane 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrillamine maleate 59-43-8, Thiamin, biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7, Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4, L-Tyrosine, biological studies 60-56-0, Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1, Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 61-90-5, L-Leucine, biological studies 62-31-7, Dopamine hydrochloride 62-44-2,

Phenacetin 62-67-9, Nalorphine 62-90-8, Nandrolone phenpropionate 63-68-3, Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8, Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1, L-Histidine, biological studies 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8, Isopropamide iodide 72-14-0, Sulfathiazole 72-17-3 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 72-33-3, Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan, biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-57-2, Oxytetracycline 80-08-0 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpantenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 88-04-0, Chloroxylonol 89-57-6, 5-Aminosalicylic acid 90-33-5 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripeleminamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 94-24-6, Tetracaine 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzene 103-86-6, Hydroxyamphetamine 103-90-2 104-28-9, Cinoxate 104-31-4, Benzonatate 106-48-9 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0, Benzethonium chloride 121-75-5, Malathion 123-31-9, Hydroquinone, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscapine 129-20-4, Oxyphenbutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clloquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2, Benztropine mesylate 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9, Methyclothiazide 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-77-6, Hexyl resorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital

sodium 144-14-9, Anileridine 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-52-4, Nafcillin 147-85-3, L-Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrine 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, Racepinefrine 343-55-5, Dicloxacillin sodium 345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 359-83-1D, Pentazocine, salts 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone 388-51-2 389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene 426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2, Phenprocoumon 437-74-1, Xantinol nicotinate 439-14-5, Diazepam 440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole 446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone 471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin 479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine 511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate 514-65-8, Biperiden 518-47-8, Fluorescein sodium 520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6 527-07-1, Sodium gluconate 532-03-6, Methocarbamol 533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0, Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol 549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaïne hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2, Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide hydrochloride 555-30-6, Methyl dopa 557-34-6, Zinc acetate 562-10-7 564-25-0 577-11-7, Docusate sodium 579-56-6, Isoxsuprine hydrochloride 587-61-1, Propylidone 590-63-6, Bethanechol chloride 595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1, Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine 620-61-1, Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 672-87-7, Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine 777-11-7, Haloproglin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7, Lincomycin hydrochloride 865-21-4, Vinblastine 866-83-1, Potassium citrate 894-71-3, Nortriptyline hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton 969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafcillin sodium 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride 1094-08-2, Ethopropazine hydrochloride 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9, Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin 1151-11-7, Ipodate calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Ipodate sodium 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride 1244-76-4 1247-42-3, Meprednisone

1263-89-4, Paromomycin sulfate 1309-48-4, Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid 1343-97-1, Selenium sulfate 1393-48-2, Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2, Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9, Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8, Phenmetrazine hydrochloride 1808-12-4, Bromo diphenhydramine hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3, Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3, Meclocycline 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2098-66-0, Cyproterone 2179-37-5, Bencyclane
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 2315-02-8, Oxymetazoline hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatadine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4759-48-2, Isotretinoin 4891-15-0, Estramustine phosphate 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, .beta.-Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts 7440-39-3D, Barium, salts 7440-69-9, Bismuth, biological studies 7440-70-2D, Calcium, salts 7447-40-7, Potassium chloride, biological studies 7491-74-9, Piracetam 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide, biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide (NaI), biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8002-55-9, Myrtol 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1 9000-92-4, Amylase 9001-00-7, Bromelin 9001-01-8, Kallidinogenase 9001-62-1, Lipase 9001-73-4, Papain 9001-92-7, Proteinase 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic

gonadotropin 9002-86-2, Polyvinyl chloride 9003-20-7, Polyvinyl acetate 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6, Cellulose, biological studies 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 9012-54-8, Cellulase 9025-49-4 9025-56-3, Hemicellulase 9032-75-1, Pectinase 9068-42-2, Pentosanase 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanazolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin 13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3 14009-24-6, Drotaverine 14028-44-5, Amoxapine 14402-89-2, Sodium nitroprusside 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalixin 15687-27-1 15687-41-9, Oxyfedrine 16034-77-8, Iocetamic acid 16051-77-7 16482-55-6 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrel sulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4, Diflunisal 22916-47-8, Miconazole 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probuco 23593-75-1, Clotrimazole 23869-24-1, O-(.beta.-Hydroxyethyl)rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25155-18-4, Methylbenzethonium chloride 25301-02-4, Tyloxapol 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26605-69-6, Carbenicillin indanyl sodium 26652-09-5, Ritodrine 26652-10-8 26675-46-7, Isoflurane 26787-78-0, Amoxycillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicyclic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepin 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30516-87-1 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0, Etoposide 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36688-78-5 36791-04-5, Ribavirin 37270-89-6, Heparin calcium

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 37341-58-5, Phytase 37517-28-5, Amikacin 37517-30-9, Acebutolol

38194-50-2, Sulindac 38260-01-4, Trientine hydrochloride 38304-91-5,
 Minoxidil 38363-40-5, Penbutolol 38396-39-3, Bupivacaine 38821-53-3,
 Cephadrine 39562-70-4, Nitrendipine 40828-46-4, Suprofen 41859-67-0
 42200-33-9, Nadolol 42399-41-7 42540-40-9, Cefamandole nafate
 49562-28-9 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil
 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3,
 Bacampicillin 51022-69-6, Amcinonide 51481-61-9, Cimetidine
 51781-06-7, Carteolol 52468-60-7, Flunarizine 53164-05-9, Acemetacin
 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase
 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide
 54182-58-0, Sucralfate 54504-70-0, Etofylline clofibrate 54965-21-8,
 Albendazole 54965-24-1, Tamoxifen citrate 55268-74-1, Praziquantel
 55837-25-7, Buflomedil 55837-27-9, Piretanide 56392-17-7, Metoprolol
 tartrate 57109-90-7, Dipotassium chlorazepate 57432-61-8,
 Methylergonovine maleate 58551-69-2, Carboprost tromethamine
 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 60166-93-0, Iopamidol
 60200-06-8, Clorsulon 61177-45-5, Clavulanate potassium 61563-18-6,
 Soquinolol 62571-86-2, Captopril 62893-19-0, Cefoperazone
 63527-52-6, Cefotaxime 63659-18-7, Betaxolol 64544-07-6, Cefuroxime
 axetil 65277-42-1, Ketoconazole 65666-07-1, Silymarin 65899-73-2,
 Tioconazole 66108-95-0, Iohexol 66357-35-5, Ranitidine 66711-21-5,
 Apraclonidine 66734-13-2, Alclometasone dipropionate 68844-77-9,
 Astemizole 70458-96-7 72558-82-8, Ceftazidime 74978-16-8, Magaldrate
 75330-75-5, Lovastatin 76095-16-4, Enalapril maleate 76420-72-9,
 Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril
 76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam
 78266-06-5, Mebrofenin 79350-37-1, Cefixime 81103-11-9, Clarithromycin
 83200-10-6, Anipamil 83905-01-5, Azithromycin 85721-33-1,
 Ciprofloxacin 92665-29-7, Cefprozil 102188-40-9, Acromycin
 189752-49-6D, metal complexes 198080-50-1 264875-48-1,
 Tyrothricin-bethamethasone mixt.

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (encapsulation of sensitive liq. components into matrix to obtain
 discrete shelf-stable particles)

IT 144114-21-6, Retropepsin

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (inhibitors; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

IT 61489-71-2, Menotropin

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (menotrophin; encapsulation of sensitive liq. components into matrix to
 obtain discrete shelf-stable particles)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Katzen; US 3786123 A 1974 CAPLUS

L26 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:618371 CAPLUS

DN 129:255004

TI Prophylactic and therapeutic methods for ocular degenerative diseases and
 inflammations, and histidine compositions therefor

IN Thomas, Peter G.

PA Cytos Pharmaceuticals LLC, USA

SO U.S., 10 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A01N043-50

ICS C07D233-60

NCL 514399000

CC 1-12 (Pharmacology)

Section cross-reference(s): 62, 63

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 5811446 | A | 19980922 | US 1997-839805 | 19970418 |
| | WO 9847366 | A1 | 19981029 | WO 1998-US7319 | 19980417 |
| | W: | | | | |
| | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, | | | | |
| | DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, | | | | |
| | KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, | | | | |
| | NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, | | | | |
| | UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, | | | | |
| | FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, | | | | |
| | CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9873583 | A1 | 19981113 | AU 1998-73583 | 19980417 |
| PRAI | US 1997-839805 | | 19970418 | | |
| | WO 1998-US7319 | | 19980417 | | |
| AB | Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods. | | | | |
| ST | histidine pharmaceutical eye degenerative disease inflammation | | | | |
| IT | Ulcer | | | | |
| | (Mooren's, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Eye, disease | | | | |
| | (Terrein's marginal degeneration, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Granulomatous disease | | | | |
| | (Wegener's granulomatosis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Burn | | | | |
| | (acid and alkali, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Glycosides | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (amino; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Fibronectins | | | | |
| | Vitronectin | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (and analogs; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Tear (ocular fluid) | | | | |
| | (artificial; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Dysentery | | | | |
| | (bacillary, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Eye, disease | | | | |
| | (blepharitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations) | | | | |
| IT | Acids, biological studies | | | | |
| | Bases, biological studies | | | | |

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(chem. burn, eye inflammation related to; histidine compns. and methods
for ocular degenerative diseases and inflammations)

- IT Eye, disease
(conjunctivitis, allergic and others, eye inflammation related to;
histidine compns. and methods for ocular degenerative diseases and
inflammations)
- IT Eye
(cornea, haze; histidine compns. and methods for ocular degenerative
diseases and inflammations)
- IT Eye
(cornea, infiltration and thinning, eye inflammation related to;
histidine compns. and methods for ocular degenerative diseases and
inflammations)
- IT Eye, disease
Eye, disease
Eye, disease
(cornea, ulcer, eye inflammation related to; histidine compns. and
methods for ocular degenerative diseases and inflammations)
- IT Autoimmune disease
Food allergy
Leukemia
Myasthenia gravis
Psoriasis
Rheumatoid arthritis
Syphilis
(corneal disorder from, eye inflammation related to; histidine compns.
and methods for ocular degenerative diseases and inflammations)
- IT Excimer lasers
(corneal procedure; histidine compns. and methods for ocular
degenerative diseases and inflammations)
- IT Antiulcer agents
(corneal ulcer; histidine compns. and methods for ocular degenerative
diseases and inflammations)
- IT Amyloidosis
(corneal; histidine compns. and methods for ocular degenerative
diseases and inflammations)
- IT Cosmetics
(creams; histidine compns. and methods for ocular degenerative diseases
and inflammations)
- IT Drugs
(cytoplegics and miotics; histidine compns. and methods for ocular
degenerative diseases and inflammations)
- IT Eye, disease
(degeneration; histidine compns. and methods for ocular degenerative
diseases and inflammations)
- IT Eye, disease
(dellen, eye inflammation related to; histidine compns. and methods for
ocular degenerative diseases and inflammations)
- IT Eye, disease
(diabetic retinopathy; histidine compns. and methods for ocular
degenerative diseases and inflammations)
- IT Drug delivery systems
(emulsions; histidine compns. and methods for ocular degenerative
diseases and inflammations)
- IT Human herpesvirus
(epithelial keratitis, eye inflammation related to; histidine compns.
and methods for ocular degenerative diseases and inflammations)
- IT Edema
Infection
Lasers
(eye inflammation related to; histidine compns. and methods for ocular

degenerative diseases and inflammations)

IT Cosmetics
(eye liners; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(eye; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Sexually transmitted diseases
(gonorrhea, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Human herpesvirus 3
(herpes zoster from, keratitis and iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Anti-inflammatory agents
Antibacterial agents
Antibiotics
Antiglaucoma agents
Antioxidants
Antiviral agents
Eye, disease
Glaucoma (disease)
Wound healing promoters
(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Corticosteroids, biological studies
Glycoproteins, general, biological studies
Sulfonamides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Chlamydia trachomatis
(infection with, trachoma, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Adenoviridae
Arbovirus
Bacteria (Eubacteria)
Borrelia burgdorferi
Corynebacterium diphtheriae
Cytomegalovirus
DNA viruses
Fungi
Haemophilus
Human enterovirus 70
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human poliovirus
Influenza virus
Measles virus
Moraxella

- Mumps virus
- Neisseria gonorrhoeae
- Neisseria meningitidis
- Papillomavirus
- Parasite
- Pseudomonas
- RNA viruses
- Rabies virus
- Rhinovirus
- Serratia marcescens
- Staphylococcus
- Staphylococcus aureus
- Staphylococcus epidermidis
- Streptococcus
 - (infection, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (injections, i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (injections, intraocular; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (keratopathy, calcific band, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Ablation
 - (laser-assisted photoablative surgical procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (liqs.; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Eye, disease
 - (macula, degeneration, age-related; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Cosmetics
 - (mascaras; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Angiogenesis
 - (neovascularization, retinal, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Anti-inflammatory agents
 - (nonsteroidal; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ointments, creams; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ointments, eye; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Surgery
 - (ophthalmic procedures, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
- IT Drug delivery systems
 - (ophthalmic, ocular inserts; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(oral; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxo; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Artery, disease
(polyarteritis nodosa; corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Radicals, biological studies
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(radical-mediated eye disease; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
Eye, disease
Eye, disease
(retina, injury, photic or ischemia-induced; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(retina, ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(retina, neovascularization, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Ischemia
(retinal injury from; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Anti-ischemic agents
(retinal ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
Eye, disease
(retinitis, cytomegalovirus, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(scleritis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(solns., i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(solns., ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cataract
(surgery, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(suspensions; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Lupus erythematosus
(systemic, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

inflammations)

IT Drug delivery systems
(tablets; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(topical; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Injury
(trauma, eye, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Intestine, disease
(ulcerative colitis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(uveitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Infection
(viral, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye
(vitreous humor, age- or disease-based posterior vitreous detachment; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 71-00-1, L-Histidine, biological studies 351-50-8, D-Histidine
4998-57-6, Histidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compns. therefor)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone
50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological studies 51-83-2, Carbachol 53-03-2, Prednisone 53-86-1, Indomethacin 54-42-2, Idoxuridine 56-75-7, Chloramphenicol 57-47-6, Physostigmine 59-02-9, .alpha.-Tocopherol 59-42-7, Phenylephrine 59-66-5, Acetazolamide 69-53-4, Ampicillin 70-00-8, Trifluridine 70-18-8, Glutathione, biological studies 92-13-7, Pilocarpine 114-07-8, Erythromycin 127-40-2, Lutein 144-68-3, Zeaxanthin 378-44-9, Betamethasone 426-13-1, Fluorometholone 472-61-7, Astaxanthin 514-78-3, Canthaxanthin 616-91-1, Acetyl cysteine 738-70-5, Trimethoprim 768-94-5, Amantadine 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 4697-36-3, Carbenicillin 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine 7235-40-7, .beta.-Carotene 7761-88-8, Silver nitrate, biological studies 7783-00-8, Selenious acid 9054-89-1, Superoxide dismutase 11111-12-9, Cephalosporin 13292-46-1, Rifampin 13392-28-4, Rimantadine 13410-01-0, Sodium selenate 15307-86-5, Diclofenac 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 25953-19-9, Cefazolin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 30516-87-1, Azidothymidine 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 51481-65-3, Mezlocillin 56272-24-3, Histidine hydrochloride 59277-89-3, Acyclovir 68767-14-6, Loxoprofen 70458-96-7, Norfloxacin 74103-06-3, Ketorolac 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82768-44-3 85721-33-1, Ciprofloxacin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 9001-03-0, Carbonic anhydrase 9001-12-1, Collagenase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histidine compns. and methods for ocular degenerative
diseases and inflammations)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Babizhayev; 1989 CAPLUS
- (2) Babizhayev; Biochimica et Biophysica Acta 1989, V1004, P363 CAPLUS
- (3) Santen; 1983 CAPLUS

L26 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:293427 CAPLUS

DN 129:8597

TI Embedding and encapsulation of controlled release particles

IN Van Lengerich, Bernhard H.

PA Van Lengerich, Bernhard H., USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM B29C047-04

ICS B01J013-04; A01N025-26

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 5

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9818610 | A1 | 19980507 | WO 1997-US18984 | 19971027 |
| | W: AU, CA, JP, NO, PL, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9749915 | A1 | 19980522 | AU 1997-49915 | 19971027 |
| | AU 744156 | B2 | 20020214 | | |
| | EP 935523 | A1 | 19990818 | EP 1997-912825 | 19971027 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002511777 | T2 | 20020416 | JP 1998-520558 | 19971027 |
| | NO 9902036 | A | 19990428 | NO 1999-2036 | 19990428 |
| PRAI | US 1996-29038P | P | 19961028 | | |
| | US 1997-52717P | P | 19970716 | | |
| | WO 1997-US18984 | W | 19971027 | | |

AB Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The addnl. component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temp. of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixt. The mixt. is extruded through a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, glycerol monostearate, and vegetable oil.

ST encapsulation controlled release particle

IT Drug delivery systems
(controlled-release; embedding and encapsulation of controlled release particles)

IT Antitumor agents
Antiviral agents
Encapsulation
(embedding and encapsulation of controlled release particles)

IT Estrogens
Polyoxyalkylenes, biological studies
Tuberculin
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT Antibiotics
Antioxidants
Detergents
Emulsifying agents
Extrusion, nonbiological
Fats and Glyceridic oils, biological studies
Fatty acids, biological studies
Flavor
Fungicides
Glass transition
Heat treatment
Herbicides
Hydrocolloids
Insecticides
Lipids, biological studies
Paraffin waxes, biological studies
Peptides, biological studies
Perfumes
Pesticides
Plasticizers
Polyolefins
Polyurethanes, biological studies
Proteins, general, biological studies
Rodenticides
Steroids, biological studies
Surfactants
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; embedding and encapsulation of controlled release particles)

IT Drug delivery systems
(particles; embedding and encapsulation of controlled release particles)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephentyoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate 50-63-5, Chloroquine phosphate 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8,

Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine
 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies
 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies
 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine
 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9,
 Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa
 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5,
 Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1,
 Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone,
 biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1,
 Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium
 salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-64-8,
 Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1,
 Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan
 56-29-1, Hexobarbital 56-47-3, Desoxycorticosterone acetate 56-53-1,
 Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol
 56-84-8, L-Aspartic acid, biological studies 56-87-1, L-Lysine,
 biological studies 57-13-6, Urea, biological studies 57-22-7,
 Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin
 57-42-1, Meperidine 57-43-2, Amobarbital 57-47-6,
 Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol
 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone,
 biological studies 57-92-1, Streptomycin, biological studies 57-96-5,
 Sulfapyrazole 58-00-4, Apomorphine 58-08-2, Caffeine, biological
 studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0
 58-25-3, Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyridamole
 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9,
 Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9,
 Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride
 58-85-5, Biotin 58-89-9, Lindane 58-93-5, Hydrochlorothiazide
 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid,
 biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin,
 biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid .
 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7,
 Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4,
 Tyrosine, biological studies 60-54-8, Tetracycline 60-56-0,
 Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1,
 Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine
 hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine
 hydrochloride 61-90-5, Leucine, biological studies 62-31-7, Dopamine
 hydrochloride 62-44-2, Phenacetin 62-67-9, Nalorphine 62-90-8,
 Nandrolone phenpropionate 63-68-3, Methionine, biological studies
 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine
 hydrochloride 63-98-9, Phenacetamide 64-31-3, Morphine sulfate
 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8,
 Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8,
 Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone
 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 67-97-0,
 Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone
 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole
 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4,
 Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1,
 Histidine, biological studies 71-58-9, Medroxyprogesterone acetate
 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8
 72-14-0, Sulfathiazole 72-17-3, Sodium lactate 72-18-4, Valine,
 biological studies 72-19-5, L-Threonine, biological studies 72-33-3,
 Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan,
 biological studies 73-48-3, Bendroflumethiazide 76-38-0,
 Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3,
 Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide
 77-26-9, Butalbital 77-27-0, Thiethylal 77-36-1, Chlorthalidone
 77-41-8, Methsuximide 78-44-4, Carisoprodol 79-57-2, Oxytetracycline

80-08-0, Dapsone 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-22-0, Tetrahydrozoline 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Phenoxymethylpenicillin 87-33-2, ISDN 89-57-6, 5-Aminosalicylic acid 90-33-5, Hymecromone 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripelennamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzene 103-86-6, Hydroxyamphetamine 103-90-2, Acetaminophen 104-28-9, Cinoxate 104-31-4, Benzonatate 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital 115-77-5, biological studies 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

IT 121-75-5, Malathion 123-31-9, 1,4-Benzenediol, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscaphine 129-20-4, Oxyphenbutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clioquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-47-0 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital sodium 144-14-9, Anileridine 144-48-9, Iodoacetamide 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-24-0, Diphenhydramine hydrochloride 147-52-4, Nafcillin 147-85-3, Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 152-97-6, Fluocortolone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrin 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]- 343-55-5, Dicloxacillin sodium 345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 359-83-1, Pentazocine 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone

389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene
 426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2,
 Phenprocoumon 437-74-1, Xantinol nicotinate 439-14-5, Diazepam
 440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole
 446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone
 471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin
 479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine
 511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate
 514-65-8, Biperiden 518-47-8, Fluorescein sodium 519-37-9, Etofylline
 520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6,
 Propranolol 527-07-1, Sodium gluconate 532-03-6, Methocarbamol
 533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide
 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0,
 Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol
 549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaine
 hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2,
 Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide
 hydrochloride 555-30-6, Methyldopa 557-34-6, Zinc acetate 562-10-7
 564-25-0, Doxycycline 577-11-7, Docusate sodium 579-56-6, Isoxsuprine
 hydrochloride 587-61-1, Propyliodone 590-63-6, Bethanechol chloride
 595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1,
 Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1,
 Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine
 620-61-1, Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate
 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 638-23-3
 642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 652-67-5
 672-87-7, Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine
 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3,
 Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine
 777-11-7, Haloprogin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine
 hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7,
 Lincomycin hydrochloride 865-21-4, Vinblastine 894-71-3, Nortriptyline
 hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton
 969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafcillin sodium
 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride
 1077-28-7, Thiocetic acid 1094-08-2, Ethopropazine hydrochloride
 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9,
 Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin
 1151-11-7, Iodate calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin
 sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Iodate sodium
 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride
 1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1309-48-4,
 Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid
 1321-23-9, Chloroxylenol 1343-97-1, Selenium sulfate 1393-48-2,
 Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3,
 Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2,
 Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin
 sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin
 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9,
 Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin
 calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide
 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide
 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3,
 Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene
 hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8,
 Phenmetrazine hydrochloride 1808-12-4, Bromodiphenhydramine
 hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3,
 Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3,
 Meclocycline

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

IT 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide
 2098-66-0, Cyproterone 2179-37-5, Bencyclane 2192-20-3, Hydroxyzine
 hydrochloride 2315-02-8, Oxymetazoline hydrochloride 2398-96-1,
 Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6,
 Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies
 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam
 2955-38-6, Prazepam 2998-57-4, Estramustine 3313-26-6, Thiothixene
 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3485-62-9, Clidinium
 bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate
 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2,
 Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate
 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride
 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline
 hydrochloride 3978-86-7, Azatadine maleate 4205-90-7, Clonidine
 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate
 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5,
 Oxtriphylline, biological studies 4697-36-3, Carbenicillin 4759-48-2,
 Isotretinoin 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4,
 Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride
 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine
 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5,
 Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride
 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine
 hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium
 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline
 6533-00-2, Norgestrel 6805-41-0, Aescin 6890-40-0, Histamine phosphate
 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7,
 .beta.-Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate
 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium
 7439-95-4D, Magnesium, salts, biological studies 7439-96-5, Manganese,
 biological studies 7439-96-5D, Manganese, salts, biological studies
 7440-39-3, Barium, biological studies 7440-69-9, Bismuth, biological
 studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium
 chloride (KCl), biological studies 7491-74-9, Piracetam 7553-56-2,
 Iodine, biological studies 7632-00-0, Sodium nitrite 7646-85-7, Zinc
 chloride, biological studies 7681-11-0, Potassium iodide (KI),
 biological studies 7681-49-4, Sodium fluoride, biological studies
 7681-82-5, Sodium iodide, biological studies 7681-93-8, Natamycin
 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7778-49-6,
 Potassium citrate 7783-00-8, Selenious acid 7786-30-3, Magnesium
 chloride, biological studies 8017-57-0, Trisulfapyrimidine 8024-48-4,
 Casanthranol 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0,
 Liotrix 8067-24-1, Ergoloid mesylates 9001-01-8, Kallidinogenase
 9001-73-4, Papain 9002-07-7, Trypsin 9002-60-2, Corticotropin,
 biological studies 9002-61-3, Chorionic gonadotropin 9002-86-2, Pvc
 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8,
 Pvp 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8,
 Insulin, biological studies 9004-32-4, Carboxymethylcellulose
 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-53-9,
 Dextrin 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies
 9005-80-5, Inulin 9008-05-3, Histoplasmin 10025-73-7, Chromic chloride
 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0,
 Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline
 hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanazolol
 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium
 chloride, biological studies 12619-70-4, Cyclodextrin 12622-73-0,
 Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin
 13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1,
 Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0,
 Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies
 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3,
 Dihydroxyaluminum aminoacetate 14009-24-6, Drotaverine 14028-44-5,

Amoxapine 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15078-28-1, Nitroprusside 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalixin 15687-27-1 15687-41-9, Oxyfedrine 16482-55-6, Dihydroxyaluminum sodium carbonate 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrel sulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4 22916-47-8 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probuco 23593-75-1, Clotrimazole 23869-24-1, O-(.beta.-Hydroxyethyl)-rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25086-89-9, Vinyl acetate-N-vinylpyrrolidinone copolymer 25155-18-4, Methylbenzethonium chloride 25167-80-0, Chlorophenol 25301-02-4, Tyloxapol 25322-68-3 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25717-80-0, Molsidomine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26652-09-5, Ritodrine 26675-46-7, Isoflurane 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicyclic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepine 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30578-37-1, Ameszium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (embedding and encapsulation of controlled release particles)

IT 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36688-78-5 36791-04-5 37270-89-6, Heparin calcium 37517-28-5, Amikacin 37517-30-9, Acebutolol 38194-50-2, Sulindac 38260-01-4, Trientine hydrochloride 38304-91-5, Minoxidil 38363-40-5, Penbutolol 38396-39-3, Bupivacaine 38821-53-3, Cephadrine 39562-70-4, Nitrendipine 40828-46-4, Suprofen 41859-67-0, Bezafibrate 42200-33-9, Nadolol 42399-41-7, Diltiazem 42540-40-9, Cefamandole nafate 49562-28-9, Fenofibrate 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-69-6, Amcinonide 51481-61-9, Cimetidine 51781-06-7, Carteolol 52468-60-7, Flunarizine 53164-05-9, Acemetacin 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide 54182-58-0, Sucralfate 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-74-1, Praziquantel 55837-25-7, Buflomedil 55837-27-9, Piretanide 56392-17-7, Metoprolol tartrate 57109-90-7, Dipotassium chlorazepate 57432-61-8, Methylegonovine maleate 57435-86-6, Premazepam 58551-69-2, Carboprost tromethamine 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60833-22-9, Pyridoxal 5'-phosphate glutamate 61177-45-5, Clavulanate potassium

61489-71-2, Menotropin 61563-18-6, Soquinolol 62571-86-2, Captopril
62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 63659-18-7, Betaxolol
64024-15-3, Pentazocine hydrochloride 64544-07-6, Cefuroxime axetil
65277-42-1, Ketoconazole 65666-07-1, Silymarin 65899-73-2, Tioconazole
66108-95-0, Iohexol 66357-35-5, Ranitidine 66711-21-5, Apraclonidine
66734-13-2, Alclometasone dipropionate 68844-77-9, Astemizole
70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 74978-16-8, Magaldrate
75330-75-5, Lovastatin 76095-16-4, Enalapril maleate 76420-72-9,
Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril
76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam
78266-06-5, Mebrofenin 79350-37-1, Cefixime 81103-11-9, Clarithromycin
83200-10-6, Anipamil 83905-01-5, Azithromycin 85721-33-1,
Ciprofloxacin 92665-29-7, Cefprozil 102188-40-9, Acromycin
150977-36-9, Bromelain

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

IT 9001-92-7, Protease

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, HIV; embedding and encapsulation of controlled release
particles)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Carr; US 5183690 A 1993 CAPLUS
- (2) Chan; US 5075058 A 1991
- (3) Katzen; US 3786123 A 1974 CAPLUS
- (4) Katzen; US 3962416 A 1976 CAPLUS
- (5) McMahon; US 5466460 A 1995 CAPLUS

L26 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1997:440981 CAPLUS

DN 127:144786

TI Rabies virus infection of IMR-32 human neuroblastoma cells and effect of
neurochemical and other agents

AU Lentz, Thomas L.; Fu, Yiguang; Lewis, Peter

CS Dep. Cell Biol., Yale Univ. School Med., New Haven, CT, 06520-8002, USA

SO Antiviral Research (1997), 35(1), 29-39

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier

DT Journal

LA English

CC 1-5 (Pharmacology)

Section cross-reference(s): 14, 15

AB IMR-32 human neuroblastoma cells are a continuous nerve cell line
expressing neuronal nicotine acetylcholine receptors. These cells were
susceptible to infection by rabies virus (CVS strain). After infection,
viral antigen accumulated in the cell body in puncta and larger masses and
spread out into the processes until at 3-4 days the entire cell was filled
with antigen and lysed. A variety of chem. agents including cholinergic
agonists and antagonists were tested for ability to inhibit infection of
IMR-32 cells in a fluorescent focus assay. Agents found to inhibit
infection were antibodies against the viral glycoprotein, gangliosides, a
synthetic peptide of the neurotoxin-binding site of Torpedo acetylcholine
receptor .alpha.1 subunit, .alpha.-bungarotoxin, and lysosomotropic
agents. All other agents tested including other cholinergic ligands and
synthetic peptides were not effective. Except for lysosomotropic agents,
the agents which inhibited infection also inhibited attachment of virus to
the cell surface. These results indicate that IMR-32 cells are a useful
model in studying the interaction of a neurotropic virus with human
neurons. The ability of .alpha.-bungarotoxin to inhibit infection
suggests that neuronal .alpha.-bungarotoxin-binding receptors might serve
as central nervous system receptors for rabies virus.

ST rabies virus infection IMR32 neuroblastoma **antiviral**; neuron
rabies virus infection **antiviral** agent; nicotinic receptor
rabies virus infection **antiviral**

IT Animal cell line
(IMR-32; rabies virus infection of IMR-32 human neuroblastoma cells and
effect of neurochem. and other agents in relation to role of nicotinic
receptors)

IT Venoms
(King Cobra, neurotoxin of; rabies virus infection of IMR-32 human
neuroblastoma cells and effect of neurochem. and other agents in
relation to role of nicotinic receptors)

IT Cholinergic receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(Torpedo; rabies virus infection of IMR-32 human neuroblastoma cells
and effect of neurochem. and other agents in relation to role of
nicotinic receptors)

IT Torpedo (fish)
(acetylcholine receptor; rabies virus infection of IMR-32 human
neuroblastoma cells and effect of neurochem. and other agents in
relation to role of nicotinic receptors)

IT Nerve
(neuron; rabies virus infection of IMR-32 human neuroblastoma cells and
effect of neurochem. and other agents in relation to role of nicotinic
receptors)

IT Toxins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(neurotoxins, of King Cobra venom; rabies virus infection of IMR-32
human neuroblastoma cells and effect of neurochem. and other agents in
relation to role of nicotinic receptors)

IT Gangliosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(of brain; rabies virus infection of IMR-32 human neuroblastoma cells
and effect of neurochem. and other agents in relation to role of
nicotinic receptors)

IT Glycoproteins, general, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of rabies virus, antibodies to; rabies virus infection of IMR-32 human
neuroblastoma cells and effect of neurochem. and other agents in
relation to role of nicotinic receptors)

IT **Antiviral** agents
Cholinergic agonists
Cholinergic antagonists
Disease models
Rabies virus
(rabies virus infection of IMR-32 human neuroblastoma cells and effect
of neurochem. and other agents in relation to role of nicotinic
receptors)

IT GABA receptors
Glycine receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(rabies virus infection of IMR-32 human neuroblastoma cells and effect
of neurochem. and other agents in relation to role of nicotinic
receptors)

IT Nicotinic receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(to rabies virus glycoprotein; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Lysosome

(tropic agents; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT 51-55-8, Atropine, biological studies 51-83-2, Carbamylcholine chloride
54-05-7, Chloroquine 57-47-6, Eserine 57-94-3, d-Tubocurarine
chloride 65-31-6 130-95-0 485-35-8, Cytisine 2609-46-3, Amiloride
9007-92-5, Glucagon, biological studies 11032-79-4, .alpha.-Bungarotoxin
12125-02-9, Ammonium chloride, biological studies 21019-30-7,
Methyllycaconitine 64285-06-9, Anatoxin-a

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

| | |
|----|--------------------|
| | E STRVUDINE |
| L1 | 0 S STRVUDINE |
| L2 | 0 S D4T |
| | E D4T |
| L3 | 5 S STAVUDINE |
| L4 | 42 S PARAOXON |
| L5 | 0 S PHYOSTIGMINE |
| L6 | 0 S PHYOSTIGMINE |
| L7 | 54 S PHYSOSTIGMINE |

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

| | |
|-----|-----------------------------------|
| L8 | 1300 S L3 |
| L9 | 2913 S L4 |
| L10 | 4718 S L7 |
| | E HIV |
| L11 | 50075 S E3 OR E7 |
| | E HERPES |
| L12 | 21343 S E3 |
| L13 | 17244 S HHV OR HSV OR HCMV OR CMV |
| L14 | 29657 S L12 OR L13 |
| L15 | 7547 S PHOSPHATE ESTER |
| L16 | 2 S L8 AND L15 |
| | E ESTER |
| L17 | 518186 S E3 |
| L18 | 2414368 S S |
| L19 | 54 S L17 AND L8 |
| L20 | 3 S L9 AND L11 |

L21 0 S L9 AND L14
L22 2 S L10 AND L11
L23 1 S L10 AND L14
E ANTIVIRAL
L24 38629 S E3-E9
L25 2 S L24 AND L9
L26 8 S L10 AND L24

=> s 18 and 19

L27 1 L8 AND L9

=>

=> d 127

L27 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2001:454452 CAPLUS
DN 135:313108
TI In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine) in mice
AU Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS Drug Discovery Program, Department of Pharmaceutical Sciences, Parker Hughes Institute, St. Paul, MN, 55113, USA
SO Drug Metabolism and Disposition (2001), 29(7), 1035-1041
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 18 and 110

L28 5 L8 AND L10

=> d 128 1-5

L28 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:454452 CAPLUS
DN 135:313108
TI In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine) in mice
AU Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS Drug Discovery Program, Department of Pharmaceutical Sciences, Parker Hughes Institute, St. Paul, MN, 55113, USA
SO Drug Metabolism and Disposition (2001), 29(7), 1035-1041
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:396644 CAPLUS
DN 135:24671
TI Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IN Patel, Manesh V.; Chen, Feng-jing
PA Lipocine, Inc., USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|--|----------|
| PI | WO 2001037808 | A1 | 20010531 | WO 2000-US32255 | 20001122 |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | |
| | US 6248363 | B1 | 20010619 | US 1999-447690 | 19991123 |
| | EP 1233756 | A1 | 20020828 | EP 2000-980761 | 20001122 |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| PRAI | US 1999-447690 | A | 19991123 | | |
| | WO 2000-US32255 | W | 20001122 | | |

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|--|----------|
| PI | WO 2001028555 | A1 | 20010426 | WO 2000-US28835 | 20001018 |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | |
| | US 2002107265 | A1 | 20020808 | US 1999-420159 | 19991018 |
| PRAI | US 1999-420159 | A | 19991018 | | |

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS

AN 2001:136991 CAPLUS

DN 134:198075

TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

IN Patel, Mahesh V.; Chen, Feng-Jing

PA Lipocine, Inc., USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2001012155 | A1 | 20010222 | WO 2000-US18807 | 20000710 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 6309663 | B1 | 20011030 | US 1999-375636 | 19990817 |
| | EP 1210063 | A1 | 20020605 | EP 2000-947184 | 20000710 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | |
| | JP 2003506476 | T2 | 20030218 | JP 2001-516502 | 20000710 |
| | US 2001024658 | A1 | 20010927 | US 2000-751968 | 20001229 |
| | US 6458383 | B2 | 20021001 | | |
| PRAI | US 1999-375636 | A | 19990817 | | |
| | WO 2000-US18807 | W | 20000710 | | |

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

AN 2000:725436 CAPLUS

DN 133:301171

TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

IN Chen, Feng-jing; Patel, Manesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 2000059475 | A1 | 20001012 | WO 2000-US7342 | 20000316 |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 6383471 | B1 | 20020507 | US 1999-287043 | 19990406 |
| | EP 1165048 | A1 | 20020102 | EP 2000-916547 | 20000316 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| PRAI | US 1999-287043 | A | 19990406 | | |
| | WO 2000-US7342 | W | 20000316 | | |

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 19 and 110

L29 152 L9 AND L10

=> d 129 100-152

L29 ANSWER 100 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1975:597775 CAPLUS

DN 83:197775

TI Germ content of some pharmaceuticals for eye medication preparation

AU Mengert, Ch.; Weiss, H.

CS Gesundheitswes. Gotha, Staatl. Tenneberg-Apotheke, Waltershausen, Ger. Dem. Rep.

SO Pharmazeutische Praxis (1975), (8), 177-80

CODEN: PHPXAK; ISSN: 0048-3656

DT Journal

LA German

L29 ANSWER 101 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1975:543468 CAPLUS

DN 83:143468

TI Significance of multiple molecular forms of acetylcholinesterase in the sensitivity of houseflies to organophosphorus poisoning

AU Tripathi, R. K.; O'Brien, R. D.

CS Sect. Neurobiol. Behav., Cornell Univ., Ithaca, NY, USA

SO Isozymes, Int. Conf., 3rd (1975), Meeting Date 1974, Volume 2, 395-407.

Editor(s): Markert, Clement. Publisher: Academic, New York, N. Y.

CODEN: 30VGAW

DT Conference

LA English

L29 ANSWER 102 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1975:491112 CAPLUS

DN 83:91112

TI Action of drugs on the repetitively stimulated superior cervical ganglion of the rat

AU Iwasaki, Mitsuyoshi

CS Res. Inst. Chemobiodyn., Chiba Univ., Chiba, Japan

SO Chiba Igaku Zasshi (1975), 51(2), 73-80

CODEN: CIZAAZ; ISSN: 0303-5476

DT Journal

LA Japanese

L29 ANSWER 103 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1975:438457 CAPLUS

DN 83:38457

TI Toxicity of DFP [diisopropylphosphorofluoridate] and related compounds to squids in relation to cholinesterase inhibition and detoxifying enzyme levels

AU Dettbarn, W. D.; Hoskin, Francis C. G.

CS Pharmacol. Dep., Vanderbilt Univ., Nashville, TN, USA

SO Bulletin of Environmental Contamination and Toxicology (1975), 13(2), 133-40

CODEN: BECTA6; ISSN: 0007-4861

DT Journal

LA English

L29 ANSWER 104 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1975:401482 CAPLUS

DN 83:1482

TI Influence of esterase inhibitors on platelet aggregation and release induced by phorbol myristate acetate

AU Rao, Gundu H. R.; White, James G.

CS Sch. Med., Univ. Minnesota, Minneapolis, MN, USA
 SO Biochemical Pharmacology (1975), 24(2), 293-5
 CODEN: BCPA6; ISSN: 0006-2952
 DT Journal
 LA English

L29 ANSWER 105 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1975:51668 CAPLUS
 DN 82:51668
 TI Effect of paraoxon on the hypnotic action of chloral hydrate
 AU Koepke, Uwe Ch.; Coon, J. M.; Triolo, Anthony J.
 CS Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA, USA
 SO Toxicology and Applied Pharmacology (1974), 30(1), 36-51
 CODEN: TXAPA9; ISSN: 0041-008X
 DT Journal
 LA English

L29 ANSWER 106 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:515001 CAPLUS
 DN 81:115001
 TI Reaction of the somatic musculature of the nematode *Ascaridia galli* to cholinergic substances
 AU Shishov, B. A.; Malyutina, T. A.
 CS USSR
 SO Trudy Gel'mintologicheskoi Laboratorii, Akademiya Nauk SSSR (1974), 24, 258-62
 CODEN: TGMLA6; ISSN: 0568-5524
 DT Journal
 LA Russian

L29 ANSWER 107 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:434164 CAPLUS
 DN 81:34164
 TI Interaction of dichlorvos and anticholinesterases on the in vitro inhibition of human blood cholinesterases
 AU Carter, M. Kathleen; Maddux, Betty
 CS Sch. Med., Tulane Univ., New Orleans, LA, USA
 SO Toxicology and Applied Pharmacology (1974), 27(2), 456-63
 CODEN: TXAPA9; ISSN: 0041-008X
 DT Journal
 LA English

L29 ANSWER 108 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:422020 CAPLUS
 DN 81:22020
 TI Toxicological tolerance of antidotes during alkyl phosphate poisoning
 AU Kermes, U.; Wiezorek, W. D.
 CS Inst. Pharmakol. Toxikol., Karl-Marx-Univ., Leipzig, Ger. Dem. Rep.
 SO Zeitschrift fuer Militaermedizin (1973), 14(6), 320-3
 CODEN: ZEMIAF; ISSN: 0514-8782
 DT Journal
 LA German

L29 ANSWER 109 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1973:439281 CAPLUS
 DN 79:39281
 TI Mechanism of action of some organophosphorus insecticides on esterase activity of *Musca domestica* larvae classified by ultramicroelectrophoresis on polyacrylamide gel
 AU Kharsun, A. I.; Liptuga, N. I.
 CS Inst. Org. Khim., Kiev, USSR
 SO Fiziologicheskii Aktivnye Veshchestva (1966-1992) (1972), No. 4, 35-41

CODEN: FAVUAI; ISSN: 0533-1153

DT Journal
LA Russian

L29 ANSWER 110 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1973:106098 CAPLUS

DN 78:106098

TI Influence of atropine and cholinesterase inhibitors on brain potentials evoked by tooth pulp stimulation

AU Schmidt, J.; Wolf, H.

CS Inst. Pharmakol. Toxikol., Med. Akad. Magdeburg, Magdeburg, Ger. Dem. Rep.

SO Acta Biologica et Medica Germanica (1972), 29(4-5), 723-8

CODEN: ABMGAJ; ISSN: 0001-5318

DT Journal
LA German

L29 ANSWER 111 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1973:80563 CAPLUS

DN 78:80563

TI Effect of diisopropyl phosphorofluoridate and paraoxon in vivo and in vitro on the sodium and potassium contents of mouse liver tissue

AU Ramachandran, B. V.; Patil, B. G.

CS Natl. Chem. Lab., Poona, India

SO Indian Journal of Experimental Biology (1972), 10(5), 371-4

CODEN: IJEBA6; ISSN: 0019-5189

DT Journal
LA English

L29 ANSWER 112 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1973:23913 CAPLUS

DN 78:23913

TI Relation of the acylation of membrane esterases and proteins to the teratogenic action of organophosphorus insecticides and eserine in developing hen eggs

AU Flockhart, Ian R.; Casida, John E.

CS Div. Entomol., Univ. California, Berkeley, CA, USA

SO Biochemical Pharmacology (1972), 21(19), 2591-603

CODEN: BCPCA6; ISSN: 0006-2952

DT Journal
LA English

L29 ANSWER 113 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1973:13185 CAPLUS

DN 78:13185

TI Effect of pH on the activity of nerve cholinesterases of the rat towards different biochemical and histochemical substrates and inhibitors

AU Eranko, Liisa

CS Dep. Anat., Univ. Helsinki, Helsinki, Finland

SO Histochemie (1973), 33(1), 1-14

CODEN: HICHAU; ISSN: 0018-2222

DT Journal
LA English

L29 ANSWER 114 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1972:483469 CAPLUS

DN 77:83469

TI Renal tubular transport of acetylcholine and atropine. Enhancement and inhibition

AU Acara, Margaret; Rennick, Barbara

CS Sch. Med., State Univ. New York, Buffalo, NY, USA

SO Journal of Pharmacology and Experimental Therapeutics (1972), 182(1), 14-26

CODEN: JPETAB; ISSN: 0022-3565

DT Journal
LA English

L29 ANSWER 115 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1972:457115 CAPLUS

DN 77:57115

TI Effect of cholinergic substances on the contractile activity of the reproductive tube of female *Ascaris suum*

AU Terenina, N. B.

CS USSR

SO Trudy Vsesoyuznogo Instituta Gel'mintologii imeni K. I. Skryabina (1971), 17, 169-70

CODEN: TVIGA8; ISSN: 0372-2759

DT Journal
LA Russian

L29 ANSWER 116 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1972:414945 CAPLUS

DN 77:14945

TI Effect of drugs on the contractile activity of the genital tube of a female ascarid

AU Terenina, N. B.

CS USSR

SO Trudy Gel'mintologicheskoi Laboratorii, Akademiya Nauk SSSR (1971), 22, 203-7

CODEN: TGMLA6; ISSN: 0568-5524

DT Journal
LA Russian

L29 ANSWER 117 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1972:414346 CAPLUS

DN 77:14346

TI Cataracts following the use of long-acting cholinesterase inhibitors in glaucoma patients

AU Axelsson, Uno

CS Dep. Ophthalmol., Sabbatsberg Hosp., Stockholm, Swed.

SO Proceedings of the European Society for the Study of Drug Toxicity (1971), 12, 199-203

CODEN: PSDTAP; ISSN: 0071-3090

DT Journal
LA English

L29 ANSWER 118 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1972:149707 CAPLUS

DN 76:149707

TI Effect of tri-o-tolyl phosphate pretreatment on the toxicity and metabolism of parathion and paraoxon in mice

AU Lynch, W. T.; Coon, J. M.

CS Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA, USA

SO Toxicology and Applied Pharmacology (1972), 21(2), 153-65

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal
LA English

L29 ANSWER 119 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1972:149092 CAPLUS

DN 76:149092

TI Potentiation of barbital narcosis in mice by cholinomimetics and cholinesterase blockers

AU Oelszner, W.; Ebert, W.; Westermann, K. H.

CS Inst. Pharmakol. Toxikol., Med. Akad. "Carl Gustav Carus", Dresden, Fed.

Rep. Ger.
SO Acta Biologica et Medica Germanica (1971), 27(5-6), 983-92
CODEN: ABMGAJ; ISSN: 0001-5318
DT Journal
LA German

L29 ANSWER 120 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:122541 CAPLUS
DN 76:122541
TI Influence of the route of exposure on the acute toxicity of cholinesterase inhibitors
AU Natoff, I. L.
CS Tunstall Lab., Shell Res. Ltd., Sittingbourne/Kent, UK
SO Arhiv za Higijenu Rada i Toksikologiju (1970), 21(4), 347-52
CODEN: AHRTAN; ISSN: 0004-1254
DT Journal
LA English

L29 ANSWER 121 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:10275 CAPLUS
DN 76:10275
TI Participation of the cholinergic system in temperature regulation in the mouse
AU Staib, A. H.; Schroeder
CS Inst. Pharmakol. Toxikol., Med. Akad. "Carl Gustav Carus", Dresden, Ger. Dem. Rep.
SO Archives Internationales de Pharmacodynamie et de Therapie (1971), 192(1), 88-95
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA German

L29 ANSWER 122 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:539261 CAPLUS
DN 75:139261
TI Effect of phenelzine on the toxicity of cholinergic drugs modified by reserpine
AU Liebmann, H.; Matthies, H.; Kumbier, E.
CS Inst. Pharmakol. Toxikol., Med. Akad. Magdeburg, Magdeburg, Fed. Rep. Ger.
SO Acta Biologica et Medica Germanica (1971), 26(3), 551-8
CODEN: ABMGAJ; ISSN: 0001-5318
DT Journal
LA German

L29 ANSWER 123 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:440395 CAPLUS
DN 75:40395
TI Vibratory comminution [of active substances] for the preparation of eye ointments
AU Quellmalz, K.; Schmidt, R.; Kastens, W.
CS Pharm. Zentrum Kreises Schmoelln, Schmoelln, Fed. Rep. Ger.
SO Pharmazeutische Praxis (1971), (5), 113-15
CODEN: PHPXAK; ISSN: 0048-3656
DT Journal
LA German

L29 ANSWER 124 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:416706 CAPLUS
DN 75:16706
TI Protein synthesis in lobster walking leg nerves
AU Welsch, Federico; Dettbarn, Wolf D.
CS Sch. Med., Vanderbilt Univ., Nashville, TN, USA

SO Comparative Biochemistry and Physiology, Part B: Biochemistry & Molecular
Biology (1971), 38(2), 393-403
CODEN: CBPBB8; ISSN: 1096-4959

DT Journal
LA English

L29 ANSWER 125 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:140083 CAPLUS
DN 74:140083
TI Influence of the route of exposure on the acute toxicity of cholinesterase
inhibitors
AU Natoff, Ian L.
CS Tunstall Lab., Shell Res. Ltd., Sittingbourne/Kent, UK
SO Journal Europeen de Toxicologie (1970), 3(6), 363-7
CODEN: JETOAS; ISSN: 0021-8219

DT Journal
LA English

L29 ANSWER 126 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:138807 CAPLUS
DN 74:138807
TI Protection of animals against soman (1,2,2-trimethylpropyl
methylphosphonofluoridate) by pretreatment with some other
organophosphorus compounds, followed by oxime and atropine
AU Berry, William K.; Davies, David Reginald; Gordon, J. J.
CS Chem. Def. Establ., Porton Down/Wiltshire, UK
SO Biochemical Pharmacology (1971), 20(1), 125-34
CODEN: BCPA6; ISSN: 0006-2952

DT Journal
LA English

L29 ANSWER 127 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:137090 CAPLUS
DN 74:137090
TI Histochemical specificity of cholinesterases to phenylthio-acetate in
differentiated neural tissues of insects and teleosts
AU Booth, Gary M.; Whitt, Gregory S.
CS Dep. Entomol., Univ. Illinois, Urbana, IL, USA
SO Tissue & Cell (1970), 2(4), 521-8
CODEN: TICEBI; ISSN: 0040-8166

DT Journal
LA English

L29 ANSWER 128 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:108765 CAPLUS
DN 74:108765
TI Mechanism of the action of phenol on the central nervous system of fish in
connection with a change in the external symptom complex of phenol
poisoning under the affect of anticholine esterase preparations
AU Luk'yanenko, V. I.
CS Tsent. Nauchno-Issled. Inst. Osetrovogo Khoz., Astrakhan, USSR
SO Vop. Vod. Toksikol. (1970), 154-62. Editor(s): Topachevskii, A. V.
Publisher: "Nauka", Moscow, USSR.
CODEN: 22TYA9

DT Conference
LA Russian

L29 ANSWER 129 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:97753 CAPLUS
DN 74:97753
TI Reaction of an isolated rat intestine to choline-potentiating agents
AU Prozorovskii, V. B.; Khromova, O. N.; Gladysheva, N. I.

CS Leningr. Pediatr. Med. Inst.; Leningrad, USSR
 SO Farmakologiya i Toksikologiya (Moscow) (1971), 34(1), 54-7
 CODEN: FATOAO; ISSN: 0014-8318
 DT Journal
 LA Russian

L29 ANSWER 130 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:518943 CAPLUS
 DN 73:118943
 TI Comparative antiparamyonic activity of cholinopotentiating agents
 AU Prozorovskii, V. B.; Vladeeva, N. V.; Khromova, O. N.; Dubovitskaya, S. I.
 CS Leningrad. Pediat. Med. Inst., Leningrad, USSR
 SO Farmakol. Tsent. Kholinolitikov Drugikh Neirotropnykh Sredstv (1969),
 225-6. Editor(s): Denisenko, P. P. Publisher: Leningrad. Sanit.-Gig. Med.
 Inst., Leningrad, USSR.
 CODEN: 17FBAU
 DT Conference
 LA Russian

L29 ANSWER 131 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:475458 CAPLUS
 DN 73:75458
 TI Significance of the content of nucleic acids and proteins in the retina
 for evaluation of side-effects of miotics on the eye
 AU Artem'ev, N. I.; Romashenkov, F. A.
 CS Astrakhan. Med. Inst., Astrakhan, USSR
 SO Oftal'mologicheskii Zhurnal (1969), 24(8), 573-7
 CODEN: OFZHAV; ISSN: 0030-0675
 DT Journal
 LA Russian

L29 ANSWER 132 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:475429 CAPLUS
 DN 73:75429
 TI Alteration of the work of the myocardium and phase structure of the
 cardiac cycle under the influence of sympatho- and vagomimetics
 AU Savitskii, N. N.; Blinova, T. A.
 CS USSR
 SO Kardiologiya (1969), 10(3), 66-74
 CODEN: KARDA2; ISSN: 0022-9040
 DT Journal
 LA Russian

L29 ANSWER 133 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:475348 CAPLUS
 DN 73:75348
 TI Antimyorelaxant effect of cholinopotentiating agents
 AU Prozorovskii, V. B.; Vladeeva, N. V.; Khromova, O. N.; Dubovitskaya, S. I.
 CS Cent. Sci.-Res. Lab., Leningrad Pediat. Med. Inst., Leningrad, USSR
 SO Byulleten Eksperimental'noi Biologii i Meditsiny (1970), 69(6), 51-4
 CODEN: BEBMAE; ISSN: 0365-9615
 DT Journal
 LA Russian

L29 ANSWER 134 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:63004 CAPLUS
 DN 72:63004
 TI Acetylcholinesterases of organophosphate-susceptible and -resistant spider
 mites
 AU Smissaert, H. R.; Voerman, Simon; Oostenbrugge, Lies; Renooy, Nel
 CS Lab. Res. Insect., Wageningen, Neth.
 SO Journal of Agricultural and Food Chemistry (1970), 18(1), 66-75

CODEN: JAFCAU; ISSN: 0021-8561

DT Journal
LA English

L29 ANSWER 135 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1969:489852 CAPLUS

DN 71:89852

TI Experimental therapy of poisoning with anticholinesterase medicinal agents

AU Prozorovskii, V. B.; Khromova, O. N.

CS Leningrad. Pediat. Med. Inst., Leningrad, USSR

SO Farmakologiya i Toksikologiya (Moscow) (1969), 32(4), 475-9

CODEN: FATOAO; ISSN: 0014-8318

DT Journal

LA Russian

L29 ANSWER 136 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1969:479642 CAPLUS

DN 71:79642

TI Glaucoma miotic therapy and cataract studies on echothiophate (phospholine iodide) and paraoxon (mintacol) with regard to cataractogenic effect

AU Axelsson, Uno

CS Sabbatsberg Hosp., Stockholm, Swed.

SO Acta Ophthalmologica, Supplementum (1969), 102, 37 pp.

CODEN: AOPSAP; ISSN: 0065-1451

DT Journal

LA English

L29 ANSWER 137 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1969:467554 CAPLUS

DN 71:67554

TI Binding sites of cholinesterases. Alkylation by an aziridinium derivative

AU O'Brien, Richard D.

CS Cornell Univ., Ithaca, NY, USA

SO Biochemical Journal (1969), 113(4), 713-19

CODEN: BIJOAK; ISSN: 0264-6021

DT Journal

LA English

L29 ANSWER 138 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1969:437337 CAPLUS

DN 71:37337

TI Sensitization of striated muscle choline receptors to acetylcholine

AU Prozorovskii, V. B.

CS Leningrad Pediat. Med. Inst., Leningrad, USSR

SO Byulleten Eksperimental'noi Biologii i Meditsiny (1969), 67(4), 56-9

CODEN: BEBMAE; ISSN: 0365-9615

DT Journal

LA Russian

L29 ANSWER 139 OF 152 CAPLUS COPYRIGHT 2003 ACS

AN 1969:429118 CAPLUS

DN 71:29118

TI Inversion of physostigmine hypertension by Para-oxon and diisopropylfluorophosphate

AU Varagic, Vladislav; Kazic, T.; Rosic, N.

CS Med. Fac., Beograd, Yugoslavia

SO Jugoslavica Physiologica et Pharmacologica Acta, Supplementum (1968), (1), 113-20

CODEN: IPPSBJ

DT Journal

LA English

L29 ANSWER 140 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:420696 CAPLUS
 DN 71:20696
 TI Inhibition of pain reactions of the mouse by cholinomimetics and the influence of antagonists
 AU Oelssner, W.; Andreas, K.
 CS Med. Akad. "Carl Gustav Carus" Dresden, Dresden, Fed. Rep. Ger.
 SO Acta Biologica et Medica Germanica (1969), 22(2), 369-85
 CODEN: ABMGAJ; ISSN: 0001-5318
 DT Journal
 LA German

L29 ANSWER 141 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:45050 CAPLUS
 DN 70:45050
 TI Direct measurement of acetylcholinesterase in living protist cells
 AU Medzon, Edward L.; Brady, Marilyn L.
 CS Univ. Western Ontario, London, ON, Can.
 SO Journal of Bacteriology (1969), 97(1), 402-15
 CODEN: JOBAAJ; ISSN: 0021-9193
 DT Journal
 LA English

L29 ANSWER 142 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:10039 CAPLUS
 DN 70:10039
 TI Effectiveness of cholinolytics as antidotes in poisoning of mice and rats with anticholinesterase agents
 AU Prozorovskii, V. B.
 CS Leningrad. Pediat. Med. Inst., Leningrad, USSR
 SO Farmakologiya i Toksikologiya (Moscow) (1968), 31(5), 553-6
 CODEN: FATOAO; ISSN: 0014-8318
 DT Journal
 LA Russian

L29 ANSWER 143 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:1615 CAPLUS
 DN 70:1615
 TI The action of ATP and cholinesterase inhibitors on mechanical properties of glycerinated muscle fibers
 AU Kalamkarova, M. B.
 CS Inst. Biol. Fiz., Moscow, USSR
 SO Biofiz. Myshechnogo Sokrashcheniya, Simp., Moscow (1966), Meeting Date 1964, 175-80. Editor(s): Frank, G. M. Publisher: Izd. "Nauka", Moscow, USSR.
 CODEN: 19YSAK
 DT Conference
 LA Russian

L29 ANSWER 144 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1968:93108 CAPLUS
 DN 68:93108
 TI Properties of an acetylcholinesterase from the face fly, *Musca autumnalis*
 AU Bratkowski, Thomas A.; Knowles, Charles O.
 CS Univ. of Missouri, Columbia, MO, USA
 SO Annals of the Entomological Society of America (1968), 61, 397-402
 CODEN: AESAAI; ISSN: 0013-8746
 DT Journal
 LA English

L29 ANSWER 145 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:506983 CAPLUS

DN 67:106983
 TI Influence of the route of administration on the toxicity of some
 cholinesterase inhibitors
 AU Natoff, I. L.
 CS "Shell" Res. Ltd., Settingbourne, UK
 SO Journal of Pharmacy and Pharmacology (1967), 19(9), 612-16
 CODEN: JPPMAB; ISSN: 0022-3573
 DT Journal
 LA English

L29 ANSWER 146 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:420336 CAPLUS
 DN 67:20336
 TI Poly(vinyl alcohol) as vehicle for eye drops
 AU Trautmann, I.
 CS Univ.-Augenklin., Leipzig, Fed. Rep. Ger.
 SO Deutsche Gesundheitswesen (1967), 22(7), 317-20
 CODEN: DEGEA3; ISSN: 0012-0219
 DT Journal
 LA German

L29 ANSWER 147 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:410012 CAPLUS
 DN 67:10012
 TI Cholinesterase inhibitors: eserine and myoticol
 AU Grijalbo Lizondo, Pilar
 CS Inst. Farmacol. Exptl., Madrid, Spain
 SO Archivos del Instituto de Farmacologia Experimental, Madrid (1966), 18(1),
 27-48
 CODEN: AIFEAR; ISSN: 0081-3303
 DT Journal
 LA Spanish

L29 ANSWER 148 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:84447 CAPLUS
 DN 66:84447
 TI Relation between cholinesterase activity and brain permeability to
 barbitone
 AU Rosic, N.; Milosevic, Milenko P.
 CS Dep. Pharmacol. Toxicol., Univ. Belgrade, Belgrade, Yugoslavia
 SO Archives Internationales de Pharmacodynamie et de Therapie (1967), 165(2),
 302-7
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English

L29 ANSWER 149 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:52702 CAPLUS
 DN 66:52702
 TI Effect of oximes on the hypertensive action of para-oxon and physostigmine
 in nonanesthetized rats
 AU Milosevic, Milenko P.
 CS Dept. Pharmacol., Med. Fac., Univ. Belgrade, Belgrade, Yugoslavia
 SO Medicina et Pharmacologia Experimentalis (1967), 16(1), 6-10
 CODEN: MPHEAE; ISSN: 0543-3002
 DT Journal
 LA English

L29 ANSWER 150 OF 152 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:17758 CAPLUS
 DN 66:17758
 TI Protective effect of aldrin against the toxicity of organophosphate

anticholinesterases
AU Triolo, Anthony J.; Coon, Julius M.
CS Jefferson Med. Coll., Philadelphia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1966), 154(3),
613-23
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA German/French

L29 ANSWER 151 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:10202 CAPLUS
DN 66:10202
TI Mode of action of organophosphate anthelmintics. Cholinesterase
inhibition in Ascaris lumbricoides
AU Knowles, Charles O.; Casida, John E.
CS Univ. of Wisconsin, Madison, WI, USA
SO Journal of Agricultural and Food Chemistry (1966), 14(6), 566-72
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L29 ANSWER 152 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:10152 CAPLUS
DN 66:10152
TI Toxicologic interactions of chlorinated hydrocarbon and organophosphate
insecticides
AU Triolo, Anthony J.; Coon, Julius M.
CS Jefferson Med. Coll., Philadelphia, PA, USA
SO Journal of Agricultural and Food Chemistry (1966), 14(6), 549-55
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

| | |
|----|--------------------|
| | E STRVUDINE |
| L1 | 0 S STRVUDINE |
| L2 | 0 S D4T |
| | E D4T |
| L3 | 5 S STAVUDINE |
| L4 | 42 S PARAOXON |
| L5 | 0 S PHYOSTIGMINE |
| L6 | 0 S PHYOSTIGMINE |
| L7 | 54 S PHYSOSTIGMINE |

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

| | |
|-----|-----------------------------------|
| L8 | 1300 S L3 |
| L9 | 2913 S L4 |
| L10 | 4718 S L7 |
| | E HIV |
| L11 | 50075 S E3 OR E7 |
| | E HERPES |
| L12 | 21343 S E3 |
| L13 | 17244 S HHV OR HSV OR HCMV OR CMV |
| L14 | 29657 S L12 OR L13 |
| L15 | 7547 S PHOSPHATE ESTER |
| L16 | 2 S L8 AND L15 |
| | E ESTER |

L17 518186 S E3
 L18 2414368 S S
 L19 54 S L17 AND L8
 L20 3 S L9 AND L11
 L21 0 S L9 AND L14
 L22 2 S L10 AND L11
 L23 1 S L10 AND L14
 E ANTIVIRAL
 L24 38629 S E3-E9
 L25 2 S L24 AND L9
 L26 8 S L10 AND L24
 L27 1 S L8 AND L9
 L28 5 S L8 AND L10
 L29 152 S L9 AND L10

=> e detoxification

E1 1 DETOXIFICATI/BI
 E2 2 DETOXIFICATING/BI
 E3 14393 --> DETOXIFICATION/BI
 E4 1 DETOXIFICATIONAL/BI
 E5 23 DETOXIFICATIONS/BI
 E6 4 DETOXIFICATIVE/BI
 E7 4 DETOXIFICATORY/BI
 E8 1 DETOXIFICING/BI
 E9 2395 DETOXIFIED/BI
 E10 52 DETOXIFIER/BI
 E11 31 DETOXIFIERS/BI
 E12 294 DETOXIFIES/BI

=> s e3-e12

14393 DETOXIFICATION/BI
 1 DETOXIFICATIONAL/BI
 23 DETOXIFICATIONS/BI
 4 DETOXIFICATIVE/BI
 4 DETOXIFICATORY/BI
 1 DETOXIFICING/BI
 2395 DETOXIFIED/BI
 52 DETOXIFIER/BI
 31 DETOXIFIERS/BI
 294 DETOXIFIES/BI
 L30 16332 (DETOXIFICATION/BI OR DETOXIFICATIONAL/BI OR DETOXIFICATIONS/BI
 OR DETOXIFICATIVE/BI OR DETOXIFICATORY/BI OR DETOXIFICING/BI OR
 DETOXIFIED/BI OR DETOXIFIER/BI OR DETOXIFIERS/BI OR DETOXIFIES/B
 I)

=> s l30 and l8

L31 0 L30 AND L8

=> e excrete

E1 4 EXCRETATORY/BI
 E2 1 EXCRETED/BI
 E3 3220 --> EXCRETE/BI
 E4 1 EXCRETEA/BI
 E5 41174 EXCRETED/BI
 E6 1 EXCRETEDAND/BI
 E7 1 EXCRETEDGLUTAMIC/BI
 E8 1 EXCRETEDIN/BI
 E9 1 EXCRETEDWITH/BI
 E10 1 EXCRETEED/BI
 E11 2 EXCRETEION/BI
 E12 1 EXCRETEN/BI

=> s e3-e5

3220 EXCRETE/BI
1 EXCRETEA/BI
41174 EXCRETED/BI

L32 43680 (EXCRETE/BI OR EXCRETEA/BI OR EXCRETED/BI)

=> s 130 and 19

L33 126 L30 AND L9

=> d 133 100-126

L33 ANSWER 100 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1986:124479 CAPLUS

DN 104:124479

TI Mechanism of enhanced parathion/paraaxon toxicity during pregnancy in the mouse

AU Weitman, Steven D.; Vodichnik, Mary Jo; Lech, John J.

CS Dep. Pharmacol. Toxicol., Med. Coll. Wisconsin, Milwaukee, WI, 53226, USA

SO Fundamental and Applied Toxicology (1986), 6(1), 155-61

CODEN: FAATDF; ISSN: 0272-0590

DT Journal

LA English

L33 ANSWER 101 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1985:466085 CAPLUS

DN 103:66085

TI Interethnic differences of human serum paraoxonase activity-relevance for the **detoxification** of organophosphorous compounds

AU Geldmacher-Von Mallinckrodt, M.; Diepgen, T. L.; Enders, P. W.

CS Inst. Rechtsmed., Univ. Erlangen-Nuernberg, Erlangen, D-8520, Fed. Rep. Ger.

SO Archives Belges de Medecine Sociale, Hygiene, Medecine du Travail et Medecine Legale (1984), Suppl. (Proc.-World Congr. "New Compd. Biol. Chem. Warf.: Toxicol. Eval., 1st, 1984), 243-51

CODEN: ABMHAM; ISSN: 0003-9578

DT Journal; General Review

LA English

L33 ANSWER 102 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1985:449626 CAPLUS

DN 103:49626

TI A fruit fly bioassay with phosphotriesterase for detection of certain organophosphorus insecticide residues

AU Chiang, Tom; Dean, Mary C.; McDaniel, C. Steven

CS Agric. Anal. Serv. Dep., Texas A and M Univ., College Station, TX, 77843, USA

SO Bulletin of Environmental Contamination and Toxicology (1985), 34(6), 809-14

CODEN: BECTA6; ISSN: 0007-4861

DT Journal

LA English

L33 ANSWER 103 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1985:161862 CAPLUS

DN 102:161862

TI Metabolic activation of phosphorothioate pesticides: role of the liver

AU Sultatos, Lester G.; Minor, Lerna D.; Murphy, Sheldon D.

CS Med. Cent., Louisiana State Univ., New Orleans, LA, USA

SO Journal of Pharmacology and Experimental Therapeutics (1985), 232(3), 624-8

CODEN: JPETAB; ISSN: 0022-3565

DT Journal

LA English

L33 ANSWER 104 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1984:565142 CAPLUS
DN 101:165142
TI Paraoxonase and paraoxon **detoxification**
AU Butler, Edward Grant
CS Univ. Michigan, Ann Arbor, MI, USA
SO (1984) 111 pp. Avail.: Univ. Microfilms Int., Order No. DA8412112
From: Diss. Abstr. Int. B 1984, 45(2), 522-3
DT Dissertation
LA English

L33 ANSWER 105 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1983:417760 CAPLUS
DN 99:17760
TI Hepatic microsomal **detoxification** of the organophosphates
paraoxon and chlorpyrifos oxon in the mouse
AU Sultatos, L. G.; Murphy, S. D.
CS Med. Sch., Univ. Texas, Houston, TX, 77025, USA
SO Drug Metabolism and Disposition (1983), 11(3), 232-8
CODEN: DMSAI; ISSN: 0090-9556
DT Journal
LA English

L33 ANSWER 106 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1983:66771 CAPLUS
DN 98:66771
TI Enzymic detoxication of organophosphorus insecticides and nerve gases in
primates
AU Losch, H.; Losch, K.; Haselmeyer, K. H.; Chemnitius, J. M.; Zech, R.
CS Zent. Biochem., Georg-August-Univ., Goettingen, 3400, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1982), 32(12), 1523-9
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA German

L33 ANSWER 107 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1983:29641 CAPLUS
DN 98:29641
TI The biochemical basis of resistance to organophosphorus insecticides in
the sheep blowfly, *Lucilia cuprina*
AU Hughes, P. B.; Devonshire, A. L.
CS Biol. Chem. Res. Inst., New South Wales Dep. Agric., Rydalmere, 2116,
Australia
SO Pesticide Biochemistry and Physiology (1982), 18(3), 289-97
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L33 ANSWER 108 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1981:615979 CAPLUS
DN 95:215979
TI Biological effect of organophosphorus pesticides at low concentration. I.
The detoxication of fenitrooxon at low concentration by mouse liver
preparation
AU Kawamura, Youko; Takeda, Mitsuharu; Uchiyama, Mitsuru
CS Natl. Inst. Hyg. Sci., Tokyo, Japan
SO Eisei Kagaku (1981), 27(4), 252-6
CODEN: ESKGA2; ISSN: 0013-273X
DT Journal
LA Japanese

L33 ANSWER 109 OF 126 CAPLUS COPYRIGHT 2003 ACS
 AN 1981:456297 CAPLUS
 DN 95:56297
 TI In vitro degradation of organophosphorus acaricides by the mites
 Sancassania berlesei (Tyroglyphidae) and Tetranychus urticae
 (Tetranychidae)
 AU Blank, R. H.
 CS Lincoln Coll., Canterbury, N. Z.
 SO New Zealand Journal of Agricultural Research (1980), 23(4), 589-93
 CODEN: NEZFA7; ISSN: 0028-8233
 DT Journal
 LA English

L33 ANSWER 110 OF 126 CAPLUS COPYRIGHT 2003 ACS
 AN 1980:20699 CAPLUS
 DN 92:20699
 TI Criteria for toxicological and epidemiological evaluation for an updating
 of the standards of primary food protection
 AU Orecchio, Fausto; Ghezzi, Floriano; Ficarra, Maria Giovanna; Villa,
 Piergiuseppe
 CS Fac. Med. Chir., Univ. Cattol. Sacro Cuore, Rome, Italy
 SO Dif. Antiparassit. Ind. Aliment. Prot. Alimenti, Atti Simp., 2nd (1979),
 Meeting Date 1977, 465-78. Editor(s): Domenichini, Giorgio. Publisher:
 Camera Commer. Ind. Artigianato Agric. Piacenza, Piacenza, Italy.
 CODEN: 41PTAN
 DT Conference
 LA Italian

L33 ANSWER 111 OF 126 CAPLUS COPYRIGHT 2003 ACS
 AN 1979:484616 CAPLUS
 DN 91:84616
 TI Biological effects of dithiocarbamates: effect of zinc
 ethylenebisdithiocarbamate (zineb) on the acute toxicity of parathion and
 paraoxon in mice
 AU Orecchio, F.; Togna, G.; Di Battista, L.; Villa, P.; Ficarra, M. G.
 CS Ist. Ig., Univ. Cattol. Sacro Cuore, Rome, Italy
 SO Igiene Moderna (1979), 72(3), 305-10
 CODEN: IGMPAX; ISSN: 0019-1655
 DT Journal
 LA Italian

L33 ANSWER 112 OF 126 CAPLUS COPYRIGHT 2003 ACS
 AN 1978:610014 CAPLUS
 DN 89:210014
 TI Effects of naturally occurring food plant components on insecticide
 degradation in rats
 AU Fuhremann, Tom W.; Lichtenstein, E. Paul; Stratman, Fredrick W.
 CS Inst. Enzyme Res., Univ. Wisconsin, Madison, WI, USA
 SO Journal of Agricultural and Food Chemistry (1978), 26(5), 1068-75
 CODEN: JAFCAU; ISSN: 0021-8561
 DT Journal
 LA English

L33 ANSWER 113 OF 126 CAPLUS COPYRIGHT 2003 ACS
 AN 1978:184105 CAPLUS
 DN 88:184105
 TI **Detoxification** of nitrophenyl phosphate and nitrophenyl
 phosphonates in tissue homogenates of white rats
 AU Galebskaya, L. V.
 CS I Leningr. Med. Inst., Leningrad, USSR
 SO Neirogumoral'n. Endokr. Regul. Funkts. (1975), 28-9. Editor(s): Denisova,

G. A.; Maslennikov, I. V.; Smirnova, N. N. Publisher: Pervyi Leningr. Med. Inst. im. I. P. Pavlova, Leningrad, USSR.

CODEN: 37TFAW

DT Conference
LA Russian

L33 ANSWER 114 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1978:46005 CAPLUS

DN 88:46005

TI DDVP (dichlorvos) **detoxification** by binding and interactions with DDT, dieldrin, and malaoxon

AU Ehrich, Marion; Cohen, Steven D.

CS Sch. Pharm., Univ. Connecticut, Storrs, CT, USA

SO Journal of Toxicology and Environmental Health (1977), 3(3), 491-500

CODEN: JTEHD6; ISSN: 0098-4108

DT Journal
LA English

L33 ANSWER 115 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1977:497026 CAPLUS

DN 87:97026

TI Effect of piperonyl butoxide on the metabolism of dimethyl and diethyl phosphorothionate insecticides

AU Levine, Barry S.; Murphy, Sheldon D.

CS Sch. Public Health, Harvard Univ., Boston, MA, USA

SO Toxicology and Applied Pharmacology (1977), 40(3), 393-406

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal
LA English

L33 ANSWER 116 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1977:463744 CAPLUS

DN 87:63744

TI Parathion and methyl parathion toxicity and metabolism in piperonyl butoxide and diethyl maleate pretreated mice

AU Mirer, Franklin E.; Levine, Barry S.; Murphy, Sheldon D.

CS Kresge Cent. Environ. Health, Harvard Sch. Public Health, Boston, MA, USA

SO Chemico-Biological Interactions (1977), 17(1), 99-112

CODEN: CBINA8; ISSN: 0009-2797

DT Journal
LA English

L33 ANSWER 117 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1977:133557 CAPLUS

DN 86:133557

TI Pharmacologic-toxicologic consequences of circadian rhythm

AU Von Mayersbach, H.; Mueller, O.; Philippens, K.; Scheving, L. E.

CS Anat. Inst., Med. Hochsch. Hannover, Hannover, Fed. Rep. Ger.

SO Acta Histochemica, Supplementband (1976), 16, 123-7

CODEN: AHSUAV; ISSN: 0567-7556

DT Journal
LA German

L33 ANSWER 118 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1976:131127 CAPLUS

DN 84:131127

TI Development of microbial systems for the disposal of concentrated pesticide suspensions

AU Munnecke, Douglas M.; Hsieh, D. P. H.

CS Inst. Bodenbiol., Forschungsanst. Landwirtsch., Braunschweig, Fed. Rep. Ger.

SO Mededelingen van de Faculteit Landbouwwetenschappen, Universiteit Gent

(1975), 40(2, Pt. 2), 1237-47
CODEN: MFLRA3; ISSN: 0368-9697

DT Journal
LA English

L33 ANSWER 119 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1974:486536 CAPLUS

DN 81:86536

TI Simplified bioassay for organophosphate **detoxification** and interactions

AU Cohen, Steven D.; Murphy, Sheldon D.

CS Kresge Cent. Environ. Health, Harvard Sch. Public Health, Boston, MA, USA

SO Toxicology and Applied Pharmacology (1974), 27(3), 537-50

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal
LA English

L33 ANSWER 120 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1974:422010 CAPLUS

DN 81:22010

TI Comparative toxicity, anticholinesterase action, and metabolism of methyl parathion and parathion in sunfish and mice

AU Benke, G. M.; Cheever, K. L.; Mirer, F. E.; Murphy, S. D.

CS Sch. Public Health, Harvard Univ., Boston, MA, USA

SO Toxicology and Applied Pharmacology (1974), 28(1), 97-109

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal
LA English

L33 ANSWER 121 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1973:449643 CAPLUS

DN 79:49643

TI Comparison of the metabolism of parathion by lobsters and rats

AU Carlson, Gary P.

CS Coll. Pharm., Univ. Rhode Island, Kingston, RI, USA

SO Bulletin of Environmental Contamination and Toxicology (1973), 9(5), 296-300

CODEN: BECTA6; ISSN: 0007-4861

DT Journal
LA English

L33 ANSWER 122 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1973:428129 CAPLUS

DN 79:28129

TI Metabolism of carbon-14-labeled parathion and carbon-14-labeled paraoxon with fractions and subfractions of rat liver cells

AU Lichtenstein, E. Paul; Führemann, Tom W.; Hochberg, Abraham A.; Zahlten, Rainer N.; Stratman, Fred W.

CS Dep. Entomol., Univ. Wisconsin, Madison, WI, USA

SO Journal of Agricultural and Food Chemistry (1973), 21(3), 416-24

CODEN: JAFCAU; ISSN: 0021-8561

DT Journal
LA English

L33 ANSWER 123 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1972:522985 CAPLUS

DN 77:122985

TI Increase in the toxicity of organophosphorus insecticides to house flies due to polychlorinated biphenyl compounds

AU Führemann, T. W.; Lichtenstein, E. P.

CS Dep. Entomol., Univ. Wisconsin, Madison, WI, USA

SO Toxicology and Applied Pharmacology (1972), 22(4), 628-40

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal
LA English

L33 ANSWER 124 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1970:519612 CAPLUS

DN 73:119612

TI Resistance to organophosphorus insecticides in tobacco budworms

AU Whitten, C. J.; Bull, Don L.

CS Entomol. Res. Div., Agr. Res. Serv., College Station, TX, USA

SO Journal of Economic Entomology (1970), 63(5), 1492-5

CODEN: JEENAI; ISSN: 0022-0493

DT Journal

LA English

L33 ANSWER 125 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1969:27255 CAPLUS

DN 70:27255

TI Effect of Melleril on the detoxication of insecticidal phosphates

AU Klotzsche, Claus

CS Med.-Biol. Forsch., Sandoz A.-G., Basel, Switz.

SO Pflanzenschutzberichte (1968), 38(10-11), 125-34

CODEN: PSBEA4; ISSN: 0031-675X

DT Journal

LA German

L33 ANSWER 126 OF 126 CAPLUS COPYRIGHT 2003 ACS

AN 1967:17758 CAPLUS

DN 66:17758

TI Protective effect of aldrin against the toxicity of organophosphate anticholinesterases

AU Triolo, Anthony J.; Coon, Julius M.

CS Jefferson Med. Coll., Philadelphia, PA, USA

SO Journal of Pharmacology and Experimental Therapeutics (1966), 154(3), 613-23

CODEN: JPETAB; ISSN: 0022-3565

DT Journal

LA German/French

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

E STRVUDINE

L1 0 S STRVUDINE

L2 0 S D4T

E D4T

L3 5 S STAVUDINE

L4 42 S PARAOXON

L5 0 S PHYOSTIGMINE

L6 0 S PHYOSTIGMINE

L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

L8 1300 S L3

L9 2913 S L4

L10 4718 S L7

E HIV

L11 50075 S E3 OR E7

E HERPES

L12 21343 S E3
 L13 17244 S HHV OR HSV OR HCMV OR CMV
 L14 29657 S L12 OR L13
 L15 7547 S PHOSPHATE ESTER
 L16 2 S L8 AND L15
 E ESTER
 L17 518186 S E3
 L18 2414368 S S
 L19 54 S L17 AND L8
 L20 3 S L9 AND L11
 L21 0 S L9 AND L14
 L22 2 S L10 AND L11
 L23 1 S L10 AND L14
 E ANTIVIRAL
 L24 38629 S E3-E9
 L25 2 S L24 AND L9
 L26 8 S L10 AND L24
 L27 1 S L8 AND L9
 L28 5 S L8 AND L10
 L29 152 S L9 AND L10
 E DETOXIFICATION
 L30 16332 S E3-E12
 L31 0 S L30 AND L8
 E EXCRETE
 L32 43680 S E3-E5
 L33 126 S L30 AND L9

=> s 130 and 110

L34 10 L30 AND L10

=> d 134 1-10

L34 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:363815 CAPLUS
 DN 136:351556
 TI Alkaloid tolerance in *Manduca sexta* and phylogenetically related sphingids
 (Lepidoptera: Sphingidae)
 AU Wink, Michael; Theile, Vera
 CS Institut für Pharmazeutische Biologie, Universität Heidelberg, Heidelberg,
 D-69120, Germany
 SO Chemoecology (2002), 12(1), 29-46
 CODEN: CHMOE9; ISSN: 0937-7409
 PB Birkhaeuser Verlag
 DT Journal
 LA English
 RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:676210 CAPLUS
 DN 135:222701
 TI **Detoxification** of humans affected by feed toxins passing through
 the food chain
 IN Kiefer, Heinz
 PA Germany
 SO Ger. Offen., 6 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

PI DE 10106530 A1 20010913 DE 2001-10106530 20010213
DE 10106530 C2 20020627
PRAI DE 2001-10106530 20010213

L34 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 2000:573354 CAPLUS

DN 134:52581

TI Mechanisms associated with methiocarb resistance in *Frankliniella occidentalis* (Thysanoptera: Thripidae)

AU Jensen, Sten E.

CS Department of Crop Protection, Research Centre Flakkebjerg, Danish Institute of Agricultural Sciences, Slagelse, DK-4200, Den.

SO Journal of Economic Entomology (2000), 93(2), 464-471

CODEN: JEENAI; ISSN: 0022-0493

PB Entomological Society of America

DT Journal

LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1998:276403 CAPLUS

DN 129:23341

TI Subchronic physostigmine pretreatment in guinea pigs: effective against soman and without side effects

AU Philippens, Ingrid H. C. H. M.; Busker, Ruud W.; Wolthuis, Otto L.; Olivier, Berend; Bruijnzeel, Piet L. B.; Melchers, Bert P. C.

CS Research Group Pharmacology, TNO Prins Maurits Lab (TNO-PML), Rijswijk, 2280 AA, Neth.

SO Pharmacology, Biochemistry and Behavior (1998), 59(4), 1061-1067

CODEN: PBBHAU; ISSN: 0091-3057

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1995:779743 CAPLUS

DN 123:191172

TI Imidacloprid binding site in *Musca* nicotinic acetylcholine receptor: interactions with physostigmine and a variety of nicotinic agonists with chloropyridyl and chlorothiazolyl substituents

AU Liu, Ming-Yie; Latli, Bachir; Casida, John E.

CS Environmental Chemistry and Toxicology Laboratory, Univ. California, Berkeley, CA, 94720-3112, USA

SO Pesticide Biochemistry and Physiology (1995), 52(3), 170-81

CODEN: PCBPBS; ISSN: 0048-3575

PB Academic

DT Journal

LA English

L34 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1988:585141 CAPLUS

DN 109:185141

TI Effect of carboxylesterase inhibition on carbamate protection against soman toxicity

AU Maxwell, Donald M.; Brecht, Karen M.; Lenz, David E.; O'Neill, Barbara L.

CS U. S. Army Med. Res. Inst. Chem. Def., Aberdeen Proving Ground, MD, 21010-5425, USA

SO Journal of Pharmacology and Experimental Therapeutics (1988), 246(3), 986-91

CODEN: JPETAB; ISSN: 0022-3565

DT Journal
LA English

L34 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1988:524378 CAPLUS

DN 109:124378

TI Reaction of Rhabditiis oxyerca after long-term exposure to aldicarb and oxamyl. II: Enzyme changes in nematicide resistance

AU Below, S.; Kaempfe, L.; Mueller, A.

CS Dep. Zool., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.

SO Nematologica (1987), 33(3), 298-309

CODEN: NEMAAT; ISSN: 0028-2596

DT Journal
LA English

L34 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1975:164856 CAPLUS

DN 82:164856

TI Effect upon drug toxicity of surgical interference with hepatic or renal function

AU Selye, H.; Mecs, I.

CS Inst. Medecine Chir. Exp., Univ. Montreal, Montreal, QC, Can.

SO Acta Hepato-Gastroenterologica (1974), 21(3), 191-202; (4), 266-73

CODEN: AHGSBY; ISSN: 0300-970X

DT Journal
LA English

L34 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1968:103714 CAPLUS

DN 68:103714

TI Effect of impaired acetylcholine tolerance on traumatic shock in the rat

AU Ninomiya, Harutada; Michaelis, Moritz

CS Univ. of Maryland Sch. of Med., Baltimore, MD, USA

SO Enzymologia (1968), 34(3), 165-70

CODEN: ENZYAS; ISSN: 0013-9424

DT Journal
LA English

L34 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1967:17758 CAPLUS

DN 66:17758

TI Protective effect of aldrin against the toxicity of organophosphate anticholinesterases

AU Triolo, Anthony J.; Coon, Julius M.

CS Jefferson Med. Coll., Philadelphia, PA, USA

SO Journal of Pharmacology and Experimental Therapeutics (1966), 154(3), 613-23

CODEN: JPETAB; ISSN: 0022-3565

DT Journal
LA German/French

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

E STRVUDINE

L1 0 S STRVUDINE

L2 0 S D4T

E D4T

L3 5 S STAVUDINE
 L4 42 S PARAOXON
 L5 0 S PHYOSTIGMINE
 L6 0 S PHYOSTIGMINE
 L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

L8 1300 S L3
 L9 2913 S L4
 L10 4718 S L7
 E HIV
 L11 50075 S E3 OR E7
 E HERPES
 L12 21343 S E3
 L13 17244 S HHV OR HSV OR HCMV OR CMV
 L14 29657 S L12 OR L13
 L15 7547 S PHOSPHATE ESTER
 L16 2 S L8 AND L15
 E ESTER
 L17 518186 S E3
 L18 2414368 S S
 L19 54 S L17 AND L8
 L20 3 S L9 AND L11
 L21 0 S L9 AND L14
 L22 2 S L10 AND L11
 L23 1 S L10 AND L14
 E ANTIVIRAL
 L24 38629 S E3-E9
 L25 2 S L24 AND L9
 L26 8 S L10 AND L24
 L27 1 S L8 AND L9
 L28 5 S L8 AND L10
 L29 152 S L9 AND L10
 E DETOXIFICATION
 L30 16332 S E3-E12
 L31 0 S L30 AND L8
 E EXCRETE
 L32 43680 S E3-E5
 L33 126 S L30 AND L9
 L34 10 S L30 AND L10

=> e synergist

E1 315 SYNERGISMS/BI
 E2 4 SYNERGISN/BI
 E3 3219 --> SYNERGIST/BI
 E4 1 SYNERGISTAICALLY/BI
 E5 2 SYNERGISTC/BI
 E6 1 SYNERGISTE/BI
 E7 1 SYNERGISTED/BI
 E8 1 SYNERGISTEIC/BI
 E9 35 SYNERGISTES/BI
 E10 1 SYNERGISTGIC/BI
 E11 2 SYNERGISTI/BI
 E12 54122 SYNERGISTIC/BI

=> s e1-e12

315 SYNERGISMS/BI
 4 SYNERGISN/BI
 3219 SYNERGIST/BI
 1 SYNERGISTAICALLY/BI
 2 SYNERGISTC/BI
 1 SYNERGISTE/BI

1 SYNERGISTED/BI
 1 SYNERGISTEIC/BI
 35 SYNERGISTES/BI
 1 SYNERGISTGIC/BI
 2 SYNERGISTI/BI
 54122 SYNERGISTIC/BI
 L35 56539 (SYNERGISMS/BI OR SYNERGISN/BI OR SYNERGIST/BI OR SYNERGISTAICAL
 LY/BI OR SYNERGISTC/BI OR SYNERGISTE/BI OR SYNERGISTED/BI OR
 SYNERGISTEIC/BI OR SYNERGISTES/BI OR SYNERGISTGIC/BI OR SYNERGIS
 TI/BI OR SYNERGISTIC/BI)

=> s 135 and 18

L36 55 L35 AND L8

=> s 135 and 19

L37 31 L35 AND L9

=> d 137 10-31

L37 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1992:146120 CAPLUS

DN 116:146120

TI Mechanisms in the selective sensitivity to insecticides of the larvae and
 imago of beet webworm (*Margaretia sticticalis*)

AU Leonova, I. N.; Slyn'ko, N. M.; Knor, I. B.

CS Inst. Tsitol. Genet., Novosibirsk, USSR

SO Agrokhimiya (1991), (3), 114-20

CODEN: AGKYAU; ISSN: 0002-1881

DT Journal

LA Russian

L37 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1989:473038 CAPLUS

DN 111:73038

TI A mutant esterase degrading organophosphates in a resistant strain of the
 predacious mite *Amblyseius potentillae* (Garman)

AU Anber, H. A. I.; Oppenoorth, F. J.

CS Lab. Exp. Entomol., Univ. Amsterdam, Amsterdam, 1098, Neth.

SO Pesticide Biochemistry and Physiology (1989), 33(3), 283-97

CODEN: PCBPBS; ISSN: 0048-3575

DT Journal

LA English

L37 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1988:217727 CAPLUS

DN 108:217727

TI Effect of organophosphorus synergists on fenitrothion resistance in rice
 stem borer, *Chilo suppressalis* (Walker)

AU Konno, Yashukio; Shishido, Takashi; Tanaka, Fukusaburo

CS Div. Pestic., Natl. Inst. Agro-Environ. Sci., Tsukuba, 305, Japan

SO Applied Entomology and Zoology (1988), 23(1), 99-102

CODEN: APEZAW; ISSN: 0003-6862

DT Journal

LA English

L37 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1987:629142 CAPLUS

DN 107:229142

TI Stimulation of defenses of biological systems using toxic substances

IN Berdal, Pascal

PA Fr.

SO Fr. Demande, 25 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | FR 2584294 | A1 | 19870109 | FR 1985-10403 | 19850708 |
| | FR 2584294 | B1 | 19920221 | | |
| PRAI | FR 1985-10403 | | 19850708 | | |

L37 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1987:419456 CAPLUS

DN 107:19456

TI Inhibition of trans-permethrin hydrolysis in *Pseudoplusia includens* (Walker) and use of inhibitors as pyrethroid synergists

AU Dowd, Patrick F.; Sparks, Thomas C.

CS Agric. Cent., Louisiana State Univ., Baton Rouge, LA, 70803, USA

SO Pesticide Biochemistry and Physiology (1987), 27(2), 237-45

CODEN: PCBPBS; ISSN: 0048-3575

DT Journal

LA English

L37 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1986:566856 CAPLUS

DN 105:166856

TI Mode of action of N-ethylmaleimide as a parathion **synergist** in *Triatoma infestans*

AU Wood, E. J.; De Villar, M. I. P.; Melgar, F. J.; Zérba, E. N.

CS CIPEIN, Buenos Aires, Argent.

SO Pesticide Biochemistry and Physiology (1986), 26(2), 170-82

CODEN: PCBPBS; ISSN: 0048-3575

DT Journal

LA English

L37 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1985:608864 CAPLUS

DN 103:208864

TI Relationships between **synergistic** and biochemical analyses of paraoxon tolerance in pea aphids

AU Al-Rajhi, Deifalla H.; Brindley, William A.

CS Dep. Biol., Utah State Univ., Logan, UT, 84322, USA

SO Alexandria Science Exchange (1985), 6(2), 142-59

CODEN: ALSEEF; ISSN: 1110-0176

DT Journal

LA English

L37 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1985:418357 CAPLUS

DN 103:18357

TI Synergism of organophosphorus insecticides by diethyl maleate and related compounds in houseflies

AU Welling, W.; De Vries, J. W.

CS Inst. Pestic. Res., Wageningen, 6709 PG, Neth.

SO Pesticide Biochemistry and Physiology (1985), 23(3), 358-69

CODEN: PCBPBS; ISSN: 0048-3575

DT Journal

LA English

L37 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2003 ACS

AN 1984:46971 CAPLUS

DN 100:46971

TI Synthesis and biological activity studies of selected organophosphorus

esters

AU McElroy, Roger D.; Chambers, Howard W.
CS Dep. Entomol., Mississippi State Univ., Mississippi State, MS, 39762, USA
SO Journal of Agricultural and Food Chemistry (1984), 32(1), 119-23
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L37 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1983:193024 CAPLUS
DN 98:193024
TI Mutagenicity of some organophosphorus compounds at the ade6 locus of
Schizosaccharomyces pombe
AU Gilot-Delhalle, J.; Colizzi, A.; Moutschen, J.; Moutschen-Dahmen, M.
CS Lab. Genet., Univ. Liege, Liege, B-4000, Belg.
SO Mutation Research (1983), 117(1-2), 139-48
CODEN: MUREAV; ISSN: 0027-5107
DT Journal
LA English

L37 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1983:102653 CAPLUS
DN 98:102653
TI Organophosphorus resistance in the sheep blowfly, *Lucilia cuprina*
(Wiedemann) (Diptera: Calliphoridae): a genetic study incorporating
synergists
AU Hughes, P. B.
CS Biol. Chem. Res. Inst., Dep. Agric., Rydalmere, 2116, Australia
SO Bulletin of Entomological Research (1982), 72(4), 573-82
CODEN: BEREAS; ISSN: 0007-4853
DT Journal
LA English

L37 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1980:463526 CAPLUS
DN 93:63526
TI Phthalate-organophosphate interactions: toxicity, penetration, and
metabolism studies with house flies
AU Al-Badry, Mahdiy S.; Knowles, Charles O.
CS Dep. Entomol., Univ. Missouri, Columbia, MO, 65211, USA
SO Archives of Environmental Contamination and Toxicology (1980), 9(2),
147-61
CODEN: AEETCV; ISSN: 0090-4341
DT Journal
LA English

L37 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1980:53312 CAPLUS
DN 92:53312
TI Biologically active components of anise: toxicity and interactions with
insecticides in insects
AU Marcus, Craig; Lichtenstein, E. Paul
CS Dep. Entomol., Univ. Wisconsin, Madison, WI, 53706, USA
SO Journal of Agricultural and Food Chemistry (1979), 27(6), 1217-23
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L37 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1979:17607 CAPLUS
DN 90:17607
TI Synergism of anticholinesterase insecticides by non-insecticidal

phosphorus esters in the boll weevil *Anthonomus grandis* Boheman
AU Urrelo, Rafael; Chambers, Howard
CS Univ. Nac. Agrar. Selva, Tingo Maria, Peru
SO Turrialba (1978), 28(1), 71-6
CODEN: TURRAB; ISSN: 0041-4360
DT Journal
LA English

L37 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1977:400070 CAPLUS
DN 87:70
TI NADH synergism of microsomal aniline metabolism in the presence of enhancing agents
AU Powis, Garth; Lyon, Linda; McKillop, David
CS Dep. Pharmacol., Glasgow Univ., Glasgow, UK
SO Biochemical Pharmacology (1977), 26(2), 137-41
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L37 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1977:166109 CAPLUS
DN 86:166109
TI DDE increases the toxicity of parathion to Coturnix quail
AU Ludke, J. Larry
CS Patuxent Wildl. Res. Cent., U. S. Fish. Wildl. Serv., Laurel, MD, USA
SO Pesticide Biochemistry and Physiology (1977), 7(1), 28-33
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L37 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1974:564303 CAPLUS
DN 81:164303
TI Effect of TOTP[triorthotolyl phosphate] pretreatment on paraoxon and methylparaoxon detoxication in rats
AU Benke, Gary M.; Murphy, Sheldon D.
CS Kresge Cent. Environ. Health, Harvard Sch. Public Health, Boston, MA, USA
SO Research Communications in Chemical Pathology and Pharmacology (1974), 8(4), 665-72
CODEN: RCOCB8; ISSN: 0034-5164
DT Journal
LA English

L37 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1974:546826 CAPLUS
DN 81:146826
TI Genetics of resistance of a dimethoate-selected strain of houseflies (*Musca domestica*) to several insecticides and methylenedioxyphenyl synergists
AU Sawicki, Roman M.
CS Dep. Insectic. Fungic., Rothamsted Exp. Stn., Harpenden/Herts, UK
SO Journal of Agricultural and Food Chemistry (1974), 22(3), 344-9
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L37 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1972:122870 CAPLUS
DN 76:122870
TI Selection for resistance to carbamate and organophosphorus insecticides in *Anopheles albimanus*
AU Ariaratnam, V.; Georgiou, G. P.

CS Dep. Entomol., Univ. California, Riverside, CA, USA
 SO Nature (London, United Kingdom) (1971), 232(5313), 642-4
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English

L37 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2003 ACS
 AN 1971:404397 CAPLUS
 DN 75:4397
 TI Effect of chlorocholine chloride on the toxicity of cholinesterase inhibitors
 AU Ackermann, Heinz; Kretzschmann, Fritz
 CS Inst. Ernaehr. Potsdam-Rehbruecke, Dtsch. Akad. Wiss. Berlin, Potsdam-Rehbruecke, Fed. Rep. Ger.
 SO Archiv fuer Experimentelle Veterinaermedizin (1970), 24(4), 1045-7
 CODEN: AXVMAW; ISSN: 0003-9055
 DT Journal
 LA German

L37 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:500248 CAPLUS
 DN 71:100248
 TI Effect of acetylcholine, anticholinesterases and cholinolytic agents on the vessels of an isolated rabbit heart
 AU Nikitin, A. I.
 CS USSR
 SO Probl. Klin. Eksp. Med. (1967), 354-5. Editor(s): Neimark, I. I. Publisher: Altai. Knizhnoe Izd., Barnaul, USSR.
 CODEN: 21FSAG
 DT Conference
 LA Russian

L37 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:46376 CAPLUS
 DN 70:46376
 TI Effect of time on the co-toxicity coefficients of insecticides with sesamex
 AU Rai, Bhupendra K.
 CS Div. Entomol., Indian Agr. Res. Inst., New Delhi, India
 SO Indian Journal of Entomology (1967), 29(Pt. 3), 311-12
 CODEN: IJENA8; ISSN: 0367-8288
 DT Journal
 LA English

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

| | |
|----|--------------------|
| | E STRVUDINE |
| L1 | 0 S STRVUDINE |
| L2 | 0 S D4T |
| | E D4T |
| L3 | 5 S STAVUDINE |
| L4 | 42 S PARAOXON |
| L5 | 0 S PHYOSTIGMINE |
| L6 | 0 S PHYOSTIGMINE |
| L7 | 54 S PHYSOSTIGMINE |

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

L8 1300 S L3

L9 2913 S L4
 L10 4718 S L7
 E HIV
 L11 50075 S E3 OR E7
 E HERPES
 L12 21343 S E3
 L13 17244 S HHV OR HSV OR HCMV OR CMV
 L14 29657 S L12 OR L13
 L15 7547 S PHOSPHATE ESTER
 L16 2 S L8 AND L15
 E ESTER
 L17 518186 S E3
 L18 2414368 S S
 L19 54 S L17 AND L8
 L20 3 S L9 AND L11
 L21 0 S L9 AND L14
 L22 2 S L10 AND L11
 L23 1 S L10 AND L14
 E ANTIVIRAL
 L24 38629 S E3-E9
 L25 2 S L24 AND L9
 L26 8 S L10 AND L24
 L27 1 S L8 AND L9
 L28 5 S L8 AND L10
 L29 152 S L9 AND L10
 E DETOXIFICATION
 L30 16332 S E3-E12
 L31 0 S L30 AND L8
 E EXCRETE
 L32 43680 S E3-E5
 L33 126 S L30 AND L9
 L34 10 S L30 AND L10
 E SYNERGIST
 L35 56539 S E1-E12
 L36 55 S L35 AND L8
 L37 31 S L35 AND L9

=> s 135 and 110

L38 40 L35 AND L10

=> d 138 10-40

L38 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1995:927588 CAPLUS

DN 123:308647

TI Purification and characterization of a resistance-associated esterase from the Colorado potato beetle, *Leptinotarsa decemlineata* (Say)

AU Anspaugh, Douglas D.; Kennedy, George G.; Roe, R. Michael

CS Dep. Entomol., North Carolina State Univ., Raleigh, NC, 27695-7613, USA

SO Pesticide Biochemistry and Physiology (1995), 53(2), 84-96

CODEN: PCBPBS; ISSN: 0048-3575

PB Academic

DT Journal

LA English

L38 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1995:865572 CAPLUS

DN 123:329289

TI Intrathecal acetyl cholinesterase inhibitors produce analgesia that is **synergistic** with morphine and clonidine in rats

AU Abram, Stephen E.; Winne, Richard P.

CS Department Anesthesia, Medical College Wisconsin, Milwaukee, WI, 53226,

USA
 SO Anesthesia & Analgesia (Baltimore) (1995), 81(3), 501-7
 CODEN: AACRAT; ISSN: 0003-2999
 PB Williams & Wilkins
 DT Journal
 LA English

L38 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:779743 CAPLUS
 DN 123:191172
 TI Imidacloprid binding site in Musca nicotinic acetylcholine receptor:
 interactions with physostigmine and a variety of nicotinic agonists with
 chloropyridyl and chlorothiazolyl substituents
 AU Liu, Ming-Yie; Latli, Bachir; Casida, John E.
 CS Environmental Chemistry and Toxicology Laboratory, Univ. California,
 Berkeley, CA, 94720-3112, USA
 SO Pesticide Biochemistry and Physiology (1995), 52(3), 170-81
 CODEN: PCBPBS; ISSN: 0048-3575
 PB Academic
 DT Journal
 LA English

L38 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:621797 CAPLUS
 DN 123:17911
 TI Combination of lithium compound and acetylcholinesterase inhibitor for
 treatment of Alzheimer's disease
 IN Lehmann, Karla
 PA Germany
 SO Ger., 4 pp.
 CODEN: GWXXAW
 DT Patent
 LA German
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | DE 4340272 | C1 | 19950511 | DE 1993-4340272 | 19931126 |
| | WO 9514481 | A1 | 19950601 | WO 1994-EP3921 | 19941126 |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ | | | | |
| | RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9510677 | A1 | 19950613 | AU 1995-10677 | 19941126 |
| | EP 730463 | A1 | 19960911 | EP 1995-901442 | 19941126 |
| | EP 730463 | B1 | 20000202 | | |
| | R: AT, CH, DE, FR, GB, IT, LI | | | | |
| | AT 189391 | E | 20000215 | AT 1995-901442 | 19941126 |
| PRAI | DE 1993-4340272 | | 19931126 | | |
| | DE 1993-4340273 | | 19931126 | | |
| | WO 1994-EP3921 | | 19941126 | | |

L38 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:400641 CAPLUS
 DN 115:641
 TI Thermic response of selective muscarinic agonists and antagonists in rat
 AU Sen, A. P.; Bhattacharya, S. K.
 CS Inst. Med. Sci., Banaras Hindu Univ., Varanasi, 221 005, India
 SO Indian Journal of Experimental Biology (1991), 29(2), 131-5
 CODEN: IJEBA6; ISSN: 0019-5189

DT Journal
LA English

L38 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1990:493280 CAPLUS
DN 113:93280
TI Resistance to trichlorfon in *Musca domestica* and the effect of synergists
AU Otto, D.; Weber, B.
CS Inst. Plant Prot. Res., Acad. Agric. Sci. GDR, Kleinmachnow, DDR-1532,
Ger. Dem. Rep.
SO Tagungsbericht - Akademie der Landwirtschaftswissenschaften der Deutschen
Demokratischen Republik (1989), 274(Insectic.-Mech. Action Resist.),
253-67
CODEN: TALDA3; ISSN: 0138-2659

DT Journal
LA English

L38 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1988:506494 CAPLUS
DN 109:106494
TI Model studies of carbamate tolerance and resistance in *Rhabditis oxyerca*
(de Man, 1985) (Nematoda)
AU Below, Silvia; Kampfe, Lothar
CS Sect. Biol., Ernst-Moritz-Arndt-Univ. Greifswald, Greifswald, DDR-2200,
Ger. Dem. Rep.
SO Archiv fuer Phytopathologie und Pflanzenschutz (1988), 24(1), 45-53
CODEN: APPZAJ; ISSN: 0323-5408

DT Journal
LA German

L38 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1987:419456 CAPLUS
DN 107:19456
TI Inhibition of trans-permethrin hydrolysis in *Pseudoplusia includens*
(Walker) and use of inhibitors as pyrethroid synergists
AU Dowd, Patrick F.; Sparks, Thomas C.
CS Agric. Cent., Louisiana State Univ., Baton Rouge, LA, 70803, USA
SO Pesticide Biochemistry and Physiology (1987), 27(2), 237-45
CODEN: PCBPBS; ISSN: 0048-3575

DT Journal
LA English

L38 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1984:603897 CAPLUS
DN 101:203897
TI Observations on the interaction between ketamine and other drugs in animal
experiments
AU Zhao, Dehua; Sheng, Baoheng; Shi, Yuwu
CS Dep. Pharmacol., 4th Mil. Med. Univ., Peop. Rep. China
SO Zhonghua Mazuixue Zazhi (1984), 4(2), 79-81
CODEN: ZMZADD; ISSN: 0254-1416

DT Journal
LA Chinese

L38 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1983:447741 CAPLUS
DN 99:47741
TI Antianoxic effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride
(MCI 2016)
AU Tobe, Akihiro; Egawa, Mitsuo; Hashimoto, Noriko
CS Res. Cent., Mitsubishi Chem. Ind., Ltd., Yokohama, 227, Japan
SO Nippon Yakurigaku Zasshi (1983), 81(5), 421-9

CODEN: NYKZAU; ISSN: 0015-5691

DT Journal
LA Japanese

L38 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1982:538549 CAPLUS

DN 97:138549

TI Choline and physostigmine enhance haloperidol-induced HVA and DOPAC accumulation

AU Millington, William R.; Wurtman, Richard J.

CS Dep. Nutr. Food Sci., Massachusetts Inst. Technol., Cambridge, MA, 02139, USA

SO European Journal of Pharmacology (1982), 80(4), 431-4

CODEN: EJPHAZ; ISSN: 0014-2999

DT Journal

LA English

L38 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1976:554251 CAPLUS

DN 85:154251

TI Pharmacological studies on the stimulation of the phospholipase A2-acylation system of synaptic membranes of brain, by neurotransmitters and other agonists

AU Gullis, R. J.; Rowe, C. E.

CS Dep. Biochem., Univ. Birmingham, Birmingham, UK

SO Journal of Neurochemistry (1976), 26(6), 1217-30

CODEN: JONRA9; ISSN: 0022-3042

DT Journal

LA English

L38 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1973:119177 CAPLUS

DN 78:119177

TI Quillaiate of choline iodide, a new monoquaternary neuromuscular blocking agent

AU Hamed, Mohamed Ismail; El-Gholmy, Zeinab

CS Fac. Pharm., Univ. Khartoum, Khartoum, Sudan

SO Arzneimittel-Forschung (1972), 22(12), 2133-6

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA English

L38 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1972:95387 CAPLUS

DN 76:95387

TI **Synergistic** action of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorine 2-oxide with soman and physostigmine

AU McKay, D. H.; Jardine, R. V.; Adie, P. A.

CS Biomed. Sect., Def. Res. Establ. Suffield, Ralston, AB, Can.

SO Toxicology and Applied Pharmacology (1971), 20(4), 474-9

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal

LA English

L38 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1972:263 CAPLUS

DN 76:263

TI Physostigmine and pentobarbital. Biphasic interaction in mice

AU Davis, W. Marvin; King, William T.; Babbini, M.

CS Sch. Pharm., Univ. Mississippi, University, MS, USA

SO Archives Internationales de Pharmacodynamie et de Therapie (1971), 192(1), 152-9

CODEN: AIPTAK; ISSN: 0003-9780

DT Journal
LA English

L38 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1969:27381 CAPLUS

DN 70:27381

TI Relation between the activating action of ATP and chemical mediation in the lingual receptors

AU Rapuzzi, Giovanni; Violante, A.

CS Univ. Pavia, Pavia, Italy

SO Bollettino - Societa Italiana di Biologia Sperimentale (1968), 44(13), 1113-16

CODEN: BSIBAC; ISSN: 0037-8771

DT Journal
LA Italian

L38 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1965:466092 CAPLUS

DN 63:66092

OREF 63:12180h,12181a

TI Effects of cholinergics on antispasmodic activity of phenacone

AU Artemenko, G. N.

CS Inst. Pharmacol. and Chemotherapy, Moscow

SO Farmakologiya i Toksikologiya (Moscow) (1965), 28(3), 290-1

CODEN: FATOAO; ISSN: 0014-8318

DT Journal
LA Unavailable

L38 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1965:85393 CAPLUS

DN 62:85393

OREF 62:15259c-d

TI Effect of parasympathomimetic and sympathomimetic drugs on secretion in vitro by ciliary processes of the rabbit eye

AU Berggren, Lennart

CS Univ. Uppsala, Swed.

SO Investigative Ophthalmology (1965), 4(1), 91-7

CODEN: INOPAO; ISSN: 0020-9988

DT Journal
LA English

L38 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:476352 CAPLUS

DN 59:76352

OREF 59:14239b-c

TI Electrophoretic properties of esterases from susceptible and resistant strains of the housefly (Musca domestica)

AU Menzel, Daniel B.; Craig, Roderick; Hoskins, W. M.

CS Univ. of California, Berkeley

SO Journal of Insect Physiology (1963), 9(4), 479-93

CODEN: JIPHAF; ISSN: 0022-1910

DT Journal
LA Unavailable

L38 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1962:479141 CAPLUS

DN 57:79141

OREF 57:15750e-i

TI Apomorphine synergism (compulsive gnawing by mice) as a test for differentiating psychotropic substances

AU Ther, L.; Schramm, H.

CS Farbwerke, Hoechst, Germany
 SO Archives Internationales de Pharmacodynamie et de Therapie (1962), 138,
 302-10
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA Unavailable

L38 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1961:101137 CAPLUS
 DN 55:101137
 OREF 55:19046e-f
 TI Effects of combinations of active compounds on Daphnia
 AU Seume, F. W.; Fuchs, W. H.
 CS Univ. Gottingen, Germany
 SO Arzneimittel-Forschung (1961), 11, 307-14
 CODEN: ARZNAD; ISSN: 0004-4172
 DT Journal
 LA Unavailable

L38 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1958:22175 CAPLUS
 DN 52:22175
 OREF 52:4017h-i,4018a-c
 TI Pharmacological and toxicological properties of thiophosphorus compounds
 AU Reut, N. A.
 CS State Med. Inst., Minsk
 SO Khim. i Primenenie Fosfororg. Soedineni, Akad. Nauk S.S.S.R., Trudy 1-oi
 Konferents. (1957), Volume Date 1955 313-17
 DT Journal
 LA Unavailable

L38 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1958:7990 CAPLUS
 DN 52:7990
 OREF 52:1467a-i,1468a-b
 TI The influence of analgesics and antonomic drugs on the blood sugar of
 rabbits
 AU Ishikawa, Masaaki
 CS Kyoto Univ.
 SO Nippon Yakurigaku Zasshi (1956), 52(Breviaria 32(in English)), 646-61
 DT Journal
 LA Unavailable

L38 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1957:91714 CAPLUS
 DN 51:91714
 OREF 51:16674h-i,16675a
 TI In vitro studies of the **synergistic** and antagonistic effects of
 physostigmine salicylate on the bacterial growth-inhibitory activity of
 some antibiotics
 AU Green, V. A.; Steber, M.; McKenna, G. F.; Davis, J. E.; Taylor, Alfred
 CS Univ. of Texas, Austin
 SO Texas J. Sci. (1957), 9, 89-98
 DT Journal
 LA Unavailable

L38 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1956:29183 CAPLUS
 DN 50:29183
 OREF 50:5909h-i
 TI Demonstration of a toxic synergy between the potassium ion and eserine and
 neostigmine

AU Hazard, Rene; Delga, Jean
CS Fac. med., Paris
SO Compt. rend. soc. biol. (1955), 149, 1106-7
DT Journal
LA Unavailable

L38 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1955:5733 CAPLUS
DN 49:5733

OREF 49:1220f-g
TI Factors that influence the analgesic action of morphine and its derivatives. I. The action of parasympatholytic compounds
AU Lecannelier, R. S.; Bardisa, U. L.; Tamayo, R. L.; Abarca, B. F.
SO Bol. soc. biol. Concepcion (1953), 28, 73-82
DT Journal
LA Unavailable

L38 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1953:74315 CAPLUS
DN 47:74315

OREF 47:12647d-f
TI Role of the protein complex in the synergism of analgetics and parasympathomimetics
AU Knoll, J.; Komlos, E.; Tardos, L.
CS Univ. Budapest, Hung.
SO Acta Physiol. Acad. Sci. Hung. (1953), 4, 131-40
DT Journal
LA German

L38 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1953:63183 CAPLUS
DN 47:63183

OREF 47:10735h-i
TI Effect of parasympathetic substances in analgesia
AU Porszasz, J.; Knoll, J.; Komlos, E.
CS Univ. Budapest
SO Acta Physiol. Acad. Sci. Hung. (1951), 2, 469-77
DT Journal
LA German

L38 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1951:24789 CAPLUS
DN 45:24789

OREF 45:4342h-i
TI Drug protection against the lethal action of parathion
AU Salerno, Paul R.; Coon, J. M.
CS Univ. of Chicago
SO Arch. intern. pharmacodynamie (1950), 84, 227-36
DT Journal
LA Unavailable

L38 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1947:26072 CAPLUS
DN 41:26072

OREF 41:5216i,5217a-e
TI Mechanism of the strengthening action of parasympathomimetic drugs on the effect of acetylcholine
AU Koiwaya, Osamu
SO Folia Pharm. Japon. (1943), 39, 116-33
DT Journal
LA Unavailable

E SYNERGIST
L35 56539 S E1-E12
L36 55 S L35 AND L8
L37 31 S L35 AND L9
L38 40 S L35 AND L10

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 333.47 | 402.42 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -9.77 | -9.77 |

STN INTERNATIONAL LOGOFF AT 16:57:36 ON 27 MAY 2003